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Abstract
The human polymeric immunoglobulin receptor, pIgR, is a glycosylated type I transmembrane
protein expressed on the basolateral surface of secretory epithelial cells. pIgR plays a key role
in mucosal immunity and, together with bound immunoglobulins (Igs), provides a first line of
specific defense against pathogens and their toxins. pIgR binds dimeric IgA (dIgA) and
pentameric IgM (pIgM) produced by local plasma cells and transports these polymeric Igs to
the apical surface of the cell where the complexes are cleaved from the membrane and
deposited into mucosal secretions. The Fc portion of dIgA initially interacts non-covalently
with the N-terminal domain (D1) of pIgR, followed by a covalent interaction with D5. In order
to gain insight into the molecular details of the initial interaction, we solved the 1.9 A
resolution crystal structure of D1 of pIgR. The structure reveals a folding topology similar to
variable Ig domains with differences in the complementarity determining regions (CDRs).
CDR1, the primary determinant in dimeric IgA binding, contains a single helical turn. CDR2,
the main determinant in binding to pIgM is very short and contains a potentially critical
glutamic acid involved in pIgM binding. CDR3 points away from the other CDRs, preventing
dimerization of D1 analogous to the variable heavy and light chains in antibodies. Surface
plasmon resonance studies showed that D1, regardless of its glycosylation state, binds dIgA
with an equilibrium dissociation constant of 300 nM in the absence of other pIgR domains, but
does not bind to monomeric IgAl-Fca. The structure of D1 allows interpretation of previous
mutagenesis studies and structure-based comparisons with other IgA and IgM receptors. To
further characterize the interaction between intact pIgR and dIgA, we have also initiated
structural studies of the other extracellular domains of pIgR, both alone and in complex with
the Fc portion of dIgA. Finally, we have also undertaken structural studies of pIgR in complex
with the choline-binding protein A, CbpA, a protein found on the surface of Streptococcus
pneumoniae, a pathogen that uses pIgR as a receptor to invade the human mucosal epithelium.
Thesis Supervisors:
Peter S. Kim, Professor of Biology, Massachusetts Institute of Technology; President, Merck
Research Laboratories
Pamela J. Bjorkman, Professor of Biology and Investigator, HHMI, California Institute of
Technology
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Introduction
The majority of human pathogens and toxins enter susceptible hosts at mucosal surfaces. Since
the adult human has approximately 400 m2 of respiratory and gastrointestinal mucosae
(Norderhaug et al., 1999), immunologic protection at these surfaces is essential. Innate defense
and local adaptive immune molecules work together to protect these surfaces. Nonspecific
antimicrobial agents such as bile, digestive enzymes, acid, and lysozyme, in combination with
the mechanical motions of cilia in the respiratory tract and smooth muscle contractions in the
intestinal, reproductive and respiratory tracts can clear some pathogens trapped in the mucosae
(Lamm, 1997). However, a more specific neutralizing defense is provided by secretory
immunoglobulins (SIgs), which are capable of binding and neutralizing specific antigens.
SIgs include polymeric IgA (mainly dimers containing joining (J) chain, but also trimers
and tetramers (Vaerman et al., 1995)) and polymeric IgM (J chain-containing pentamers), which
are secreted by local plasma cells in the lamina propria, just beneath the epithelium. J chain-
lacking IgM hexamers are also secreted by these plasma cells, but only J chain-containing
polymeric Igs (pIgs) bind the transmembrane polymeric Ig receptor (pIgR) (Vaerman et al.,
1998a), also known as the transmembrane secretory component (SC), expressed on the
basolateral surface of epithelial cells. The pIgR-pIg complexes are transported to the apical
surface where they are released by the cleavage of pIgR from the membrane, forming SIgs
(Figure 1). Actively transcytosed secretory IgA (SIgA), and to some extent secretory IgM
(SIgM), provide protection by binding to pathogens and blocking their adherence to, and
invasion of, epithelial cells, a process known as immune exclusion. pIgR is constitutively
expressed and transcytosed to the apical surface, where uncomplexed pIgR is also cleaved to
release free SC (Brandtzaeg, 1973). In addition to actively transporting pIgs across the
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epithelium, pIgR also protects the antibodies from proteolytic cleavage in the harsh environment
of the mucosae (Crottet and Corthesy, 1998), especially in the gastrointestinal tract.
Immunoglobulin structure
Antibodies are tetramers of two heavy and two light chains, arranged in an approximately Y
shape. The light chain contains an N-terminal variable and C-terminal constant region, while the
heavy chain contains one N-terminal variable and three or four C-terminal regions. The Fab
(fragment antigen binding) is composed of a light chain and the two N-terminal Ig domains of
the heavy chain, and is connected by a hinge region to the Fc (fragment crystalline, named for its
ability to crystallize readily), which is a dimer of the two C-terminal domains of the heavy
chains. The Fab fragments recognize and specifically bind antigens at the antibody-combining
site, and the Fc fragments interact with Fc receptors that either elicit immune effector functions,
transport the antibody to specific cellular locations, or stabilize the antibody to protect it from
proteolytic degradation. The five classes of antibody isotypes (IgG, IgE, IgD, IgM and IgA) are
determined by the features of their heavy chains, which differ in their sequences, the number and
position of their disulfide bonds, the number and type of carbohydrates attached, the length of
their hinge regions, and the number of C-terminal domains (Janeway et al., 1999).
IgG, the most abundant serum Ig, was the first antibody isotype for which high-resolution
structural information became available. Crystal structures of IgG Fab fragments and Fab-
antigen complexes revealed their four domain -barrel arrangement and showed that in some
cases the antibody combining site is a concave pocket that the antigen fits into, but in other cases
the antibody protrudes into the antigen (reviewed in (Wilson et al., 1991)). Similar to the Fab
structures, Fc fragments also have four 3-barrel Ig domains with extensive contact surface
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between the Cy3 domains and no contact between the Cy2 domains (Huber et al., 1976). A
carbohydrate attached to the inner surface of the Cy2 domain interacts with this domain through
both polar and hydrophobic residues (Deisenhofer, 1981). Intact IgG structures have provided
several snapshots of these flexible molecules with an overall Y or T shape but each with an
asymmetric arrangement of the Fab and Fc fragments, consistent with antibodies' dynamic nature
(Harris et al., 1992; Harris et al., 1998). Another Ig isotype, IgE, is present at low concentrations
in serum and is produced mainly against parasites. The interaction of IgE with its receptor is
responsible for inflammation and allergic reactions. IgE contains an Ig constant domain in place
of the hinge region. The crystal structure of Fce revealed the overall structure is very similar to
Fcy, including the position of the N-linked carbohydrate in between the CE3 domains, which is
an analogous location to the carbohydrate on Cy2 in IgG (Wan et al., 2002; Wurzburg et al.,
2000).
IgA has two subclasses, IgAl and IgA2, which differ from each other in the number of
N-linked oligosaccharide attachment sites and in the hinge region. IgAl contains a heavily O-
linked glycosylated 23-residue hinge region and two N-linked glycosylation sites, whereas IgA2
has a 13-residue deletion that removes the five O-linked glycosylation sites, and contains
additional N-linked oligosaccharide attachment sites. Serum IgA is predominantly monomeric
IgAl while mucosal IgA is mainly dimeric with a relative increase in IgA2 (Kerr, 1990; Kett et
al., 1986; Mestecky and McGhee, 1987). Early electron microscopy studies of IgA showed that
the attachment of the Fab and Fc fragments resembled that of IgG (Svehag and Bloth, 1970).
More recently, small-angle X-ray and neutron solution scattering and homology modeling
experiments, however, suggest that the hinge regions of IgAl (Boehm et al., 1999) and IgA2
(Furtado et al., 2004) cause an extended Fab and Fc conformation that is different from the
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arrangement seen in IgG. This results in a predominantly T shape for IgA versus the overall Y
shape for IgG. These studies also suggested that IgA2, with its shorter hinge region, is
significantly more compact than IgAl, and that the C-terminal 18-residue extension (the
tailpiece) in both IgA subtypes is probably folded up against the Ca3 domain (Boehm et al.,
1999).
Although a high-resolution crystal structure of intact IgA is presently not available,
crystal structures of the Fab and Fc fragments have been solved. Murine Fab fragment crystal
structures confirmed the -sandwich conformation of the individual domains, with an overall
arrangement similar to IgG Fab structures (Satow et al., 1986; Suh et al., 1986). A recent crystal
structure of Fca (Herr et al., 2003), however, has revealed differences between the Fc fragments
of IgA and previously determined structures of Fcy and Fce. It should be noted that the structure
of Fca was extracted from the co-crystal structure of Fca in complex with the FcaRI receptor,
but significant conformational changes between the FcaRI-bound Fca structure and free Fca are
not expected (Herr et al., 2003). Although the overall architectures of Fca, Fcy and FcE are very
similar, the different features of Fca include the presence of unusual disulfide bonds in the Cat2
domain and at the base of the hinge region, and external, rather than internal, N-linked
oligosaccharides (Herr et al., 2003) (Figure 2).
Humoral immunity at mucosal surfaces
IgA, found in both serum and mucosal secretions, is the most abundant human Ig isotype and the
principal mucosal antibody (Kerr, 1990). IgA in mucosal secretions has been described as the
"first line of defense", while serum IgA is a "second line of defense" against antigens that have
penetrated the epithelial barrier. dIgA is delivered to mucosal secretions by pIgR, a receptor that
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actively transcytoses J chain-containing pIgs from the basolateral side of epithelial cells
(Mostov, 1994). Once in secretions, SIgA binds pathogens and their toxins and prevents their
attachment to, and penetration of, the host. SIgA can neutralize pathogens by directly blocking
interactions between bacterial adhesins and their cellular receptors or by inhibiting the movement
of the bacteria by crosslinking them or interacting with their flagella (reviewed in (Lamm,
1997)). Binding can occur to specific antigens by the IgA antigen-binding site (Armstrong and
Dimmock, 1992; Lamm, 1997; Outlaw and Dimmock, 1990) or nonspecifically to bacterial
lectins by carbohydrate moieties on IgA or pIgR (Wold et al., 1990). In addition to its barrier
function in mucosal secretions, SIgA is also a major component in human breast milk and
provides passive immunization to newborns (reviewed in (Brandtzaeg, 2003; Cleary, 2004; Van
de Perre, 2003)).
IgA has long been considered non-inflammatory because it does not bind and activate
compliment by the classical pathway (Russell et al., 1989). However, many studies have now
shown that aggregated serum IgA triggers cellular functions such as phagocytosis, antibody-
dependent cell-mediated cytotoxicity (ADCC), degranulation and respiratory burst similar to IgG
after binding to its receptor, FcaRI (reviewed in (Monteiro and Van De Winkel, 2003)).
Intracellular signaling by IgA, IgG and IgE receptors is transduced via the same intracellular
protein, the y chain (Monteiro and Van De Winkel, 2003). Monomeric and dimeric forms of
IgA, but not SIgA, can elicit these cellular responses in the absence of an integrin co-receptor
(van Egmond et al., 2000; Vidarsson et al., 2001). As described above, the main function of
SIgA is immune exclusion at mucosal surfaces, where the body is in constant contact with
antigens from both pathogens and commensal bacteria and ingested food. Therefore, it would
actually be disadvantageous for SIgA to elicit inflammatory signals to foreign substances
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because the body would be in a constant state of mucosal inflammation, which would eventually
damage the protective barrier of the epithelial lining. However the ability of IgA to trigger these
cellular functions after interacting with antigens that have already crossed the epithelium
provides additional protection in the serum. The structural basis for the ability of monomeric
and dimeric IgA but not SIgA to initiate phagocytosis is described later.
IgM, the first antibody produced in the humoral response to infection, is also present in
both serum and mucosal secretions (Janeway et al., 1999). While SIgA is the primary Ig in
secretions, SIgM is also present at lower concentrations and clears pathogens via similar
mechanisms (Norderhaug et al., 1999). Similarly to IgA, serum IgM is able to activate
complement very effectively, while mucosal IgM does not (Davis et al., 1988; Randall et al.,
1990; Wiersma et al., 1998). In patients with IgA deficiency, IgM is thought to substitute for the
function of IgA (Brandtzaeg et al., 1987).
A minority of the plasma cells in the lamina propria secrete IgG. While there is no
known active transport of IgG to mucosal secretions in humans, damage to the epithelial layer
can result in passively-transferred IgG molecules at mucosal surfaces with low proteolytic
activity, such as the respiratory and reproductive tracts. Therefore, IgG provides some, albeit
minimal, protection at mucosal surfaces (Lamm, 1997; Norderhaug et al., 1999).
Polymeric immunoglobulins
IgA and IgM, unlike IgG, IgD and IgE, are unique in that they can form higher ordered
oligomers. While serum IgA is monomeric, mucosal IgA is predominantly dimeric, with trimers
and tetramers present at lower levels (Vaerman et al., 1995). Similarly, serum IgM is hexameric,
and mucosal IgM is pentameric (Davis et al., 1988; Niles et al., 1995). Because of their
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multivalency, pIgs can effectively crosslink multiple pathogens to limit their mobility and
facilitate their clearance (Lamm, 1997). pIgs, especially IgM, bind their antigens with relatively
low affinity, an effect that is compensated for by the high avidity effects due to the presence of
four identical binding sites in the case of dIgA and ten sites in pIgM.
Polymeric forms of both IgA and IgM contain a C-terminal 18-residue extension, called
the tailpiece, which is required for J chain incorporation and polymerization. The tailpiece
sequences in human IgA and IgM differ at seven amino acid positions (Yoo et al., 1999), but
both contain a penultimate cysteine residue that is essential for efficient polymerization and a
highly conserved N-linked glycosylation site that is required for efficient polymer assembly
(Atkin et al., 1996; Wiersma et al., 1997). Besides the tailpiece, additional structural elements
within the Ca3, and to a lesser extent Ca2, domains of IgA and the C¢4 and C¢3 domains of
IgM are required for J chain incorporation and polymer formation (Yoo et al., 1999).
Based on mutagenesis experiments and electron microscopy, a model for dIgA structure
has been proposed (Bastian et al., 1995; Feinstein et al., 1971; Garcia-Pardo et al., 1981;
Krugmann et al., 1997) (Figure 3A). One J chain molecule covalently bridges two IgA
molecules arranged in an end-to end configuration (Garcia-Pardo et al., 1981). J chain Cysl5
forms a disulfide bond with tailpiece Cys471 in the first Fca homodimer, and J chain Cys69
forms a second disulfide bond with Cys471 in the tailpiece from the second Fca homodimer.
The two remaining tailpieces, one from each homodimer, are linked directly to each other by a
disulfide bond between their penultimate cysteine residues (Bastian et al., 1995; Krugmann et al.,
1997).
Pentameric IgM contains J chain and, like pIgA, is actively transported to mucosal
secretions by pIgR, but hexameric IgM lacks J chain, and therefore does not bind to or get
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secreted by pIgR (Randall et al., 1990). The polymerization state of IgM depends on the amount
of J chain, where in the absence of J chain IgM is secreted as hexamers and an increase in J chain
production results in an increase in pentameric IgM (Niles et al., 1995). J chain is not found in
small IgM assembly intermediates, suggesting that it does not get incorporated until late in the
assembly (Brewer and Corley, 1997; Randall et al., 1990). Pentameric IgM appears to be the
substrate for J chain incorporation. A model proposes that five IgM molecules are joined by J
chain, excluding a sixth IgM molecule that would normally be added to form hexameric IgM in
the absence of J chain (Brewer and Corley, 1997) (Figure 3B).
Joining (J) chain
J chain, a 15 kDa polypeptide, was first identified about 35 years ago as a component of SIgA
(Halpern and Koshland, 1970) (Figure 3C) and SIgM (Mestecky et al., 1971). This polypeptide is
expressed by immunocytes containing various Ig classes (Brandtzaeg, 1974), however, in the
absence of IgA or IgM, J chain is degraded intracellularly (Mosmann et al., 1978). The number
of J chain molecules in dIgA and pIgM is commonly accepted to be one (Zikan et al., 1986),
however early immunochemical studies suggested dIgA may contain two and pIgM may contain
three to four J chains (Brandtzaeg, 1975b).
Although the exact function of J chain is not clear, it appears to be essential for the
specific transport of pIgs by pIgR, and while it facilitates or stabilizes polymer formation, it is
not essential for Ig polymerization (Hendrickson et al., 1995) (Vaerman et al., 1998b) (Johansen
et al., 2001). In J chain knockout mice, a higher ratio of monomeric to dimeric IgA was
observed, but low levels of dIgA were still present (Hendrickson et al., 1995). Increased serum
IgA and reduced biliary and fecal IgA levels were also reported because J chain-deficient IgA
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are not actively transported by the hepatobiliary transport mechanism in rodents, and the lack of
transfer of IgA from knockout mice was confirmed in vitro in Madin-Darby Canine Kidney
(MDCK) cells (Hendrickson et al., 1995). Further analyses of these mice showed that SC was
not associated with IgA, and although IgA levels were decreased in bile and feces, they were
unaffected in mucosal and glandular secretions, suggesting the possibility of an alternative
mechanism for the transport of J chain-deficient IgA from wild type IgA (Hendrickson et al.,
1996). J chain knockout mice showed no change in serum IgM levels in one study (Hendrickson
et al., 1995), but a reduction in serum IgM with impaired ability to activate complement was
observed in another study (Erlandsson et al., 1998).
J chain has a hydrophobic secretion signal that directs its synthesis into the endoplasmic
reticulum for processing and secretion. Mature human J chain contains 137 amino acids
including eight cysteine residues (Max and Korsmeyer, 1985) of which six are involved in
intramolecular disulfide bonds and two disulfide bonds to the tailpiece penultimate cysteine in
polymeric Igs (Bastian et al., 1992; Bastian et al., 1995; Frutiger et al., 1992). J chain also has an
N-linked oligosaccharide attachment site, which appears to be important for the efficient
assembly of dIgA (Krugmann et al., 1997). J chain is highly conserved across different species
and is also found in invertebrates and amphibians that lack adaptive immunity, suggesting it
originated as a component of the ancient innate immune system (Takahashi et al., 1996). In
addition to sequence conservation, J chain is also functionally conserved since it is
interchangeable between species to form pIgA molecules capable of binding SC, although with
lower affinity (Johansen et al., 2000).
The three dimensional structure of J chain remains elusive. It is normally found as an
extracellular protein in complex with IgA or IgM and it is found as a free protein only inside Ig
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secreting plasma cells. It is sequestered within pIgs so it is not readily available, and separation
from pIgs requires reduction of the intermolecular disulfide bonds, which results in the reduction
of the intramolecular disulfide bonds as well (Morrison and Koshland, 1972). While J chain
does not resemble any known protein, several models have been proposed about its secondary
structure. In the first model, a two domain structure was proposed in which the N-terminal
domain was predicted to contain -sheet structure and a mixture of a-helical, -sheet and
random coil structures in the C-terminal domain (Cann et al., 1982). In the second model, J
chain was modeled as an eight stranded (A-H) P-sandwich based on its circular dichroism (CD)
spectrum and amino acid profiles for -sheet propensity and hydrophobicity (Zikan et al., 1985)
despite having only a low degree of sequence similarity with other Ig domains. However, the
assigned disulfide bonds in this model were incorrect (Frutiger et al., 1992). A third model
based on conserved sequence features and the inter- and intra-molecular disulfide bond pattern of
J chain was also proposed (Frutiger et al., 1992). In this model J chain contains a domain with
two antiparallel -sheets held together by two disulfide bonds, which is associated with a second
domain with both a-helical and P-strand propensities (Frutiger et al., 1992). A similar two
domain, although less specific, model with mostly P-strands, extended coils and two short a-
helices based on disulfide bonds and predicted secondary structure was recently proposed
(Johansen et al., 2001).
IgA and IgM receptors
There are two functional classes of Fc receptors (FcRs). One class of receptors is involved in
transporting Igs to specific places and protecting them from proteolytic degradation, and include
the pIgR and the neonatal Fc receptor (FcRn). The second class, consisting of the FcyRs, FceRs
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and FccaRI, is responsible for eliciting effector immune responses, such as phagocytosis,
endocytosis, ADCC, B cells activation and activation of cytokines and inflammation. Fc
receptors can also be grouped into three distinct structural groups (Wurzburg and Jardetzky,
2003) (Figure 4). The receptors in the first group are composed of tandem Ig domains and
include the IgG receptors (FcyRI, FcyRII and FcyRIII) (Hulett and Hogarth, 1994; van de Winkel
and Anderson, 1991), the high affinity IgE receptor (FcERI) (Metzger, 1991), the IgA specific
receptor (FcaRI) (Maliszewski et al., 1990), and two receptors that bind both IgA and IgM (pIgR
(Mostov et al., 1984) and Fca/[tR (Shibuya et al., 2000)). The second group resembles MHC
class I homologs, and its sole member is the IgG receptor, FcRn (Simister and Mostov, 1989).
The third group belongs to the C-type lectin superfamily and includes the low-affinity IgE
receptor (FceRII) (Kikutani et al., 1986) and the recently identified chicken FcY receptor (FcRY)
(West et al., 2004).
Polymeric Ig receptor
The most extensively studied IgA and IgM receptor is pIgR, also known as the secretory
component, which was identified almost 40 years ago as a component of pIgA isolated from
musocal secretions (Brandtzaeg, 1996). This glycoprotein was shown to occur in both a
transmembrane bound and a secreted free form, expressed by secretory epithelial cells
(Brandtzaeg, 1974; Tomasi et al., 1965). Since then, pIgR transport of J chain-containing pIgs
has been demonstrated both in vivo and in vitro. Expression of the rabbit pIgR cDNA in
polarized MDCK cells, which normally do not express pIgR, results in the basolateral expression
of pIgR and the transport of the receptor to the apical surface in a ligand-independent manner
(Mostov and Deitcher, 1986). Similar results were observed in MDCK cells transfected with the
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human pIgR cDNA (Tamer et al., 1995). Although pIgR transcytosis is constitutive, binding by
dIgA stimulates increased transcytosis (Song et al., 1994). Knocking out the mouse pIgR gene
results in a drastic increase of serum IgA, a slight increase in serum IgG and IgE, but unchanged
IgM levels (Shimada et al., 1999). Additionally, IgA levels were reduced but not negligible in
bile, feces and intestinal secretions, further suggesting dIgA is mainly transported by pIgR
although a small amount may be secreted via an alternative pathway (Shimada et al., 1999).
pIgR is a type I transmembrane glycoprotein consisting of a 620 residue extracellular
region arranged as five tandem Ig-like domains, a 23 residue transmembrane anchor and a 103
residue cytoplasmic region. Human pIgA and pIgM bind to the extracellular region of SC with
an affinity of approximately 10 nM (Natvig et al., 1997; Roe et al., 1999). Binding of human
pIgR to dIgA takes place in two steps. In the first step, the pIgR N-terminal domain (D1), which
contains regions analogous to the three antigen-binding complementarity determining regions
(CDR) loops of Ig variable domains, binds the Ca3, and possibly Cct2, domains of dIgA
(Frutiger et al., 1986; Geneste et al., 1986). In the second step, Cys467 of the human pIgR
domain 5 (D5) forms a disulfide bridge with Cys311 in the Ca2 domain of the second IgA
molecule in dIgA (Fallgreen-Gebauer et al., 1993) in a late transcytotic compartment
(Chintalacharuvu et al., 1994), however this disulfide bond does not form in all species (Knight
et al., 1975). Also, pIgM, in contrast to dIgA, does not become covalently bound to human pIgR
(Brandtzaeg, 1975a). Further, transport of pIgs by pIgR is species dependent. For example,
human pIgR binds and transports both pIgA and pIgM, but pIgR from some other species (e.g.
rabbit, rodents and chicken) only bind pIgA (Socken and Underdown, 1978; Underdown et al.,
1992; Wieland et al., 2004).
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Mutagenesis and peptide binding experiments have been used to localize the pIgR D1
regions responsible for binding pIgA and pIgM. For dIgA binding, all three pIgR D1 CDR loops
were shown to be essential, in addition to the EF loop, which is located on the opposite side of
the domain from the CDRs (Coyne et al., 1994). In pIgM binding, pIgR D1 CDR2 appears to
contribute most to the binding, however, for maximal binding the CDR1 and CDR3 loops are
also required (Roe et al., 1999). Peptide binding studies also identified residues in dIgA that
participate in binding to pIgR. The potential binding sites are in the Ca3 domain of dIgA and
involve residues 402-410 in the DE loop and residues 430-443 in the FG loop (Hexham et al.,
1999; White and Capra, 2002) (Figure 5A). Since J chain-containing pIgs are preferentially
bound and transcytosed by pIgR (Vaerman et al., 1998a), J chain may also contact pIgR directly.
The intracellular trafficking of pIgR and SIgA has been studied extensively (Rojas and
Apodaca, 2002). The 103 residue cytoplasmic tail of pIgR contains a number of cellular sorting
signals. Deletion of the cytoplasmic tail results in a truncated pIgR that is able to bind ligand,
but is transported from the Golgi apparatus directly to the apical surface where it can be cleaved
to SC (Mostov et al., 1986). Newly synthesized wild type protein is targeted from the trans-
Golgi network to the basolateral surface of epithelial cells via a 17 residue signal immediately C-
terminal to the transmembrane region (Casanova et al., 1991). pIgR-pIg complexes are initially
internalized by clathrin-coated pits and delivered to basolateral early endosomes (Mostov, 1994).
After sorting in this compartment, pIgR-pIgs are targeted to common recycling endosomes.
Next, the complex is either delivered to apical recycling and from there, or directly from the
common recycling endosome (Mostov, 1994), the protein arrives at the apical surface where
pIgR is cleaved from the cell by an unidentified protease releasing free SC or SIg. Multiple C-
terminal truncations of released pIgR have been identified, indicating multiple cleavage sites
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exist ( Eiffert et al., 1984; Asano et al., 2004). Some pIgR escapes cleavage, however, and is
internalized and delivered to apical early endosomes and recycled to either the apical surface or
the basolateral surface by a process known as reverse transcytosis. Recently, a subcomplex of
the mammalian retromer, a multimeric complex that mediates intracellular sorting of a vacuolar
enzyme-transporting receptor (VpslOp) (Seaman et al., 1998), has been implicated in the proper
sorting of pIgR (Verges et al., 2004).
Protection from pathogens has been proposed to occur at three different stages during
pIgR mediated transport of dIgA (Monteiro and Van De Winkel, 2003). As discussed
previously, SIgA in external secretions can bind and crosslink pathogens thereby slowing their
mobility and inhibiting their ability to adhere to epithelial cells (Lamm, 1997). Additionally,
SIgA can also intercept and neutralize pathogens, primarily viruses, intracellularly during
transepithelial transport, assuming the pathogen and SIgA go through the same intracellular
compartment (Mazanec et al., 1992). Finally, dIgA can bind bacteria and viruses that have
already invaded target cells at the basolateral surface of the protective epithelial layer, and pIgR
can shuttle the antibody-antigen complex to the apical surface, safely removing the pathogen
(Kaetzel et al., 1991; Lamm et al., 1992).
FcaRI
Another well-characterized IgA receptor is FcaRI (also known as CD89), which is a membrane-
bound glycoprotein with two extracellular Ig domains, a transmembrane anchor and a
cytoplasmic tail lacking recognized signaling motifs (Maliszewski et al., 1990; Monteiro and
Van De Winkel, 2003). Although FcaRI is a member of the Ig superfamily of Fc receptors, it
shares higher sequence similarity with the killer inhibitory receptors (KIRs) and the leukocyte
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Ig-like receptors (LIRs) (Wende et al., 1999). FcaRI is expressed on the surface of monocytes,
eosinophils, neutrophils and macrophages, and binds both monomeric and dimeric forms of IgA
(Monteiro and Van De Winkel, 2003). FcaRI mediates immune effector responses such as
phagocytosis, ADCC, respiratory burst and cytokine release (Monteiro et al., 1990). Monomeric
and polymeric IgA, but not SIgA, can bind FcaRI to trigger phagocytosis through the clustering
of the receptor (van Egmond et al., 2000; Vidarsson et al., 2001).
The recent crystal structures of FcctRI (Herr et al., 2003; Ding et al., 2003) and the
complex between FcaRI and IgAl-Fc (Herr et al., 2003) have shed some light on IgA-mediated
immune responses. FcaRI contains two Ig domains oriented at approximately right angles to
each other (Ding et al., 2003; Herr et al., 2003). Although the FcyRs (Maxwell et al., 1999;
Sondermann et al., 1999; Sondermann et al., 2000) and FceRI (Garman et al., 1998) also have
overall bent structures, FcaRI domains are rotated to resemble the KIR and LIR folds (Chapman
et al., 2000; Fan et al., 1997; Wurzburg and Jardetzky, 2003). Another difference between the
Fca-FcaRI structure from the Fcy-FcyRs (Sondermann et al., 2000) and FcE-FcERI (Garman et
al., 2000) structures is that the latter interact with a 1:1 stoichiometry at the hinge region,
whereas two molecules of FcaRI bind to one Fca homodimer at the Ca2-Ca3 interface (Herr et
al., 2003). This binding surface is analogous to the Cy2-Cy3 interface of Fcy, where a number of
proteins, including FcRn, bind to IgG (Martin et al., 2001). The cocrystal structure also revealed
the FcaRI binding regions on Fca, which include residues in the FG loop of the Ca3 domain of
Fca (Herr et al., 2003) (Figure 5B). This loop was shown to be one of the binding sites for pIgR
D1 (White and Capra, 2002) (Figure 5A) and is only -10A away from Fca Cys311 (Herr et al.,
2003), which forms a disulfide bond with pIgR D5. The overlapping binding site (Figure 5C),
and the close proximity of the pIgR D5 disulfide bridge, has been suggested (Herr et al., 2003) to
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explain why SIgA does not bind to or activate FcaRI in the absence of an integrin coreceptor
(van Egmond et al., 2000; Vidarsson et al., 2001).
Fca/tR
Fca/tR, a relatively recently-identified receptor, can bind to monomeric and polymeric IgA as
well as IgM (McDonald et al., 2002; Shibuya et al., 2000). It is expressed on the surface of B
lymphocytes, macrophages and mesangial cells and has been identified as a candidate for a
receptor responsible for the deposition of immune complexes in IgA nephropathy (McDonald et
al., 2002), a condition that can result in kidney failure. Fca/[tR expressed on B cells can mediate
the endocytosis of IgM-coated microbes and may therefore also play a role in antigen
presentation (Shibuya et al., 2000). Additionally, the authors suggested that uptake of IgM
through Fca/[tR plays a role in priming T helper lympyhocytes (Shibuya et al., 2000) based on
the observations that mice lacking SIgM have a delayed development of specific IgG antibodies
to T cell dependent antigens (Ehrenstein et al., 1998) and dissemination of pathogens in
peripheral but not secondary lymphoid organs (Ochsenbein et al., 1999). Sequence analysis of
Fca/[tR predicts an approximately 50 kDa extracellular region with an N-terminal Ig domain that
shares 43% sequence identity with the human pIgR D1, a transmembrane anchor, and a
cytoplasmic tail that contains a di-leucine motif in the mouse protein, which is potentially
involved in receptor internalization (Shibuya et al., 2000).
Alternative IgA receptors
The asialoglycoprotein receptor (ASGPR) and transferrin receptor (TfR) have also been shown
to interact with IgA. ASGPR, a C-type lectin, recognizes galactose and N-acetylgalactosamine
21
on desialylated glycoproteins and mediates the endocytosis of serum glycoproteins, including
IgA (Stockert et al., 1982). The ASGPR recognition site appears to be the O-linked
carbohydrates in the hinge region of IgAl (Stockert et al., 1982). ASGPR is thought to provide a
degradative pathway to maintain glycoprotein homeostasis in the blood (Stockert, 1995). TfR
(also known as CD71) has also been shown to interact with IgA1, and suggested to be involved
in tissue deposition of IgA (Moura et al., 2001). TfR was implicated in the pathogenesis of IgA
nephropathy because its expression is upregulated in cultured mesangial cells and on glomerular
mesangial cells in patients with the disease (Moura et al., 2001).
Streptococcus pneumoniae and pIgR
Treatment of human infection by gram-positive bacteria is becoming increasingly challenging
mainly due to the emergence of antibiotic-resistant bacterial strains. Streptococcus pneumoniae
(S. pneumoniae or pneumococcus), a bacterium that colonizes the upper respiratory tract is an
example of such a pathogen (Tuomanen et al., 1995). A number of pneumococcal virulence
factors have been identified including the polysaccharide capsule, cell-wall components and a
variety of bacterial proteins that facilitate adhesion and invasion, or inhibit host defense
(Jedrzejas, 2001). One of these virulence factors, the choline-binding protein, is secreted by the
pneumococcus and is anchored to the cell surface by binding to the terminal phosphorylcholine
moieties of teichoic or lipoteichoic acid structures on the bacterial cell wall (Jedrzejas, 2001).
The choline binding protein A, CbpA, is anchored to choline on the surface of S.
pneumoniae via a highly conserved choline-binding motif, which consists of about ten tandem
repeats of -20 residues at the C-terminus (Jedrzejas, 2001). CbpA was shown to be important
for bacterial adherence (Rosenow et al., 1997) and the host receptor for S. pneumoniae was
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identified as the human pIgR (Zhang et al., 2000). An insertional knockout of cbpA, or
antibodies against either CbpA or pIgR, abolished bacterial adherence and invasion, and two
CbpA domains, R1 and R2, were shown to bind to the extracellular domains of human pIgR
(Zhang et al., 2000). R1 and R2 share 89% sequence identity and are highly conserved in CbpA
from many strains of the bacteria. Peptide mapping and mutagenesis results highlighted the
importance of a conserved hexapeptide motif (YRNYPT) within the R domains (Elm et al.,
2004b; Hammerschmidt et al., 2000). Domain deletion, mutagenesis and peptide binding studies
have recently revealed that domains 3 and 4 of pIgR (D3-4) are necessary and sufficient to bind
and uptake CbpA (Elm et al., 2004a; Lu et al., 2003). Interestingly, while SIgA and free SC in
mucosal secretions inhibit pneumococcal invasion, pneumococci translocate across
nasopharyngeal epithelial cells using the pIgR reverse transcytosis pathway (Zhang et al., 2000).
When I started this project, an extensive amount of work had been done to characterize IgA-
based immunity, however there was no high-resolution structural information available for any
of the proteins involved. Shortly after I began, the crystal structures of FcaRI (Herr et al., 2003;
Ding et al., 2003) and the cocrystal structure of FcaRI-Fcct were published (Herr et al., 2003),
but the structures of pIgR, J chain, dIgA (or dFca), and CbpA remained unknown. For my thesis
project I wanted to use structural biology to contribute to the understanding of the molecular
mechanisms between these key IgA-based immunological proteins. The subsequent chapters
describe the structural characterization of the human polymeric Ig receptor and two of its binding
partners, dIgA and CbpA. In Chapter 2, I describe the 1.9 A resolution crystal structure of the N-
terminal, ligand-binding domain of pIgR (D1) and present complementary surface plasmon
resonance binding experiments between pIgR D1 and dIgA. Based on the D1 structure, I
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interpret previous mutagenesis results and make comparisons to other IgA receptors. This work
was done in collaboration with Dr. Anthony P. West, Jr. who taught me how to use the biosensor
instrument and the crystallographic software used to solve the structure. Chapter 3 describes the
solution structure of an adhesion domain (R2) of CbpA, the S. pneumoniae surface protein
responsible for pIgR binding. Additional biophysical experiments are also presented that were
used to characterize the binding properties of CbpA domains and pIgR. This work was done in
collaboration with several groups at St. Jude Children's Research Hospital. My contribution to
the project was providing purified pIgR and performing the initial binding experiments to show
that the recombinant protein was able to bind to CbpA. In Chapter 4, I describe ongoing work
toward crystallizing the full-length extracellular region of pIgR, the Fc region of J chain-
containing dIgA (dFca), CbpA, and the pIgR binding regions of CbpA, R1 and R2, all of them
alone and in complex with each other.
24
References
Armstrong, S. J., and Dimmock, N. J. (1992). Neutralization of influenza virus by low
concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion
activity, but activation of the ribonucleoprotein is also inhibited. J Virol 66, 3823-3832.
Asano, M., Takenouchi-Ohkubo, N., Matsumoto, N., Ogura, Y., Nomura, H., Suguro, H., and
Moro, I. (2004). Multiple cleavage sites for polymeric immunoglobulin receptor. Immunology
112, 583-589.
Atkin, J. D., Pleass, R. J., Owens, R. J., and Woof, J. M. (1996). Mutagenesis of the human IgAl
heavy chain tailpiece that prevents dimer assembly. J Immunol 157, 156-159.
Bastian, A., Kratzin, H., Eckart, K., and Hilschmann, N. (1992). Intra- and interchain disulfide
bridges of the human J chain in secretory immunoglobulin A. Biol Chem Hoppe Seyler 373,
1255-1263.
Bastian, A., Kratzin, H., Fallgren-Gebauer, E., Eckart, K., and Hilschmann, N. (1995). Intra- and
inter-chain disulfide bridges of J chain in human S-IgA. Adv Exp Med Biol 371A, 581-583.
Boehm, M. K., Woof, J. M., Kerr, M. A., and Perkins, S. J. (1999). The Fab and Fc fragments of
IgAl exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution
scattering and homology modelling. J Mol Biol 286, 1421-1447.
Brandtzaeg, P. (1973). Structure, synthesis and external transfer of mucosal immunoglobulins.
Ann Immunol (Paris) 124, 417-438.
Brandtzaeg, P. (1974). Presence of J chain in human immunocytes containing various
immunoglobulin classes. Nature 252, 418-420.
Brandtzaeg, P. (1975a). Human secretory immunoglobulin M. An immunochemical and
immunohistochemical study. Immunology 29, 559-570.
Brandtzaeg, P. (1975b). Immunochemical studies on free and bound J chain of human IgA and
IgM. Scand J Immunol 4, 439-450.
Brandtzaeg, P. (1996). History of oral tolerance and mucosal immunity. Ann N Y Acad Sci 778,
1-27.
Brandtzaeg, P. (2003). Mucosal immunity: integration between mother and the breast-fed infant.
Vaccine 21, 3382-3388.
Brandtzaeg, P., Karlsson, G., Hansson, G., Petruson, B., Bjorkander, J., and Hanson, L. A.
(1987). The clinical condition of IgA-deficient patients is related to the proportion of IgD- and
IgM-producing cells in their nasal mucosa. Clin Exp Immunol 67, 626-636.
25
Brewer, J. W., and Corley, R. B. (1997). Late events in assembly determine the polymeric
structure and biological activity of secretory IgM. Mol Immunol 34, 323-331.
Cann, G. M., Zaritsky, A., and Koshland, M. E. (1982). Primary structure of the immunoglobulin
J chain from the mouse. Proc Natl Acad Sci U S A 79, 6656-6660.
Casanova, J. E., Apodaca, G., and Mostov, K. E. (1991). An autonomous signal for basolateral
sorting in the cytoplasmic domain of the polymeric immunoglobulin receptor. Cell 66, 65-75.
Chapman, T. L., Heikema, A. P., West, A. P., Jr., and Bjorkman, P. J. (2000). Crystal structure
and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2).
Immunity 13, 727-736.
Chintalacharuvu, K. R., Tavill, A. S., Louis, L. N., Vaerman, J. P., Lamm, M. E., and Kaetzel, C.
S. (1994). Disulfide bond formation between dimeric immunoglobulin A and the polymeric
immunoglobulin receptor during hepatic transcytosis. Hepatology 19, 162-173.
Cleary, T. G. (2004). Human milk protective mechanisms. Adv Exp Med Biol 554, 145-154.
Coyne, R. S., Siebrecht, M., Peitsch, M. C., and Casanova, J. E. (1994). Mutational analysis of
polymeric immunoglobulin receptor/ligand interactions. Evidence for the involvement of
multiple complementarity determining region (CDR)-like loops in receptor domain I. J Biol
Chem 269, 31620-31625.
Crottet, P., and Corthesy, B. (1998). Secretory component delays the conversion of secretory IgA
into antigen-binding competent F(ab')2: a possible implication for mucosal defense. J Immunol
161, 5445-5453.
Davis, A. C., Roux, K. H., and Shulman, M. J. (1988). On the structure of polymeric IgM. Eur J
Immunol 18, 1001-1008.
Deisenhofer, J. (1981). Crystallographic refinement and atomic models of a human Fc fragment
and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A
resolution. Biochemistry 20, 2361-2370.
Ding, Y., Xu, G., Yang, M., Yao, M., Gao, G. F., Wang, L., Zhang, W., and Rao, Z. (2003).
Crystal structure of the ectodomain of human FcalphaRI. J Biol Chem 278, 27966-27970.
Ehrenstein, M. R., O'Keefe, T. L., Davies, S. L., and Neuberger, M. S. (1998). Targeted gene
disruption reveals a role for natural secretory IgM in the maturation of the primary immune
response. Proc Natl Acad Sci U S A 95, 10089-10093.
Eiffert, H., Quentin, E., Decker, J., Hillemeir, S., Hufschmidt, M., Klingmuller, D., Weber, M.
H., and Hilschmann, N. (1984). [The primary structure of human free secretory component and
the arrangement of disulfide bonds]. Hoppe Seylers Z Physiol Chem 365, 1489-1495.
26
Elm, C., Braathen, R., Bergmann, S., Frank, R., Vaerman, J. P., Kaetzel, C. S., Chhatwal, G. S.,
Johansen, F. E., and Hammerschmidt, S. (2004a). Ectodomains 3 and 4 of human polymeric
Immunoglobulin receptor (hpIgR) mediate invasion of Streptococcus pneumoniae into the
epithelium. J Biol Chem 279, 6296-6304.
Elm, C., Rohde, M., Vaerman, J. P., Chhatwal, G. S., and Hammerschmidt, S. (2004b).
Characterization of the interaction of the pneumococcal surface protein SpsA with the human
polymeric immunoglobulin receptor (hpIgR). Indian J Med Res 119 Suppl, 61-65.
Erlandsson, L., Andersson, K., Sigvardsson, M., Lycke, N., and Leanderson, T. (1998). Mice
with an inactivated joining chain locus have perturbed IgM secretion. Eur J Immunol 28, 2355-
2365.
Fallgreen-Gebauer, E., Gebauer, W., Bastian, A., Kratzin, H. D., Eiffert, H., Zimmermann, B.,
Karas, M., and Hilschmann, N. (1993). The covalent linkage of secretory component to IgA.
Structure of sIgA. Biol Chem Hoppe Seyler 374, 1023-1028.
Fan, Q. R., Mosyak, L., Winter, C. C., Wagtmann, N., Long, E. O., and Wiley, D. C. (1997).
Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic
receptors. Nature 389, 96-100.
Feinstein, A., Munn, E. A., and Richardson, N. E. (1971). The three-dimensional conformation
of M and A globulin molecules. Ann N Y Acad Sci 190, 104-121.
Frutiger, S., Hughes, G. J., Hanly, W. C., Kingzette, M., and Jaton, J. C. (1986). The amino-
terminal domain of rabbit secretory component is responsible for noncovalent binding to
immunoglobulin A dimers. J Biol Chem 261, 16673-16681.
Frutiger, S., Hughes, G. J., Paquet, N., Luthy, R., and Jaton, J. C. (1992). Disulfide bond
assignment in human J chain and its covalent pairing with immunoglobulin M. Biochemistry 31,
12643-12647.
Furtado, P. B., Whitty, P. W., Robertson, A., Eaton, J. T., Almogren, A., Kerr, M. A., Woof, J.
M., and Perkins, S. J. (2004). Solution structure determination of monomeric human IgA2 by X-
ray and neutron scattering, analytical ultracentrifugation and constrained modelling: a
comparison with monomeric human IgAl. J Mol Biol 338, 921-941.
Garcia-Pardo, A., Lamm, M. E., Plaut, A. G., and Frangione, B. (1981). J chain is covalently
bound to both monomer subunits in human secretory IgA. J Biol Chem 256, 11734-11738.
Garman, S. C., Kinet, J. P., and Jardetzky, T. S. (1998). Crystal structure of the human high-
affinity IgE receptor. Cell 95, 951-961.
Garman, S. C., Wurzburg, B. A., Tarchevskaya, S. S., Kinet, J. P., and Jardetzky, T. S. (2000).
Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha.
Nature 406, 259-266.
27
Geneste, C., Iscaki, S., Mangalo, R., and Pillot, J. (1986). Both Fc alpha domains of human IgA
are involved in in vitro interaction between secretory component and dimeric IgA. Immunol Lett
13, 221-226.
Halpern, M. S., and Koshland, M. E. (1970). Noval subunit in secretory IgA. Nature 228, 1276-
1278.
Hammerschmidt, S., Tillig, M. P., Wolff, S., Vaerman, J. P., and Chhatwal, G. S. (2000).
Species-specific binding of human secretory component to SpsA protein of Streptococcus
pneumoniae via a hexapeptide motif. Mol Microbiol 36, 726-736.
Harris, L. J., Larson, S. B., Hasel, K. W., Day, J., Greenwood, A., and McPherson, A. (1992).
The three-dimensional structure of an intact monoclonal antibody for canine lymphoma. Nature
360, 369-372.
Harris, L. J., Skaletsky, E., and McPherson, A. (1998). Crystallographic structure of an intact
IgGl monoclonal antibody. J Mol Biol 275, 861-872.
Hendrickson, B. A., Conner, D. A., Ladd, D. J., Kendall, D., Casanova, J. E., Corthesy, B., Max,
E. E., Neutra, M. R., Seidman, C. E., and Seidman, J. G. (1995). Altered hepatic transport of
immunoglobulin A in mice lacking the J chain. J Exp Med 182, 1905-1911.
Hendrickson, B. A., Rindisbacher, L., Corthesy, B., Kendall, D., Waltz, D. A., Neutra, M. R.,
and Seidman, J. G. (1996). Lack of association of secretory component with IgA in J chain-
deficient mice. J Immunol 157, 750-754.
Herr, A. B., Ballister, E. R., and Bjorkman, P. J. (2003). Insights into IgA-mediated immune
responses from the crystal structures of human FcalphaRI and its complex with IgAl-Fc. Nature
423, 614-620.
Hexham, J. M., White, K. D., Carayannopoulos, L. N., Mandecki, W., Brisette, R., Yang, Y. S.,
and Capra, J. D. (1999). A human immunoglobulin (Ig)A calpha3 domain motif directs
polymeric Ig receptor-mediated secretion. J Exp Med 189, 747-752.
Huber, R., Deisenhofer, J., Colman, P. M., Matsushima, M., and Palm, W. (1976).
Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature 264, 415-420.
Hulett, M. D., and Hogarth, P. M. (1994). Molecular basis of Fc receptor function. Adv Immunol
57, 1-127.
Janeway, C. A., Travers, P., Walport, M., and Capra, J. D. (1999). Immunobiology: the immune
system in health and disease, 4th edn (New York, Garland Publishing).
Jedrzejas, M. J. (2001). Pneumococcal virulence factors: structure and function. Microbiol Mol
Biol Rev 65, 187-207 ; first page, table of contents.
28
Johansen, F. E., Braathen, R., and Brandtzaeg, P. (2000). Role of J chain in secretory
immunoglobulin formation. Scand J Immunol 52, 240-248.
Johansen, F. E., Braathen, R., and Brandtzaeg, P. (2001). The J chain is essential for polymeric
Ig receptor-mediated epithelial transport of IgA. J Immunol 167, 5185-5192.
Kaetzel, C. S., Robinson, J. K., Chintalacharuvu, K. R., Vaerman, J. P., and Lamm, M. E.
(1991). The polymeric immunoglobulin receptor (secretory component) mediates transport of
immune complexes across epithelial cells: a local defense function for IgA. Proc Natl Acad Sci
U S A 88, 8796-8800.
Kerr, M. A. (1990). The structure and function of human IgA. Biochem J 271, 285-296.
Kett, K., Brandtzaeg, P., Radl, J., and Haaijman, J. J. (1986). Different subclass distribution of
IgA-producing cells in human lymphoid organs and various secretory tissues. J Immunol 136,
3631-3635.
Kikutani, H., Inui, S., Sato, R., Barsumian, E. L., Owaki, H., Yamasaki, K., Kaisho, T.,
Uchibayashi, N., Hardy, R. R., Hirano, T., and et al. (1986). Molecular structure of human
lymphocyte receptor for immunoglobulin E. Cell 47, 657-665.
Knight, K. L., Vetter, M. L., and Malek, T. R. (1975). Distribution of covalently bound and non-
covalently bound secretory component on sbuclasses of rabbit secretory IgA. J Immunol 115,
595-598.
Krugmann, S., Pleass, R. J., Atkin, J. D., and Woof, J. M. (1997). Structural requirements for
assembly of dimeric IgA probed by site-directed mutagenesis of J chain and a cysteine residue of
the alpha-chain CH2 domain. J Immunol 159, 244-249.
Lamm, M. E. (1997). Interaction of antigens and antibodies at mucosal surfaces. Annu Rev
Microbiol 51, 311-340.
Lamm, M. E., Robinson, J. K., and Kaetzel, C. S. (1992). Transport of IgA immune complexes
across epithelial membranes: new concepts in mucosal immunity. Adv Exp Med Biol 327, 91-94.
Lu, L., Lamm, M. E., Li, H., Corthesy, B., and Zhang, J. R. (2003). The human polymeric
immunoglobulin receptor binds to Streptococcus pneumoniae via domains 3 and 4. J Biol Chem
278, 48178-48187.
Maliszewski, C. R., March, C. J., Schoenborn, M. A., Gimpel, S., and Shen, L. (1990).
Expression cloning of a human Fc receptor for IgA. J Exp Med 172, 1665-1672.
Martin, W. L., West, A. P., Jr., Gan, L., and Bjorkman, P. J. (2001). Crystal structure at 2.8 A of
an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 7, 867-877.
29
Max, E. E., and Korsmeyer, S. J. (1985). Human J chain gene. Structure and expression in B
lymphoid cells. J Exp Med 161, 832-849.
Maxwell, K. F., Powell, M. S., Hulett, M. D., Barton, P. A., McKenzie, I. F., Garrett, T. P., and
Hogarth, P. M. (1999). Crystal structure of the human leukocyte Fc receptor, Fc gammaRIIa. Nat
Struct Biol 6, 437-442.
Mazanec, M. B., Kaetzel, C. S., Lamm, M. E., Fletcher, D., and Nedrud, J. G. (1992).
Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A
89, 6901-6905.
McDonald, K. J., Cameron, A. J., Allen, J. M., and Jardine, A. G. (2002). Expression of Fc
alpha/mu receptor by human mesangial cells: a candidate receptor for immune complex
deposition in IgA nephropathy. Biochem Biophys Res Commun 290, 438-442.
Mestecky, J., and McGhee, J. R. (1987). Immunoglobulin A (IgA): molecular and cellular
interactions involved in IgA biosynthesis and immune response. Adv Immunol 40, 153-245.
Mestecky, J., Zikan, J., and Butler, W. T. (1971). Immunoglobulin M and secretory
immunoglobulin A: presence of a common polypeptide chain different from light chains. Science
171, 1163-1165.
Metzger, H. (1991). The high affinity receptor for IgE on mast cells. Clin Exp Allergy 21, 269-
279.
Monteiro, R. C., Kubagawa, H., and Cooper, M. D. (1990). Cellular distribution, regulation, and
biochemical nature of an Fc alpha receptor in humans. J Exp Med 171, 597-613.
Monteiro, R. C., and Van De Winkel, J. G. (2003). IgA Fc receptors. Annu Rev Immunol 21,
177-204.
Morrison, S. L., and Koshland, M. E. (1972). Characterization of the J chain from polymeric
immunoglobulins (IgA-IgM-immunological specificity-primary structure). Proc Natl Acad Sci U
S A 69, 124-128.
Mosmann, T. R., Gravel, Y., Williamson, A. R., and Baumal, R. (1978). Modification and fate of
J chain in myeloma cells in the presence and absence of polymeric immunoglobulin secretion.
Eur J Immunol 8, 94-101.
Mostov, K. E. (1994). Transepithelial transport of immunoglobulins. Annu Rev Immunol 12, 63-
84.
Mostov, K. E., de Bruyn Kops, A., and Deitcher, D. L. (1986). Deletion of the cytoplasmic
domain of the polymeric immunoglobulin receptor prevents basolateral localization and
endocytosis. Cell 47, 359-364.
30
Mostov, K. E., and Deitcher, D. L. (1986). Polymeric immunoglobulin receptor expressed in
MDCK cells transcytoses IgA. Cell 46, 613-621.
Mostov, K. E., Friedlander, M., and Blobel, G. (1984). The receptor for transepithelial transport
of IgA and IgM contains multiple immunoglobulin-like domains. Nature 308, 37-43.
Moura, I. C., Centelles, M. N., Arcos-Fajardo, M., Malheiros, D. M., Collawn, J. F., Cooper, M.
D., and Monteiro, R. C. (2001). Identification of the transferrin receptor as a novel
immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA
nephropathy. J Exp Med 194, 417-425.
Natvig, I. B., Johansen, F. E., Nordeng, T. W., Haraldsen, G., and Brandtzaeg, P. (1997).
Mechanism for enhanced external transfer of dimeric IgA over pentameric IgM: studies of
diffusion, binding to the human polymeric Ig receptor, and epithelial transcytosis. J Immunol
159, 4330-4340.
Niles, M. J., Matsuuchi, L., and Koshland, M. E. (1995). Polymer IgM assembly and secretion in
lymphoid and nonlymphoid cell lines: evidence that J chain is required for pentamer IgM
synthesis. Proc Natl Acad Sci U S A 92, 2884-2888.
Norderhaug, I. N., Johansen, F. E., Schjerven, H., and Brandtzaeg, P. (1999). Regulation of the
formation and external transport of secretory immunoglobulins. Crit Rev Immunol 19, 481-508.
Ochsenbein, A. F., Fehr, T., Lutz, C., Suter, M., Brombacher, F., Hengartner, H., and
Zinkernagel, R. M. (1999). Control of early viral and bacterial distribution and disease by natural
antibodies. Science 286, 2156-2159.
Outlaw, M. C., and Dimmock, N. J. (1990). Mechanisms of neutralization of influenza virus on
mouse tracheal epithelial cells by mouse monoclonal polymeric IgA and polyclonal IgM directed
against the viral haemagglutinin. J Gen Virol 71 ( Pt 1), 69-76.
Randall, T. D., King, L. B., and Corley, R. B. (1990). The biological effects of IgM hexamer
formation. Eur J Immunol 20, 1971-1979.
Roe, M., Norderhaug, I. N., Brandtzaeg, P., and Johansen, F. E. (1999). Fine specificity of
ligand-binding domain 1 in the polymeric Ig receptor: importance of the CDR2-containing
region for IgM interaction. J Immunol 162, 6046-6052.
Rojas, R., and Apodaca, G. (2002). Immunoglobulin transport across polarized epithelial cells.
Nat Rev Mol Cell Biol 3, 944-955.
Rosenow, C., Ryan, P., Weiser, J. N., Johnson, S., Fontan, P., Ortqvist, A., and Masure, H. R.
(1997). Contribution of novel choline-binding proteins to adherence, colonization and
immunogenicity of Streptococcus pneumoniae. Mol Microbiol 25, 819-829.
31
Russell, M. W., Reinholdt, J., and Kilian, M. (1989). Anti-inflammatory activity of human IgA
antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation. Eur
J Immunol 19, 2243-2249.
Satow, Y., Cohen, G. H., Padlan, E. A., and Davies, D. R. (1986). Phosphocholine binding
immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A. J Mol Biol 190, 593-604.
Seaman, M. N., McCaffery, J. M., and Emr, S. D. (1998). A membrane coat complex essential
for endosome-to-Golgi retrograde transport in yeast. J Cell Biol 142, 665-681.
Shibuya, A., Sakamoto, N., Shimizu, Y., Shibuya, K., Osawa, M., Hiroyama, T., Eyre, H. J.,
Sutherland, G. R., Endo, Y., Fujita, T., et al. (2000). Fc alpha/mu receptor mediates endocytosis
of IgM-coated microbes. Nat Immunol 1, 441-446.
Shimada, S., Kawaguchi-Miyashita, M., Kushiro, A., Sato, T., Nanno, M., Sako, T., Matsuoka,
Y., Sudo, K., Tagawa, Y., Iwakura, Y., and Ohwaki, M. (1999). Generation of polymeric
immunoglobulin receptor-deficient mouse with marked reduction of secretory IgA. J Immunol
163, 5367-5373.
Simister, N. E., and Mostov, K. E. (1989). An Fc receptor structurally related to MHC class I
antigens. Nature 337, 184-187.
Socken, D. J., and Underdown, B. J. (1978). Comparison of human, bovine and rabbit secretory
component-immunoglobulin interactions. Immunochemistry 15, 499-506.
Sondermann, P., Huber, R., and Jacob, U. (1999). Crystal structure of the soluble form of the
human fcgamma-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A
resolution. Embo J 18, 1095-1103.
Sondermann, P., Huber, R., Oosthuizen, V., and Jacob, U. (2000). The 3.2-A crystal structure of
the human IgG Fc fragment-Fc gammaRIII complex. Nature 406, 267-273.
Song, W., Bomsel, M., Casanova, J., Vaerman, J. P., and Mostov, K. (1994). Stimulation of
transcytosis of the polymeric immunoglobulin receptor by dimeric IgA. Proc Natl Acad Sci U S
A 91, 163-166.
Stockert, R. J. (1995). The asialoglycoprotein receptor: relationships between structure, function,
and expression. Physiol Rev 75, 591-609.
Stockert, R. J., Kressner, M. S., Collins, J. C., Sternlieb, I., and Morell, A. G. (1982). IgA
interaction with the asialoglycoprotein receptor. Proc Natl Acad Sci U S A 79, 6229-6231.
Suh, S. W., Bhat, T. N., Navia, M. A., Cohen, G. H., Rao, D. N., Rudikoff, S., and Davies, D. R.
(1986). The galactan-binding immunoglobulin Fab J539: an X-ray diffraction study at 2.6-A
resolution. Proteins 1, 74-80.
32
Svehag, S. E., and Bloth, B. (1970). Ultrastructure of secretory and high-polymer serum
immunoglobulin A of human and rabbit origin. Science 168, 847-849.
Takahashi, T., Iwase, T., Takenouchi, N., Saito, M., Kobayashi, K., Moldoveanu, Z., Mestecky,
J., and Moro, I. (1996). The joining (J) chain is present in invertebrates that do not express
immunoglobulins. Proc Natl Acad Sci U S A 93, 1886-1891.
Tamer, C. M., Lamm, M. E., Robinson, J. K., Piskurich, J. F., and Kaetzel, C. S. (1995).
Comparative studies of transcytosis and assembly of secretory IgA in Madin-Darby canine
kidney cells expressing human polymeric Ig receptor. J Immunol 155, 707-714.
Tomasi, T. B., Jr., Tan, E. M., Solomon, A., and Prendergast, R. A. (1965). Characteristics of an
Immune System Common to Certain External Secretions. J Exp Med 121, 101-124.
Tuomanen, E. I., Austrian, R., and Masure, H. R. (1995). Pathogenesis of pneumococcal
infection. N Engl J Med 332, 1280-1284.
Underdown, B. J., Switzer, I., and Jackson, G. D. (1992). Rat secretory component binds poorly
to rodent IgM. J Immunol 149, 487-491.
Vaerman, J. P., Langendries, A., Giffroy, D., Brandtzaeg, P., and Kobayashi, K. (1998a). Lack of
SC/pIgR-mediated epithelial transport of a human polymeric IgA devoid of J chain: in vitro and
in vivo studies. Immunology 95, 90-96.
Vaerman, J. P., Langendries, A., and Vander Maelen, C. (1995). Homogenous IgA monomers,
dimers, trimers and tetramers from the same IgA myeloma serum. Immunol Invest 24, 631-641.
Vaerman, J. P., Langendries, A. E., Giffroy, D. A., Kaetzel, C. S., Fiani, C. M., Moro, I.,
Brandtzaeg, P., and Kobayashi, K. (1998b). Antibody against the human J chain inhibits
polymeric Ig receptor-mediated biliary and epithelial transport of human polymeric IgA. Eur J
Immunol 28, 171-182.
Van de Perre, P. (2003). Transfer of antibody via mother's milk. Vaccine 21, 3374-3376.
van de Winkel, J. G., and Anderson, C. L. (1991). Biology of human immunoglobulin G Fc
receptors. J Leukoc Biol 49, 511-524.
van Egmond, M., van Garderen, E., van Spriel, A. B., Damen, C. A., van Amersfoort, E. S., van
Zandbergen, G., van Hattum, J., Kuiper, J., and van de Winkel, J. G. (2000). FcalphaRI-positive
liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med 6,
680-685.
Verges, M., Luton, F., Gruber, C., Tiemann, F., Reinders, L. G., Huang, L., Burlingame, A. L.,
Haft, C. R., and Mostov, K. E. (2004). The mammalian retromer regulates transcytosis of the
polymeric immunoglobulin receptor. Nat Cell Biol 6, 763-769.
33
Vidarsson, G., van Der Pol, W. L., van Den Elsen, J. M., Vile, H., Jansen, M., Duijs, J., Morton,
H. C., Boel, E., Daha, M. R., Corthesy, B., and van De Winkel, J. G. (2001). Activity of human
IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J
Immunol 166, 6250-6256.
Wan, T., Beavil, R. L., Fabiane, S. M., Beavil, A. J., Sohi, M. K., Keown, M., Young, R. J.,
Henry, A. J., Owens, R. J., Gould, H. J., and Sutton, B. J. (2002). The crystal structure of IgE Fc
reveals an asymmetrically bent conformation. Nat Immunol 3, 681-686.
Wende, H., Colonna, M., Ziegler, A., and Volz, A. (1999). Organization of the leukocyte
receptor cluster (LRC) on human chromosome 19q13.4. Mamm Genome 10, 154-160.
West, A. P., Jr., Herr, A. B., and Bjorkman, P. J. (2004). The chicken yolk sac IgY receptor, a
functional equivalent of the mammalian MHC-related Fc receptor, is a phospholipase A2
receptor homolog. Immunity 20, 601-610.
White, K. D., and Capra, J. D. (2002). Targeting mucosal sites by polymeric immunoglobulin
receptor-directed peptides. J Exp Med 196, 551-555.
Wieland, W. H., Orzaez, D., Lammers, A., Parmentier, H. K., Verstegen, M. W., and Schots, A.
(2004). A functional polymeric immunoglobulin receptor in chicken (Gallus gallus) indicates
ancient role of secretory IgA in mucosal immunity. Biochem J 380, 669-676.
Wiersma, E. J., Chen, F., Bazin, R., Collins, C., Painter, R. H., Lemieux, R., and Shulman, M. J.
(1997). Analysis of IgM structures involved in J chain incorporation. J Immunol 158, 1719-1726.
Wiersma, E. J., Collins, C., Fazel, S., and Shulman, M. J. (1998). Structural and functional
analysis of J chain-deficient IgM. J Immunol 160, 5979-5989.
Wilson, I. A., Rini, J. M., Fremont, D. H., Fieser, G. G., and Stura, E. A. (1991). X-ray
crystallographic analysis of free and antigen-complexed Fab fragments to investigate structural
basis of immune recognition. Methods Enzymol 203, 153-176.
Wold, A. E., Mestecky, J., Tomana, M., Kobata, A., Ohbayashi, H., Endo, T., and Eden, C. S.
(1990). Secretory immunoglobulin A carries oligosaccharide receptors for Escherichia coli type
1 fimbrial lectin. Infect Immun 58, 3073-3077.
Wurzburg, B. A., Garman, S. C., and Jardetzky, T. S. (2000). Structure of the human IgE-Fc C
epsilon 3-C epsilon 4 reveals conformational flexibility in the antibody effector domains.
Immunity 13, 375-385.
Wurzburg, B. A., and Jardetzky, T. S. (2003). The IgA receptor complex: a two-for-one deal. Nat
Struct Biol 10, 585-587.
34
Yoo, E. M., Coloma, M. J., Trinh, K. R., Nguyen, T. Q., Vuong, L. U., Morrison, S. L., and
Chintalacharuvu, K. R. (1999). Structural requirements for polymeric immunoglobulin assembly
and association with J chain. J Biol Chem 274, 33771-33777.
Zhang, J. R., Mostov, K. E., Lamm, M. E., Nanno, M., Shimida, S., Ohwaki, M., and Tuomanen,
E. (2000). The polymeric immunoglobulin receptor translocates pneumococci across human
nasopharyngeal epithelial cells. Cell 102, 827-837.
Zikan, J., Mestecky, J., Kulhavy, R., and Bennett, J. C. (1986). The stoichiometry of J chain in
human secretory dimeric IgA. Mol Immunol 23, 541-544.
Zikan, J., Novotny, J., Trapane, T. L., Koshland, M. E., Urry, D. W., Bennett, J. C., and
Mestecky, J. (1985). Secondary structure of the immunoglobulin J chain. Proc Natl Acad Sci U S
A 82, 5905-5909.
35
Apical
surface
I Tight Junction SIgA pIgR
~ or Dimeric gA pgR
Figure 1. Model for pIgR transcytosis. Newly synthesized pIgR is expressed on the basolateral
surface of epithelial cells where it binds to dIgA secreted by local plasma cells in the lamina
propria. pIgR-dIgA complexes are initially internalized by clathrin-coated pits (1) and are
delivered to the apical surface (2) where pIgR is cleaved from the cell releasing SIgA (3) or free
SC (4). pIgR that escapes cleaveage is internalized (5), and recycled to either the apical surface
(6) or the basolateral surface by a process known as reverse transcytosis (7).
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Figure 2. Crystal structures of Fc fragments. Ribbon diagrams showing front views of (A)
Fcct(PDB code lOWO), (B) Fcy (PDB code 1DN2), and (C) FcE (PDB code 1O0V). One
monomer in each Fc homodimer is shown in green, the other in blue. N-linked carbohydrates are
shown in magenta and disulfide bonds are yellow in ball-and-stick representation.
Hil •
AFigure 3. Putative models for the structures of dIgA, plgM and SIgA. Monomeric Igs are
composed of two light chains (yellow) and two heavy chains (blue). One molecule of J chain
(pink) bridges two IgA molecules in an end-to-end arrangement to form dIgA (A), or five IgM
molecules in a cyclic configuration to form plgM (B). One molecule of plgR D1-5 (red) binds
noncovalently to Ca3 (and possibly Ca2) of one IgA via D and covalently to Ca2 in the second
IgA molecule in dIgA via D5, to form SIgA (C). Red spheres in (A) and (B) indicate tailpiece-
tailpiece and tailpiece-J chain disulfide bonds. Figure adapted from (Rojas and Apodaca, 2002).
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Figure 4. Schematic representation of the three structural groups of Fc receptors. The first group
is composed of tandem Ig domains, and include the FcyRs (FcyRI, FcyRII and FcyRIII), the high
affinity IgE receptor (FcERI), the IgA specific receptor (FcaRI), and two receptors that bind both
IgA and IgM (pIgR and Fca/[tR) (A). FcRn resembles MHC class I homologs (B) and the third
group belongs to the C-type lectin superfamily and includes the low-affinity IgE receptor
(FceRII) (FceRII) and the chicken FcY receptor (FcRY).
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Figure 5. Receptor binding sites on Fca. The two monomers in the Fca homodimer structure
are colored grey and light grey. The residues in the Ca3 domain implicated in binding to plgR
D1 are shown in blue (A) and the residues involved in binding to FcaRI are shown in green.
Overlapping residues in the two binding sites are shown in red (C). Circles in (A) indicate
Cys311 (yellow) in Ca2, the residue that forms a disulfide bond with plgR D5.
CHAPTER 2
Crystal Structure of a Polymeric Immunoglobulin-Binding Fragment of the Human
Polymeric Immunoglobulin Receptor
This chapter describes the 1.9 A resolution crystal structure of pIgR D1 and characterization of
the interaction between D1 and dimeric IgA. My contribution to this work included construction
of the pIgR D1 and Fca-tp expression vectors, establishing a stable mammalian cell line
expressing Fca-tp, protein purification, performing the binding experiments, crystallization of
D1, data collection and solving the structure of D1. Dr. Anthony P. West Jr. taught me how to
use the biosensor instrument and the crystallographic software used to solve the structure.
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Summary
The polymeric immunoglobulin receptor (pIgR) is a type I transmembrane protein that delivers
dimeric IgA (dIgA) and pentameric IgM to mucosal secretions. Here, we report the 1.9 A
resolution X-ray crystal structure of the N-terminal domain of human pIgR, which binds dIgA in
the absence of other pIgR domains with an equilibrium dissociation constant of 300 nM. The
structure of pIgR domain 1 reveals a folding topology similar to immunoglobulin variable
domains, but with differences in the counterparts of the complementarity determining regions
(CDRs), including a helical turn in CDR1 and a CDR3 loop that points away from the other
CDRs. The unusual CDR3 loop position prevents dimerization analogous to the pairing of
antibody variable heavy and variable light domains. The pIgR domain 1 structure allows
interpretation of previous mutagenesis results and structure-based comparisons between pIgR
and other IgA receptors.
Introduction
Polymeric immunoglobulins (pIgs) at mucosal surfaces provide the first line of defense against
pathogens and toxins. Polymeric IgA (mainly dimeric IgA; dIgA) is the predominant Ig found in
secretions, with pentameric IgM (pIgM) present at lower levels (Norderhaug et al., 1999b).
Unlike other antibody isotypes, IgA and IgM can form polymers via an 18-residue extension at
their C termini called the tailpiece. The joining (J) chain, a 15 kDa polypeptide, promotes the
oligomerization of IgA and IgM to form pIgs by cross-linking the homodimeric Fc regions of
two or five antibody molecules, respectively (Halpern and Koshland, 1970; Mestecky et al.,
1971). In dIgA, J-chain forms two intermolecular disulfide bonds, the first with one of two
tailpieces in the first Fc homodimer and the second with a tailpiece from the second Fc
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homodimer. The two IgA heavy chains that are not covalently attached to J-chain form a
disulfide bond to each other via Cys471 in their tailpieces (Bastian et al., 1992).
The polymeric immunoglobulin receptor (pIgR) transports pIgs across mucosal epithelia
into mucosal secretions. pIgR is expressed on the basolateral surface of epithelial cells, where it
binds selectively to J-chain-containing pIgs secreted by local plasma cells (Brandtzaeg and
Prydz, 1984; Radl et al., 1971; Vaerman et al., 1998a). Human pIgR binds and transports both
dIgA and pIgM, whereas pIgRs from other species (e.g., rabbit, rodents and chicken) only bind
dIgA (Socken and Underdown, 1978; Underdown et al., 1992; Wieland et al., 2004).
Biochemical and mutagenesis studies revealed that pIgR binding to dIgA takes place in two
steps. First, the N-terminal pIgR domain (D1) makes a noncovalent interaction with the Ca3,
and possibly Ca2, domains of one of the Fc regions of dIgA (Frutiger et al., 1986; Geneste et al.,
1986; Hexham et al., 1999). In the second step, Cys467 in the C-terminal domain of the
extracellular portion of human pIgR (D5) makes a disulfide bond with Cys311 in the Ca2
domain of the second IgA molecule (Fallgreen-Gebauer et al., 1993). pIgR/pIg complexes are
transcytosed to the apical surface of the epithelial monolayer, where the pIgR/pIg complex is
released from the membrane by the proteolytic cleavage of pIgR, forming secretory Ig (SIg).
The cleaved ectodomain of human pIgR, also known as secretory component (SC), is covalently
attached via a disulfide bond to dIgA or noncovalently to pIgM (Brandtzaeg, 1975; Mostov et al.,
1980). Free SC that is not complexed to a pIg is also released into secretions (Brandtzaeg,
1973).
pIgR is a glycosylated type I transmembrane protein, consisting of a 620 residue
extracellular region, a 23 residue transmembrane region and a 103 residue cytoplasmic tail. The
extracellular region contains five domains (domains 1-5; D1-D5) that share sequence similarity
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with Ig variable (V) regions (Mostov et al., 1984). Thus, the pIgR D1-D5 domains are predicted
to be 13 sandwich structures each containing two j3 sheets (composed of strands A, B, E, and D
and strands C", C', C, F, G and A' in the case of D1 -D4, and strands A, B, E, D and strands A',
C, F, and G in the case of D5). D1-D4 each contain regions homologous to the three antigen
binding complementarity-determining region (CDR) loops of Ig variable domains.
Mutagenesis and peptide binding studies have identified probable binding sites on pIgR
and dIgA. pIgR D1 is necessary and sufficient for binding to dIgA (Frutiger et al., 1986) and all
three of its CDR loops have been implicated in the interaction with the antibody (Coyne et al.,
1994). Potential pIgR binding sites on dIgA involve the dIgA Ca3 domain and include residues
402-410 in the loop connecting strands D and E and residues 430-443 in the FG loop (Hexham et
al., 1999; White and Capra, 2002). Since pIgR preferentially binds and transcytoses dIgA
molecules containing J-chain, pIgR D1 may also directly interact with J-chain (Brandtzaeg and
Prydz, 1984; Vaerman et al., 1998a; Vaerman et al., 1998b). In order to contribute to the
molecular description of the interaction between pIgR and pIgs, we determined the 1.9 A crystal
structure of a pIg binding fragment of the human pIgR consisting of the N-terminal or D1
domain. The structure reveals an Ig variable-like domain that allows interpretation of previous
mutagenesis studies and comparison with other IgA receptors.
Results and Discussion
Biosensor Binding Experiments
The ligand binding domain of human pIgR, an Fc receptor that is specific for dimeric and
polymeric forms of IgA and IgM, was expressed in E. coli and refolded from inclusion bodies.
A glycosylated form of the protein was also expressed in baculovirus-infected insect cells. D1
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was tested for binding to dimeric and monomeric versions of the IgA Fc region. For the dimeric
version of IgA, we used dIgA/J-chain complexes purified from human serum (Vaerman et al.,
1995), and for the monomeric version, we used recombinant IgA Fc regions expressed in CHO
cells. One Fc region was expressed without the tailpiece (Fca) as described (Herr et al., 2003b),
and the other Fc region included the tailpiece (Fca-tp). Binding was evaluated using a surface
plasmon resonance-based binding assay. Both the glycosylated and nonglycosylated forms of
D1 bind to dIgA with an equilibrium dissociation constant (KD) of -300 nM (Figure 1A),
consistent with other binding studies (Bakos et al., 1994). Both versions of D1 show greatly
reduced or negligible binding to the monomeric Fca and Fca-tp proteins at concentrations up to
5 tM (Figure B). By contrast, another IgA Fc receptor, FcaRI, binds dIgA, Fca-tp and Fcca
when injected at a concentration of 5 FM (data not shown) (Herr et al., 2003b).
Structure of pIgR D1
The 1.9 A crystal structure of the human pIgR D1 was solved by multiple isomorphous
replacement with anomalous scattering (MIRAS). As predicted by sequence analysis, the
folding topology of pIgR D1 resembles the topologies of Ig variable heavy (VH) and variable
light (VL) domains (Mostov et al., 1984). Like Ig variable domains, pIgR D1 contains ten 3
strands assembled into two antiparallel sheets with strands A, B, E and D on one face and C",
C', C, F, G and A' on the other (Figure 2A-2C). Five residues that are characteristic of Ig
regions (Williams and Barclay, 1988) are found in the expected positions in pIgR DI: Cys22 and
Cys92, which form a disulfide bond linking the two 13 sheets, Trp37, the "invariant" tryptophan
(Figure 2D) that packs into the hydrophobic core, and Arg63 and Asp86, which form a salt
bridge (Figure 3). In addition, pIgR D1 contains a second disulfide bond between Cys38 and
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Cys46 that link the C and C' strands, which is also found in NKp44, a natural killer cell
cytotoxicity activating receptor (Cantoni et al., 2003).
Antibody VH and VL domains each contain three hypervariable complementarity-
determining region (CDR) loops (CDR1, CDR2, and CDR3), which together form the antigen
combining site in a VH-VL heterodimer (Alzari et al., 1988). Although the pIgR D1 structure
closely resembles an isolated Ig variable domain, the positions of the three CDR loops in D1
differ substantially from their antibody counterparts. Comparative analyses of the CDR regions
in antibody structures have allowed classification of CDR loops into a set of canonical structures
(Chothia and Lesk, 1987). Although the sequence of the D1 CDR1 loop shares similarity with
sequences found in type 1 of the six canonical CDR1 structures in Ig VK domains (Bakos, 1993),
the CDR1 structure in pIgR D1 differs considerably. Unlike any of the canonical structures for
CDR1 loops in VL or VH domains (Al-Lazikani et al., 1997), the pIgR D1 CDR1 includes a
single helical turn composed of residues that are highly conserved among sequences of pIgR
from different species (Figure 3). By contrast, CDR1 loops in VH and VL domains are composed
of extended structures joined by short links or hairpin turns (Chothia et al., 1989). CDR2 and
CDR3 in pIgR D1 do not appear to resemble any of the canonical sequence or structure patterns.
The pIgR CDR2 loop is very short, with only two residues in the loop region between the C' and
C" strands. By contrast, CDR2 loops in VK domains consist of three residues that form a classic
y-turn (Al-Lazikani et al., 1997). Unlike its position in antibody VH and VL domains, the CDR3
loop of pIgR D1 is tilted toward the C"C'CFGA' sheet, away from the other CDRs (Figure 4A).
A conserved hydrophobic residue, Tyr36, is buried at the interface of the D1 CDR3 and the
C"C'CFGA' sheet (Figure 4B). The position of the CDR3 loop is stabilized by hydrogen bonds
between Asn97 within the loop and two residues on the C"C'CFGA' sheet: Arg34 in the C strand
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and Thr48 in the C' strand. The observed conformation of the D1 CDR3 loop is likely to
represent its conformation in solution because the loop is not involved in crystal contacts. The
different orientation of the pIgR CDR3 loop as compared to the CDR3 loops of Ig V domains
(Figure 4A) is consistent with why D1 does not form dimers analogous to antibody VH-VL
heterodimers (Figure 4C) or VL-VL homodimers. When pIgR D1 is superimposed on an Ig VH-
VL combining site (Zdanov et al., 1994) (Figure 4C) to create a D1 dimer, the CDR3 regions
clash with the CC' loop from the partner molecule (Figure 4D). Although two different dimers
of pIgR D1 are observed in the crystal packing, neither is analogous to Ig VH-VL dimers. The D1
dimers in the crystals are unlikely to be biologically relevant because there are two different
dimeric arrangements and the D1 protein migrates in the position expected for a monomer on a
gel filtration column (data not shown).
Although the protein used for our structural studies is not glycosylated because it was
expressed in bacteria, the pIgR D1 structure can be used to locate residues to which carbohydrate
would normally be attached. Human pIgR D1 contains two N-linked carbohydrates attached to
Asn65 and Asn72 (Hughes et al., 1999). These residues are located on the D strand and the DE
loop, respectively, and their sidechains are accessible to solvent (Figure 2B). Studies comparing
the binding of bacterially expressed nonglycosylated D1 with glycosylated D1 expressed in
insect cells revealed nearly identical binding affinities for dIgA (Figure 1A), consistent with
earlier studies showing that pIgR glycosylation is not necessary for specific binding to dIgA
(Bakos et al., 1991). Carbohydrates may be required, however, for efficient transport or release
of the pIgR ectodomain during transcytosis of dIgA, since nonglycosylated pIgR is released from
the apical surface at low levels (Matsumoto et al., 2003). In addition, carbohydrates on SC
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contribute to stabilization of SIgs by protecting it from proteolytic degradation (Crottet and
Corthesy, 1998).
Structure-Based Interpretations of Binding Studies
Previous mutational and peptide-mapping experiments to define the regions of pIgR that form
the binding sites for dIgA and pIgM can now be interpreted using the pIgR D1 structure. CDR1
of pIgR D1 was proposed to make essential contacts with dIgA because it is the most highly
conserved region of D1 among different species of pIgR, and a synthetic peptide corresponding
to residues 15-37 of SC, a region that contains the D1 CDR1 loop, is capable of binding pIgs
(Bakos et al., 1991). Interestingly, this peptide binds Igs indiscriminately, interacting with pIgs
as well as with monomeric IgA and IgG (Bakos et al., 1991). The promiscuous binding of this
peptide suggests that other parts of D1, in addition to the CDR1 loop, likely contribute to pIg
binding specificity. The D1 structure reveals a solvent-exposed helix within the CDR1 loop
containing residues with the potential to make direct contacts with pIgs (Figure 5).
Point mutations in the CDR1 region of the rabbit pIgR D1 highlighted the importance of
three charged residues (two arginines and a lysine, which correspond to Arg31, Arg34 and Lys35
in the sequence of human pIgR D1). Substitution of these residues with alanine abolished pIgR
binding to dIgA (Coyne et al., 1994). The human pIgR D1 structure shows that Arg31 (rabbit
Arg37) is solvent exposed and could interact directly with dIgA. Although Arg34 and Lys35
were predicted to be in the CDR1 loop (Coyne et al., 1994), an analysis of main chain hydrogen
bonds in the D1 structure shows that they are both in the C strand. Arg34 is the first residue in
the strand, as its main chain carbonyl group forms a hydrogen bond with the main chain amino
group of Gly95 in the F strand. Human D1 Arg34 (rabbit Arg40) points in the opposite direction
from Arg31 and is occluded by the CDR3 loop, forming a hydrogen bond to CDR3 loop residue
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Asn97 (Figure 4B). Arg34 is thus unlikely to interact directly with a ligand, but may affect
ligand binding indirectly by stabilizing the CDR3 loop. This interpretation is consistent with the
results of mutagenesis experiments involving rabbit pIgR in which replacing the rabbit
counterpart of Arg34 with a glutamic acid, a residue that can still form a hydrogen bond with
Asn97 in CDR3, had no affect on ligand binding, whereas substitution to an alanine, which
cannot form the hydrogen bond, abolished binding (Coyne et al., 1994). Lys35 (rabbit Lys41) is
buried between the two j3 sheets and is also unlikely to represent a direct point of contact with
the antibody. However, it stabilizes the position of the CDR1 loop by forming hydrogen bonds
with Arg31 and Thr33 in the conserved helical turn in the CDR1 loop (Figure 5). Single point
mutations in surrounding residues corresponding to human pIgR residues Thr27, Ser28, Asn30,
His32 and Thr33 resulted in decreased dIgA binding (Coyne et al., 1994). Residues Ser28
through His32 comprise the helical turn in CDR1 and, together with the adjacent Thr27 and
Thr33, are surface exposed in positions that could interact with dIgA directly. The rabbit
counterpart of human D1 Val29 was not substituted because it was predicted to be buried (Bakos
et al., 1993; Coyne et al., 1994), however the crystal structure reveals that it is a surface-exposed
residue located on the helix within the CDR1 loop (Figure 5). Although its role in binding dIgA
is difficult to predict because it points in the opposite direction from another critical residue,
Arg31, solvent-exposed hydrophobic residues are often located at binding interfaces (Dall'Acqua
et al., 1996; Kelley and O'Connell, 1993; Lebron and Bjorkman, 1999; Tsumoto et al., 1995;
Vaughn et al., 1997; Wells and de Vos, 1996).
In addition to CDR1, mutagenesis and binding experiments using rabbit pIgR have
implicated the other CDRs in binding dIgA. Replacing the CDR2 or CDR3 regions in D1 with
their corresponding regions from D2 results in complete loss of dIgA binding (Coyne et al.,
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1994). The human pIgR D1 structure reveals that CDR3 is positioned away from the other
CDRs (Figure 2B), unlike the CDR3 loops of Ig V domains, which form a contiguous binding
surface with CDRs 1 and 2 (Alzari et al., 1988). It may therefore be difficult for a ligand
contacting the CDR1 and CDR2 regions of pIgR D1 to simultaneously contact CDR3. Thus it is
possible that the loss of affinity upon replacing the D1 CDR3 with another sequence may be due
to steric interference with dIgA binding rather than alteration of a direct binding surface. The
results of other loop replacements are harder to interpret using the pIgR D1 structure: replacing
the rabbit D1 EF loop with its counterpart in D2 led to the loss of dIgA binding, whereas
replacing the C"D loop had little effect (Coyne et al., 1994). Both loops are on the opposite side
of the D1 domain from the CDRs (Figure 5) and are not expected to contact the ligand.
Although human pIgR binds both dIgA and pIgM, rabbit pIgR only binds dIgA (Roe et
al., 1999; Socken and Underdown, 1978). By taking advantage of these binding differences,
studies using site-directed mutants and human/rabbit chimeric pIgR molecules have identified
regions required for binding pIgM (Roe et al., 1999). All three CDR loops were shown to
contribute to binding pIgM, but to different extents. For maximal binding of rabbit pIgR to
pIgM, replacing all three CDR loops with their human counterparts was required, but CDR2
appears to be the most critical: replacing rabbit CDR2 with the human equivalent transferred
pIgM binding, and replacing human CDR2 with the rabbit sequence resulted in substantial loss
of binding (Roe et al., 1999). Sequence alignment shows large differences in the human and
rabbit CDR2 loops, including a deletion of a charged residue, Glu54, in the rabbit CDR2 (Figure
3). Thus, deletion of the surface-exposed Glu54 may eliminate a point of electrostatic interaction
between pIgR and pIgM. Interestingly, only bovine and human pIgR D1 regions contain the
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glutamic acid in their CDR2 loops (Figure 3), and these are the only species of pIgR that show
high affinity pIgM binding (Socken and Underdown, 1978).
The Human pIgR D1 Structure as a Model for Similar Domains
Amino acid sequence alignment of pIgR D1 sequences from eight different species reveals
conservation of residues identified as critical for the human pIgR D1 structure (Figure 3), thus
the human pIgR D1 structure can be used as a first-order model for the D1 domains of pIgR
proteins from other species. In addition to the five residues characteristic of Ig V domains
(asterisks in Figure 3), the cysteines that participate in the second disulfide bond and the three
CDR loops (which are 67-100% conserved in CDR1, 50-100% in CDR2 and 40-80% in CDR3),
residues that participate in anchoring the CDR1 and CDR3 loops are also highly conserved. All
of the residues comprising the helical turn in CDR1 are either conserved or conservatively
substituted in all eight species, and Lys35, a buried residue that stabilizes the helix, is also
conserved (Figure 3). Tyr36, the residue buried under the CDR3 loop (Figure 4B), is conserved
in 7 of 8 species of pIgR, and conservatively substituted by a phenylalanine in the eighth species
(rabbit) (Figure 3). Three other residues that interact to stabilize the CDR3 loop position are
either conserved or conservatively substituted in D1 sequences: CDR3 residue Asn97 (a polar
residue in all sequences), Arg34 (conserved), and Thr48 (conserved) (Figure 3). Conservation of
these critical residues suggests that the helical turn in CDR1 and the unusual CDR3 location
observed in the human pIgR D1 structure are preserved in other pIgR D1 domains. The most
notable difference in the D1 sequence alignments is seen in the CC' loop in all of the sequences.
The pIgR D1 structure can also be used to make predictions about the structures of the
remaining domains in the human pIgR extracellular region. The characteristic disulfide bond
seen in members of the Ig superfamily (Williams and Barclay, 1988) is retained in all five
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domains. Also, pIgR domains 3, 4 and 5 each contain cysteines in positions to make the second
disulfide bond that bridges the C and C' f strands of D1 (Figure 2C). In addition, D5 contains a
third disulfide bond that rearranges as a result of the covalent association with dIgA, whereby
Cys467 of pIgR is linked to Cys311 in the IgA heavy chain (Fallgreen-Gebauer et al., 1993).
The characteristic salt-bridge in Ig-like domains, which involves Arg63 and Asp86 in D1, is
conserved in D2-D4, and the "invariant" tryptophan is present in D4 and D5 (Figure 3). By
contrast with these conserved sequence features, which suggest an overall similar folding
topology to that observed for the human D1 structure, the three CDR loops in human pIgR D1 do
not share significant sequence identity with their counterparts in D2-D5 (Figure 3), suggesting
local differences in loop structures. Such differences are not unexpected since the CDR loops
are implicated in binding to dIgA, and only D1 can bind to dIgA in isolation (Frutiger et al.,
1986). Overall, the sequences of D2-D5 are more variable than D1 across species (Piskurich et
al., 1995). This observation is not surprising given the differences across species that D2-D5
make to dIgA binding. In the case of human pIgR, D2 and D3 enhance pIgR's affinity for dIgA
(Norderhaug et al., 1999a). The presence of D2-D3 in bovine pIgR also increases ligand binding
affinity (Beale, 1988), but D2-D5 in rabbit pIgR do not contribute significantly to dIgA binding
(Frutiger et al., 1986). Thus, the full length ectodomain (D1-D5), an alternatively spliced
version (lacking D2-D3), and D1 of rabbit pIgR bind to pIgs with similar affinities (Deitcher and
Mostov, 1986; Frutiger et al., 1986). Murine pIgR D2-D3 are not necessary for high affinity
noncovalent binding to dIgA (Crottet and Corthesy, 1999), and chicken pIgR contains only four
extracellular Ig-like domains, with no ortholog to D2 of mammalian pIgRs (Wieland et al.,
2004).
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Sequence alignment suggests that human pIgR D1 also shares structural similarities with
the corresponding region of another IgA and IgM receptor, the Fca/!x receptor (Fca/!pR) (Figure
3) (Shibuya et al., 2000). Fca/!R, which can bind to monomeric and polymeric IgA and IgM,
but not IgG, is expressed by the majority of B lymphocytes and macrophages (McDonald et al.,
2002; Shibuya et al., 2000). Human pIgR D1 and the Ig-like domain of Fca/xR share 43%
sequence identity. The five characteristic residues in Ig V domains (Figure 3) and the second
disulfide bond linking strands C and C' are conserved between pIgR D1 and Fca/tR, suggesting
similar tertiary structures. In addition, Fca/!tR shares 67% sequence identity with pIgR D1 in
one of the identified ligand binding sites, the CDR1 loop, including complete conservation of all
of the residues that comprise the helical turn within this loop in pIgR D1. The unusual CDR3
position is potentially another feature shared by the two proteins since the buried D1 residues
Tyr36, Arg34 and Thr48 are conserved in Fca/IR, and D1 Asn97 is replaced by a glutamic acid.
A hydrogen bond between Fca/!xR Glu97 and Thr48 (analogous to the Asn97 to Thr48 hydrogen
bond in pIgR D1) and a salt bridge between Fca/iiR Glu97 and Arg34 (replacing the hydrogen
bond in pIgR D1 between Asn97 and Arg34) (Figure 4B) would preserve the downward
orientation of the CDR3 loop. The overall conservation of structurally important residues within
the CDR loops of Fca/iR and pIgR D1 suggests a similar mode of interaction with the common
ligands of these receptors.
Another IgA receptor, FcacRI, shares an overlapping binding site on the IgA Fc region
with pIgR that includes the FG loop of Fca (Herr et al., 2003a; Hexham et al., 1999; White and
Capra, 2002). The overlap of the binding site has been suggested (Herr et al., 2003a) to explain
why secretory IgA (dIgA plus the pIgR ectodomain) cannot bind to or activate FcaRI in the
absence of an integrin co-receptor (van Egmond et al., 2000; Vidarsson et al., 2001). Although
54
pIgR and FcaRI appear to recognize at least some of the same portion of Fca, their structures do
not share detailed common features beyond the fact that both molecules are Ig superfamily
members. The crystal structure of an FcaRI/Fca complex shows that the site on FcctRI at the
interface with Fca involves residues in the FcaRI BC loop, the D strand, the DE loop, and the
FG loop (Herr et al., 2003a). The BC and FG loops in FcaRI are topologically equivalent to
CDR1 and CDR3, respectively, but are not technically CDRs because FcaRI does not resemble
an Ig variable domain. Further, the two Ig-like domains of FcctRI lack C" strands and therefore
a loop equivalent to the CDR2 region. Thus, although pIgR and FcaRI bind to the same or to an
overlapping site on Fca, they do so with different recognition modes and folding topologies.
Further structural studies of pIgR in complex with dimeric Fca will be required to compare the
recognition properties of pIgR, Fca/[tR, and FcaRI, and to fully understand the mechanism by
which pIgR is specific for the binding and transport of polymeric Igs.
Experimental Procedures
Protein Expression and Purification
The cDNA encoding the full-length human pIgR was kindly provided by Roland Strong (Fred
Hutchinson Cancer Research Center, Seattle, WA). For bacterial expression, pIgR D1 (encoding
residues Lysl-Vall09) was subcloned into the pET20b expression vector (Novagen) in frame
with the C-terminal 6x-His tag using the following primers: 5'-G GAA TCC CAT ATG AAG
AGT CCC ATA TTT GGT CC-3' and 5'-GG AAT TCA CTC GAG GAC CTC CAG GCT
GAC-3'. The protein was expressed in E. coli BL21(DE3) cells (Novagen) by induction at
ODw=0.5-0.6 with isopropyl-j3-D-thiogalactoside (IPTG) at a final concentration of 0.4 mM for
5 hours at 37C. pIgR D1 inclusion bodies were solubilized in 8 M guanidine-HCl and 10 mM
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DTT. The protein was refolded by the rapid dilution method in refolding buffer (100 mM Tris
[pH 8.0], 400 mM L-arginine, 2 mM EDTA, 0.5 mM oxidized glutathione and 5 mM reduced
glutathione) (Garboczi et al., 1992). The refolded protein was concentrated in a stirred-cell
pressurized concentrator (Amicon) and loaded onto a Superdex 75 26/60 column (Amersham
Biosciences) for size exclusion chromatography.
For insect cell expression to produce glycosylated protein, pIgR D1 containing a C-
terminal 6x-His tag was subcloned into the baculovirus transfer vector pAcGP67A (BD
Biosciences) in frame with the gp67 secretion signal. Recombinant baculovirus was generated
by cotransfection of the transfer vector with linearized viral DNA (Baculogold; BD Biosciences).
pIgR D1 was harvested from the supernatant of baculovirus infected High 5 insect cells, which
was concentrated and buffer exchanged into TBS (20 mM Tris [pH 8.0], 150 mM NaCl) and
purified by Ni-NTA affinity followed by size exclusion chromatography on a Superdex 200
16/60 column (Amersham Biosciences).
Human pIgA isolated from the sera of a patient with a pIgA-producing myeloma was
kindly provided by Jean-Pierre Vaerman (Catholic University of Louvain, Brussels, Belgium)
(Song et al., 1995; Vaerman et al., 1995). pIgA was further purified by size exclusion
chromatography on a Superdex 200 HR 10/30 column (Amersham Biosciences) to separate dIgA
from higher order polymers. The peak corresponding to dIgA (two IgA molecules linked by J-
chain) was used for the binding studies. Soluble FcaRI and monomeric Fca (Fca homodimers
lacking a tailpiece that are not linked by J-chain) was purified from the supernatants of stably
transfected Chinese hamster ovary (CHO) cells as described previously (Herr et al., 2003b).
Monomeric Fca with the 18 residue tailpiece (Fca-tp) and an N-terminal 6x-His tag was
generated and purified as described for Fca (Herr et al., 2003b).
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Protein concentrations were determined spectrophotometrically at 280 nm using
extinction coefficients of 13,370 M-'cm-' for pIgR D1 and 64,940 M-'cm1- for monomeric Fca
and Fca-tp, calculated from their amino acid sequences using the ProtParam tool on the ExPASy
Proteomics Server (Gill and von Hippel, 1989).
Binding Studies
Surface plasmon resonance (SPR) biosensor assays were carried out using a BIAcore 2000
instrument (Pharmacia Biosensor, Uppsala, Sweden). In this system, binding between a
molecule coupled to a biosensor chip (the "ligand") and a second molecule injected over the chip
(the "analyte") results in changes in the SPR signal that are read out in real time as resonance
units (RUs) (Malmqvist, 1993). dIgA was covalently coupled to a reagent-grade CM5 sensor
chip (Biacore) at three different densities (412, 763 and 1426 RUs) using the primary amine
coupling method described in the BIAcore manual. The first flow cell was mock coupled with
buffer only for background subtraction. A two-fold dilution concentration series (from 10.24
RM to 20 nM glycosylated D1 or from 6.4 tM to 12.5 nM nonglycosylated D1) of 180 FLL of
pIgR D1 (the analyte) was injected over the chip at 5 RL/min in 50 mM HEPES (pH 8.0), 150
mM NaCl and 0.005% (v/v) P20, and the binding reactions were allowed to closely approach or
to reach equilibrium. Two-minute injections of 1.5 M MgCl2 were used to regenerate the surface
of the chip between injections. The sensorgrams were processed and analyzed with the Scrubber
software package (BioLogic Software, Campbell, Australia). Equilibrium dissociation constants
(KDs) were derived by nonlinear regression analysis of plots of Req (the equilibrium binding
response) versus the log of the concentration of analyte, and the resulting binding data were fit to
a single-site binding model. Data collection and binding analyses were performed identically for
the glycosylated and nonglycosylated forms of pIgR D1. To compare the binding of pIgR D1 to
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monomeric and dimeric versions of the Fc region of IgA, Fca, Fca-tp, and dIgA were coupled to
a CM5 biosensor chip at densities of 2457 RUs, 1411 RUs and 3153 RUs, respectively, as
described above. 100 iL of 5 FM glycosylated D1, nonglycosylated D1, or FcaRI were injected
over the chip at 50 !xL/min in 50 mM HEPES (pH 8.0), 150 mM NaCl, 0.005% (v/v) P20.
Crystal Growth and Data Collection
Crystals were grown by vapor diffusion in 1:1 hanging drops containing bacterially-expressed
pIgR D1 (10 mg/mL in 20 mM HEPES (pH 7.0), 150 mM NaCl), 20% (w/v) polyethylene
glycol 8000 (PEG 8000), 0.2 M magnesium acetate tetrahydrate, 0.1 M sodium cacodylate pH
6.5 and reproduced by streak seeding. Before data collection, crystals were cryopreserved in
23% (w/v) PEG 8000, 0.2 M magnesium acetate tetrahydrate, 0.1 M sodium cacodylate (pH 6.5)
with 15% (v/v) glycerol. Heavy atom derivatives were prepared by soaking crystals in the
following solutions: 1 mM di-IA-iodobis (ethylenediamine) diplatinum (II) nitrate (PIP), 40 mM
trimethyl lead acetate, or 100 mM gadolinium (III) chloride. Data from a native crystal and the
PIP derivative were collected at -1700 C using an R-AXIS IV mounted on a Rigaku RU-200
rotating anode generator. This native data set (Native I) was used for initial phase determination
and model building. A higher resolution native data set (Native II), which was used for
refinement, and the lead and gadolinium derivative data sets were collected on beamline 8.2.2 at
the Advanced Light Source (ALS, Berkeley, CA) at -1700 C (Table 1).
Structure Determination and Refinement
Data were processed and scaled with DENZO and SCALEPACK (Otwinowski and Minor,
1997). The data could be indexed in either primitive monoclinic (P2,) or C-centered
orthorhombic (C2221) space groups with unit-cell parameters a = 42.1 A, b = 156.4 A, c = 53.9
A; f3 = 113.0 ° or a = 42.1 A, b = 99.2 A and c = 156.4 A, respectively. The overall scaling
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statistics for C2221 were significantly worse than for P2 (Rsym = 14.3% (47.7%) versus Rym =
8.5% (34.3%)) and the h01 plane did not show mm symmetry, indicating the crystals were
monoclinic. After examination of systematic absences in the OkO reflections, the space group
was assigned as P21. The asymmetric unit contains six molecules with a solvent content of
~40% (VM=2.1 A3/Da) as calculated from the Matthews coefficient (Matthews, 1968).
For merging the native and derivative data sets, two options for indexing had to be
considered. Two identical but nonequivalent unit cells can be defined in monoclinic space
groups when cosp=-a/(2c) (Rudolph et al., 2004), a condition met by the D1 unit cell parameters.
Each derivative data set was compared to two versions of the Native I data set: as originally
indexed, and reindexed using the transformation (h, k, 1) to (h, -k, -h-l). The correct indexing of
each derivative as compared to the native I data was determined by comparing Rmerge values,
which were systematically higher when the opposite indexing had been chosen for the two data
sets being compared (Tucker et al., 1996).
In addition to indexing ambiguities, the D1 diffraction data exhibited evidence of
pseudomerohedral twinning, a rare type of twinning that can occur in monoclinic and
orthorhombic crystal systems when the unit cell parameters meet certain conditions (Rudolph et
al., 2004). One such condition, as discussed above, is when cosl=-a/(2c), in which case twinned
crystals in the monoclinic system can mimic an orthorhombic space group. Since the D1 crystal
parameters meet this condition, all data sets were checked for twinning. The cumulative
distribution of intensities (I/<I>), as calculated with TRUNCATE (Collaborative Computational
Project No. 4., 1994) showed a sigmoidal shape, suggesting twinning in all of the crystals.
However, the second moment of intensities (<II12/(<III>)2) for some of the data sets was 2.0,
which is the expected value for untwinned data. For the data sets with the seemingly
59
contradictory twin test results, further examination of a related value (<IFI>2/<F2>) confirmed
twinning (Brunger et al., 1998). The estimated twin fractions calculated with CNS (Brunger et
al., 1998) ranged from 20.7% to 37.3% (Table 1). Similar cases of pseudomerohedreal twinning
in monoclinic crystal forms have been described by others (De La Fortelle and Bricogne, 1997;
Larsen et al., 2002; Rudolph et al., 2004).
Heavy atom positions and initial phases were derived with the programs SOLVE
(Terwilliger and Berendzen, 1999) and SHARP (De La Fortelle and Bricogne, 1997; Terwilliger
and Berendzen, 1999) using the Native I, trimethyl lead acetate, gadolinium chloride and PIP
derivative data sets with no corrections for twinning. An initial electron density map was
calculated to 2.7 A and solvent flattened with Solomon (Collaborative Computational Project
No. 4., 1994). The first four molecules in the asymmetric unit were located in the initial
experimental map using the program MOLREP (Vagin and Teplyakov, 1997) and a "3 strands-
only" model of NKp44 (PDB code 1HKF) (Cantoni et al., 2003) (nonconserved side chains
truncated to alanine and residues 5-9, 14-15, 25-31, 40-45, 53-55, 69-71, 80-85, 95-101 and 112
omitted). The remaining two molecules were located using the real space search program
ESSENS (Kleywegt and Jones, 1997). Maps were calculated by solvent flattening and histogram
matching with DM in CCP4 (Collaborative Computational Project No. 4., 1994). NKp44
(Cantoni et al., 2003) served as a starting point for model building with the program O (Jones
and Kjeldgaard, 1997).
Refinement was performed using the CNS suite of programs (Brunger et al., 1998). The
test set of reflections for calculating Rfre was generated with the thin shell method in
DATAMAN (Kleywegt and Jones, 1996) to minimize the bias from the 6-fold
noncrystallographic symmetry (NCS) and twin-related reflections. Initial refinement was
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conducted using the 2.5 A Native I data with NCS constraints, grouped temperature (B) factors,
bulk solvent and anisotropic temperature-factor corrections. In subsequent refinement using the
1.9 A Native II data set, the NCS constraints were relaxed to NCS restraints (300 kcal/mol A2)
and individual B factors were calculated, taking into account the twin fraction of 37.3% and
maintaining the same set of test reflections for calculating Rfre. NCS restraints were limited to
the main chain atoms of the 15 strands, excluding regions that differed in the six molecules
(mostly at crystal contacts and in the loops). R,t and Rfire improved by 5.1% and 3.4%,
respectively, after inclusion of the corrections for twinning.
The final model (Rcry,,t = 18.3%, Rfee = 24.4%) contains six D1 domains (residues 2-109)
arranged as three dimers, five or six residues of the C-terminal 6x-His tag in two of the six D1
domains (molecules B and A, respectively), 158 water molecules, and two Mg2+ ions. Each of
the two Mg2+ ions are coordinated by three histidine residues in the 6x-His tags from two
molecules (His112 and Hisl15 from molecule A with His112 from molecule F coordinate one
ion and His 112 and His 15 from molecule B with His 112 from molecule E from the adjacent
asymmetric unit coordinate the other). Residue 2 in molecules B, C and D, the CC' loop
(residues 41-45) in molecules A, B, C and D and the 6x-His tag for molecules C, D, E and F
were disordered and are not included in the refined model and 2.8% of the residues were
modeled as alanine. The electron density is weak for residues 97-101 (with B factors averaging
49.6 A2, compared with an average of 32.3 A2 for the rest of the model). Ramachandran plot
statistics were calculated using PROCHECK (Laskowski et al., 1993). Automated structural
comparisons of pIgR D1 were done using the DALI server (Holm and Sander, 1993). Least-
squares alignments of pIgR D1 and its closest structural homolog, the VL and VH domains of a
mouse scFv (PDB code 1MFA), were done using O (Jones and Kjeldgaard, 1997). Sequence
61
alignments were performed with T-Coffee (Notredame et al., 2000). Figures were generated
with Molscript (Kraulis, 1991), Bobscript (Esnouf, 1997), and Raster 3D (Esnouf, 1997; Kraulis,
1991; Merrit and Murphy, 1994).
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Table 1. Data Collection, Phasing, and Refinement Statistics for pIgR D1
No. Unique Twin
Wavelength Resolution Reflections/Total Completeness Fraction Rmerge Phasing
Data Set (A) (A) Reflections (%)a (%) (%) I/ Powerc
Native I 1.54 2.5 21,524/ 97.4 26.5 8.5 19.6
(2.59 - 2.50) 76,172 (80.7) (34.3) (2.5)
Native II 1.078 1.9 49,755/ 99.6 37.3 7.8 17.7
(1.93-1.90) 185,798 (99.1) (46.2) (2.6)
PIP 1.54 3.2 10,464/ 98.5 20.7 9.7 11.3 0.4
(3.31 -3.20) 28,678 (94.3) (20.8) (5.3)
Gd 1.7108 2.8 27,967/ 89.6 30.3 10.4 8.6 1.0
(2.85 -2.80) 47,501 (58.7) (41.3) (1.5)
Pb 0.9509 2.0 79,649/ 94.1 37.0 6.5 12.2 0.6
(2.03 -2.00) 153,910 (92.7) (23.8) (3.5)
Refinement Statistics (P21) Number of Nonhydrogen Atoms
Resolution (A) 30-1.9 Protein 4993
Number of reflections in working set 47,117 (93.4%) Water 158
Number of reflections in test set 2,476 (4.9%) Mg2+ 2
Rcryst (%)d 18.3
Rfree (%) 24.4
Ramachandran plot quality (%)
Nonglycine residues in
most favored 87.3
Rmsd from ideality additionally allowed 12.3
Bond lengths (A) 0.007 generously allowed 0.4
Bond angles (deg) 1.30 disallowed 0.0
Values in parentheses indicate data in the highest resolution shell.
a Completeness is defined as the number of independent reflections/total theoretical number.
b Rmerge= 100 X 2(II-<I>I)/EI, where I is the integrated intensity of a given reflection.
c Rms fh/E (phasing power), where fh is the heavy atom structure factor amplitude and E is the lack of closure error.
The phasing power statistics were derived using twinned data and may therefore not be accurate.
d R,,st(F)=IhllFobs(h)I-IFlc(h)ll/IhIFob,(h)l, where IFobs(h)l and IFca(h)l are the observed and calculated structure factor
amplitudes for the hkl reflection.
Rfree is calculated from reflections in a test set not included in the atomic refinement.
Table 1. Data Collection, phasing and refinement statistics for pIgR D1.
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Figure 1. Biosensor Analyses of pIgR D1 Binding to dIgA
(A) Equilibrium binding data for biosensor experiments in which nonglycosylated (expressed in
bacteria) and glycosylated (expressed in insect cells) versions of pIgR D1 were injected over
dIgA immobilized at three different densities (412, 763 and 1426 RUs). The plot shows the
equilibrium binding response (Req) versus the log of concentration of the indicated proteins.
Best-fit binding curves based on a 1:1 binding model are superimposed on the binding data.
(B) Sensorgram from binding experiments in which 5 [M glycosylated or nonglycosylated forms
of D1 were injected over monomeric (with and without the tailpiece) and dimeric versions of the
IgA Fc region. The injected protein is indicated in front of an arrow pointing to the immobilized
protein.
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Figure 2. The Structure of Human pIgR D1
(A) Ca trace (molecule E). The 6xHis tag from molecule A (dashed line) was superimposed
onto molecule E.
(B) Ribbon diagram showing side and front views of pIgR D1. strands A, B, E, D are shown
in blue, P strands C", C', C, F, G, A' are in green and the three CDR loops (including the a helix
within CDR1) are red. Cysteines involved in disulfide bonds are shown in yellow in ball-and-
stick representation and the locations of potential N-linked glycosylation sites are indicated by
pink spheres.
(C) Topology diagram of pIgR D1. The color schemes for the 13 strands, a helix and CDR loops
are the same as in (A).
(D) Stereoview of the pIgR D1 model in the region of the "invariant" tryptophan, Trp37,
superimposed on a 2.7 A experimental electron density map (calculated with MIRAS phases)
contoured at 1.0 o.
72
C(j
C
c.
Helix D
Figure 2. The Structure of Human pIgR D1
B CDR1 CDR1
I
o900
R2
Figure 3. Amino Acid Sequence Alignment of Human pIgR D1 and Related Proteins
Top panel: pIgR D1 from eight different species and the Ig-like domain from the human Fca/[tR
were aligned. Cysteines involved in disulfide bonds are shown in red, conserved residues are
highlighted in yellow and conservatively substituted residues are highlighted in blue. Asterisks
indicate the positions of five characteristic residues in Ig V domains. Sequences within the three
CDR loops are shown in bold and underlined. Crystallographically determined secondary
structure elements are shown above the sequences. Accession codes for the pIgR sequences are:
P01833 (human), P01832 (rabbit), 070570 (mouse), P15083 (rat), P81265 (bovine), AAK69593
(Macropus eugenii (tammar wallaby)), AAD41688 (Trichosurus vulpecula (silver-grey brushtail
possum)), and AAP69598 (Gallus gallus (chicken)); and AAL51154 (human Fca/[tR).
Bottom panel: The D1 domain of pIgR is aligned with the other domains within the human pIgR
extracellular region.
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Figure 3. Amino Acid Sequence Alignment of Human pIgR D1 and Related Proteins
Figure 4. Structural Consequences of the Position of the pIgR D1 CDR3 Loop
(A) Stereoview of the superposition of pIgR D1 (red) with an Ig VL domain (blue) derived from a
mouse single-chain Fv (PDB code 1MFA).
(B) Stereoview of the region in the vicinity of the pIgR D1 CDR3 loop showing Tyr36 buried at
the interface between CDR3 and the C"C'CFGA' sheet. A ball-and-stick representation of Tyr36
is shown in red. Atoms in residues that stabilize this position of CDR3 are highlighted with an
atom-based color code (carbon: black; oxygen: red; nitrogen: blue), and hydrogen bonds are
indicated as black dashed lines.
(C-D) Comparison of an Ig VH-VL heterodimer (PDB code 1MFA) (panel C) with a computer
model of a pIgR D1 homodimer (panel D) created by superimposing D1 on the VH and VL
domains of a VH-VL heterodimer (panel C). The rmsd values are 1.39 A for the VH-D1
superposition (calculated for 101 Ca atoms) and 1.38 A for the VL-D1 superposition (calculated
for 78 Ca atoms). CDR3 loops are highlighted in pink.
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Figure 5. Mutagenesis Data Mapped onto Structure
The positions of substitutions that abolished (red) or decreased (blue) pIgA binding to rabbit
pIgR (Coyne et al., 1994) are mapped onto the human pIgR D1 structure. A close-up of the
CDR1 region is shown in the upper right, and the sequence of CDR1 in human and rabbit pIgR
D1 is shown in the lower right. Val29 (black), which is solvent exposed in the D1 structure, was
assumed to be buried and was therefore not substituted (Bakos et al., 1993; Coyne et al., 1994).
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CHAPTER 3
Solution Structure of Choline Binding Protein A, the Major Adhesin
of Streptococcus pneumoniae
This chapter describes the solution structure of an adhesion domain (R2) of CbpA, the S.
pneumoniae surface protein responsible for pIgR binding, and biophysical experiments
characterizing the binding properties of CbpA domains and pIgR. This work was done in
collaboration with several groups at St. Jude Children's Research Hospital and my contribution
included providing purified pIgR and performing the initial binding experiments to show that the
recombinantly expressed pIgR binds CbpA, R1 and R2.
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Abstract
Streptococcus pneumoniae (pneumococcus) remains a significant health threat world-wide,
especially to the young and old. While some of the biomolecules involved in pneumococcal
pathogenesis are known and understood in mechanistic terms, little is known about the molecular
details of bacterium/host interactions. We report here the solution structure of the "repeated"
adhesion domains (domains R1 and R2) of the principal pneumococcal adhesin, choline binding
protein A (CbpA). Further, we provide insights into the mechanism by which CbpA binds its
human receptor, polymeric immunoglobulin receptor (pIgR). The R domains, comprised of 12
imperfect copies of the leucine zipper heptad motif, adopt a unique 3-a-helix, raft-like structure.
Each pair of a-helices is anti-parallel and conserved residues in the loop between Helixes 1 and
2 exhibit a novel "tyrosine fork" structure that is involved in binding pIgR. This and other
structural features that we show are conserved in most pneumococcal strains appear to generally
play an important role in bacterial adhesion to pIgR. Interestingly, pneumococcus is the only
bacterium known to adhere to and invade human cells by binding to pIgR.
Running title
Solution structure of the pneumococcal adhesin, CbpA
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Introduction
Streptococcus pneumoniae (pneumococcus) remains the most common invasive bacterial agent
leading to hospitalization in all age groups (Schuchat et al., 2001), with the majority of these
cases affecting either children or the elderly. Penicillin remains the primary mode of treatment
but the emergence of antibiotic resistance has intensified the search for new therapeutic
approaches (Whitney et al., 2000). While disease prevention through vaccination is partially
effective, this approach is less effective in the youngest and oldest patients (Butler et al., 1993).
Hence, studies of disease mechanisms may provide insights into new anti-bacterial therapies.
The pneumococcus invades human nasopharyngeal epithelial (NE) cells and enters the blood
stream through a process termed reverse transcytosis mediated by polymeric immunoglobulin
receptor (pIgR) (Zhang et al., 2000). The normal function of pIgR is to transport secretory IgA
(sIgA) from the basolateral to the apical surface of NE cells (Mostov and Kaetzel, 1999). A
protein on the bacterial surface, choline binding protein A (CbpA), binds specifically to an
extracellular domain of pIgR and hijacks the endocytosis machinery to translocate pneumococci
across NE cells into the blood stream. While the participation of CbpA in pneumococcal
adhesion and invasion is well established (Rosenow et al., 1997), the molecular details of these
processes are not understood.
CbpA (also referred to as PspC, SpsA, and PbcA) is one of 15 proteins identified in the
genome of the TIGR4 strain (Tettelin et al., 2001) that exhibit multiple C-terminal repeats of a
-19 amino acid motif that binds choline moieties present on the bacterial cell wall (Gosink and
Tuomanen, 2000). The mechanism of bacterial surface attachment by CbpA can be understood
on the basis of structural studies of another choline binding protein (Cbp), LytA. [Note: We use
the generic term CbpA to refer to the CbpA protein from the TIGR4 strain.] The C-terminal
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domain of LytA contains seven repeats of the choline binding motif and adopts a unique P-
solenoid structure, with choline groups binding between P-hairpin "steps" of the staircase-like
structure (Fernandez-Tornero et al., 2001). Similarly, CbpA has eight repeats of this motif in its
C-terminus (Fig. 1A) and is predicted to bind surface-exposed choline groups in similar manner
(Fernandez-Tornero et al., 2001). The N-terminal domains of the 15 TIGR4 Cbps differ widely,
with functions ranging from bacterial autolysis (LytA) and glucosaminidase activity (LytB) to
adhesion to human NE cells (CbpA) (Gosink et al., 2000; Tettelin et al., 2001). The sequence of
the CbpA N-terminus (residues 39-514 (Tettelin et al., 2001)) exhibits numerous repeats of the
leucine zipper (LZ) motif (Landschulz et al., 1988) that cluster within five domains termed A, B,
R1, R2 and C (Fig. 1A). Domains A, B and C are 21 to 25 amino acids in length and are
predicted to form coiled-coil dimers (Fig. B) (Lupas et al., 1991). The -110 amino acid-long,
"repeated" domains, R1 and R2 (78% identical) (Zhang et al., 2000) are also predicted to form
self-associated, coiled-coil structures. We refer to these as "R" domains. The segments that
connect these domains are predicted to lack secondary structure. In general, LZ motifs mediate
intra- or inter-molecular a-helix/a-helix interactions, and are well understood as the basis for
parallel self-association into a-helical dimers, trimers, and tetramers (Lupas, 1996). LZ motifs
also mediate anti-parallel a-helix/a-helix interactions (Oakley and Hollenbeck, 2001). To date,
however, the R domains of CbpA have not been structurally characterized.
CbpA R domains bind the extracellular, immunoglobulin-like (Ig-like) domains of pIgR
termed secretory component (SC) (Hammerschmidt et al., 1997; Zhang et al., 2000). SC
covalently binds to IgA dimers and, after transcytosis from the basolateral to apical surface of
NE cells, the SC/IgA2 complex is proteolytically cleaved from pIgR to release sIgA (Mostov,
1994). A conserved hexapeptide motif within the R domains is required for binding to sIgA
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(Hammerschmidt et al., 2000). Here we present the solution structure of domain R2 of CbpA
containing this motif determined using NMR spectroscopy. Further, we used this structure to
model that for domain R1. Surface plasmon resonance (SPR) and isothermal titration calorimetry
(ITC) were used to gain insight into the mechanism by which CbpA binds components of pIgR.
Our results provide the first molecular insights into the structurally novel mechanism by which
pneumococcus binds pIgR and subsequently invades human cells.
Results
Conserved features of CbpA sequences from many pneumococcal strains
The R domains of CbpA from the TIGR4 strain of Streptococcus pneumoniae are highly
conserved in CbpA sequences from other pneumococcal strains (Iannelli et al., 2002). We
compared CbpA sequences (excluding the choline binding motifs) from 47 pneumococcal strains
and quantified R domain conservation (Fig. 2A and B). Thirty-nine sequences exhibit R1 and R2
domains that are >50% identical to the TIGR4 domains, six exhibit one R2-like (>50% identical)
domain, and one exhibits one RI-like (93% identical) domain. Residues at 22 positions are
identical in these R1 and R2 domains, 87 in total, including five residues within the hexapeptide
motif discussed earlier. Thus, our structural and biophysical results for the R domains of the
TIGR4 strain are relevant to CbpA from virtually all known pneumococcal strains.
Solution Structure of CbpA, Domains R1 and R2
The secondary structure of N-terminal CbpA domains was elucidated using circular dichroism
(CD) and NMR spectroscopy. Domains R1 and R2 (78 % identical) each contain 12 imperfect
copies of the LZ motif and span residues 175-285 and 327-442, respectively. Eight of the 24
differences between R1 and R2 correspond to substitution of Glu by Lys, or vice versa (Fig. 1C).
85
The CbpA R domain LZ motifs are similar to those found in coiled-coil proteins (Fig. 1C)
(Lupas et al., 1991); however, the amino acid at position d of the heptad motif, which is usually
Leu in the classical LZ motif, is most frequently Ala in the R domains.
CbpA-R1 and -R2 possess extensive a-helical structure on the basis of CD spectra (Fig.
3B) and we used NMR spectroscopy to determine the CbpA-R2 structure in solution. Secondary
13C, chemical shifts for CbpA-R2 (Fig. 4A), which are indicative of secondary structure, clearly
revealed three a-helices: Helix 1 (residues 330-357), Helix 2 (residues 366-390) and Helix 3
(residues 396-425). These adopt an unusual three-a-helix, raft-like structure through anti-parallel
a-helix/a-helix interactions (Fig. 4B). The a-helices, while anti-parallel, are not exactly co-axial
due to slight coiling (Fig. 4C). The crossing angle for Helices 1 and 2 is -178° and that for
Helices 2 and 3 is -176 °. In addition, we generated a homology model of CbpA-R1 based on the
structure of CbpA-R2. The structures of CbpA-R2 (Fig. 4B) and -R1 indicate that many
hydrophobic residues are buried at the two a-helix/a-helix interfaces and that the protein
surfaces are dominated by polar and charged residues (Fig. 4D). CbpA-R2 exhibits a bi-lobed
electrostatic potential, with one face of the structure highly electronegative (red contours in Fig.
4D, left) and the other electropositive (blue contours). The differences in charged residues
between CbpA-R2 and -R1 cause increased electronegative character on one face of CbpA-R1
and reduced electropositive character on the other (Fig. 4D, right).
Peptides with the sequence RNYPT bind to sIgA and SC, and mutations in this motif in
SpsA, a CbpA variant with one R domain, abolish binding to sIgA (Hammerschmidt et al.,
2000). The YPT motif, which occurs once in each of the two TIGR4 CbpA R domains (Fig. 1C),
is found in the loop between Helix 1 and Helix 2 in the CbpA-R2 structure (Fig. 4B and E).
Interestingly, these and other conserved residues in the loop protrude into solvent from an
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electrostatically neutral region of CbpA-R2, with two partially stacked Tyr residues forming a
"tyrosine fork" structure (Fig. 4D, left, and E). Most residues in the Helix 1/Helix 2 loop are
conserved in CbpA-R1 and thus the homology model of domain R1 exhibits a similar tyrosine
fork feature. While the differences in charged residues mentioned above affects the electrostatic
properties of domain R1, the potentials in the vicinity of the YPT motif in this domain are very
similar to those of the R2 domain (Fig. 4G, right), suggesting that the negative charge of this
region, and the protruding YPT motif, are involved in binding to pIgR. Many of the residues in
this region have significant hydrophobic character, including Tyr 358 and 363, Pro 359, and Thr
360 and 362 (Fig. 4E) (Creighton, 1993; Nozaki and Tanford, 1971), suggesting that
hydrophobic interactions are involved in receptor binding.
Proteins that contain multiple LZ motifs often self-associate. However, the results of
equilibrium analytical ultracentrifugation (AUC) experiments showed that CbpA-R1 and -R2 are
predominantly monomers in solution (Suppl. Fig. 1C & D). Analysis of sedimentation data for
both domains did, however, provide evidence for very weak self-association at high protein
concentration (Suppl. Table 1). Further, we showed using equilibrium AUC that CbpA-R1 and
Cbp-R2 do not interact to form hetero-oligomers (data not shown). Importantly, these results
show that the principal role of the CbpA LZ motifs is to mediate the folding, not oligomerization,
of the R domains.
Structural properties of CbpA-N (residues 39-174)
The role of the N-terminal domain of CbpA (containing LZ domains A and B, Fig. 1A) in
adhesion and invasion is not known. To provide preliminary insights into function, we
characterized the structure and self-association properties of CbpA-N (residues 39-174). CD
results show that CbpA-N adopts a-helical secondary structure (Fig. 3B) and that it has a stable
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fold (Fig. 3C). As observed for CbpA-R1 and -R2, AUC analysis showed that CbpA-N is
monodisperse; however, a small degree of oligomerization was observed at 0 and 50 mM NaCl
(Suppl. Table 1).
The full CbpA N-terminus (residues 39-442) is comprised of three a-helical domains
We used CD to compare the structure of a 404 amino acid fragment of CbpA (CbpA-NR12; Fig.
3A) with that of the three domains within this fragment (CbpA-N, -R1 and -R2). CD spectra for
CbpA-N, -R1, -R2 and -NR12 (Fig. 3B) showed that all constructs are highly a-helical. Further,
we monitored ellipticity at 222 nm for each construct as the temperature was raised from 5 C to
95 C to characterize thermal stability. CbpA-R1 and -R2 exhibited thermal unfolding transitions
at 44 C and 47 C, respectively (Fig. 3C). CbpA-N also exhibits a single thermal transition but
at a much higher temperature, 71 C (Fig. 3C). Based on these data we conclude that CbpA-N, -
R1 and -R2 are individually folded, stable a-helical domains. The thermal melting curve for
CbpA-NR12 is a composite of those for the individual domains, exhibiting two thermal
transitions, one at 45 C and a second at 71 C. These data suggest strongly that the structure of
the individual CbpA domains is preserved in the multi-domain construct, CbpA-NR12.
We also compared the structure of CbpA-R2 with that of the R2 domain within CbpA-
NR12 by analyzing 2D H-15N TROSY spectra. The spectrum of CbpA-R2 (Fig. 5A) exhibited
the appropriate number of resonances, most of which appeared outside the crowded central
region. The resonance pattern of CbpA-R2 was well reproduced in the spectrum of CbpA-NR12.
The similarity between the two spectra is illustrated by the blue overlays in Fig. 5A and 5B; the
blue layer identifies resonances that appeared at identical positions in the two spectra. In Fig. 5A,
the spectrum of CbpA-R2 is the red colored layer; however, most resonances appear blue
because they also appeared in Fig. 5B. In Fig. 5B, approximately 40 isolated resonances
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(excluding obvious side chain resonances) are colored blue, indicating that they also appeared in
Fig. 5A. CbpA-R2 is comprised of 119 amino acids and the fact that resonances for one third of
these appeared at identical chemical shift values in the two spectra suggests that the structure of
CbpA-R2 is the same in the two constructs. These data provide further support for the conclusion
that the N-terminus of CbpA (residues 39-442) is comprised of three independent, a-helical
domains.
Role of CbpA "R" domains in pIgR binding
We studied the binding of domains of CbpA to components of pIgR using several approaches to
understand the underlying interaction mechanism. First, we used ELISA to measure the extent to
which CbpA constructs bind to sIgA. In agreement with previous studies (Hammerschmidt et al.,
2000; Zhang et al., 2000), our results show that multi-domain fragments of CbpA, including
CbpA-R12 and -NR12, bind to immobilized sIgA (Suppl. Fig. 2). However, this assay detected
only a weak interaction between sIgA and CbpA-N, -R1 and -R2. These results suggested that
multiple CbpA domains cooperate in binding sIgA.
To clarify the role of domains R1 and R2 in pIgR binding, we performed binding
experiments using surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC).
We immobilized either sIgA or SC expressed in Sf9 insect cells (SC-D15) on SPR biosensor
surfaces and monitored CbpA binding. The experiments were performed at several different
concentrations of each CbpA construct (Suppl. Fig. 2B) and a global fitting procedure was used
to determine association (ka) and dissociation (kd) rate constants (Fig. 6A, Suppl. Table 2).
Further, these rate constants were used to calculate the apparent Gibbs free energy of binding
(AGSPR) for each reaction (AGSPR = -RT ln(kd/ka); Fig. 6A). SPR data for CbpA fragments
binding sIgA and SC-D 15 showed similar trends and, therefore, only those for binding to sIgA
89
are illustrated in Fig. 6A and Suppl. Fig. 2B. Kinetic constants for all reactions (sIgA and SC-
D15) are given in Suppl. Table 2. Because CbpA-NR12 and -R12 each contain two "R" domains,
each with one YPT motif, we determined whether the individual R domains bound to
components of pIgR. CbpA-R1 and -R2 bound to the sIgA surface more rapidly than did those
containing two R domains (CbpA-R12 and -NR12) (Fig. 6A and Suppl. Table 2), as would be
expected if association was controlled by diffusion. These constructs dissociated from the sIgA
surface with rates that depended on the number of R domains; CbpA-R1 and -R2 dissociated
more rapidly than did CbpA-R12 and -NR12. CbpA-R1 and -R2 exhibited similar AGSPR values
(-13.4 kcal/mol and -12.8 kcal/mol, respectively), and the value for CbpA-NR12 was only
slightly more negative (-14.0 kcal/mol). In this surface-based assay, the presence of two R
domains in CbpA-NR12 appears to enhance binding to sIgA only slightly.
While the SPR data provided important insights into CbpA:sIgA (and SC) interactions,
due to the surface-based format of this assay, AGSPR values may not reflect binding behavior in
solution. Further, the analysis of binding stoichiometry from SPR data can be problematic. To
overcome these limitations, we used ITC to monitor binding of the CbpA constructs to SC-D 15.
Solutions of CbpA-R1, CbpA-R2, CbpA-R12, or CbpA-NR12 were injected into a solution of
SC-D15 and the evolved heat was measured (Fig. 6B and Table 1). These data were fit using
standard equations to give values of the enthalpy (AHITC), Gibbs free energy (AGITC), and entropy
(-TASITC) of binding. In addition, the CbpA:SC-D15 mole ratio (N) for each construct was
determined (Table 1). Binding to SC-D15 was studied because only this protein could be
obtained with sufficient purity and in sufficient quantities. The absolute values of AGITC are
between 3 to 4 kcal/mol smaller than those determined from SPR-derived rate constants;
however, only a small difference was observed between the values for the different CbpA
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constructs, which parallels the results from SPR (Table 1 and Fig. 6A). Surface immobilization
of sIgA and SC-D 15 in the SPR experiments may promote association relative to the situation in
solution, and give rise to anomalously large values of AGSPR. Despite this caveat, AGSPR values
can be compared to give an accurate measure of relative binding affinities for different CbpA
constructs. The ITC results show that two moles of CbpA-R1 or CbpA-R2, or one mole of
CbpA-R12 or CbpA-NR12, bind to one mole of SC-D15. This latter result, along with the
similarity of the AGITC values and kinetic constants for CbpA-R1 and -R2 binding SC-D15,
strongly suggests that there are two thermodynamically indistinguishable binding sites in SC-
D15 for CbpA R domains. AGITC values for CbpA-R12 and -NR12, each with two R domains,
are only marginally larger in absolute magnitude than those for CbpA-R1 and -R2 which, at first,
may seem inconsistent with the presence of two binding sites in SC-D 15. However, the values of
the entropy parameter (-TAS) for the former constructs are twice those for the latter (Table 1),
which largely nullifies the enthalpic benefits (in CbpA-R12 and -NR12) associated with having
two R domains. The large entropic penalty of binding for constructs with two R domains may
arise from restriction upon binding of a highly flexible polypeptide linker between domains R1
and R2.
Mutation of residues within the YPT motif of CbpA interferes with sIgA binding
(Hammerschmidt et al., 2000). To further confirm our binding model, we prepared three CbpA-
NR12 constructs in which the Tyr residue of the YPT motif was mutated to Gly in the R1
domain (CbpA-NR12-Y205G), the R2 domain (CbpA-NR12-Y358G) or both domains (CbpA-
NR12-Y205G/Y358G) and used SPR to determine ka,, kd and AGSPR values (Fig. 6A). Similar
mutant CbpA constructs in which the Pro residue of the YPT motif was mutated to Gly were also
prepared and analyzed. We reasoned that Gly would readily mimic the backbone conformation
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of Tyr and Pro residues and, therefore, other than eliminating a side chain, this substitution
would not disrupt the structure of the R domains, as was shown by CD studies of CbpA-NR12-
Y205G/Y358G (data not shown). The results for the GPT and YGT mutants binding to sIgA and
SC-D15 were similar (Suppl. Table 2), and only those for the GPT mutants binding sIgA are
discussed here. The ka values for the mutant constructs binding to immobilized sIgA were similar
to that of CbpA-NR12. However, the kd values were different and depended on the number of
intact YPT motifs. These rates are on average 5-fold larger (faster) than that observed for CbpA-
NR12. Mutation of both YPT motifs increased the dissociation rate further to a value that is
approximately 500-fold larger than that for CbpA-NR12. The value of AGSPR for CbpA-NR12
binding to sIgA is -13.2 kcal mol' while those for the single GPT mutants are -12.2 kcal mol-'
and -12.3 kcal mol' l (for CbpA-NR12-Y205G and -Y358G, respectively). The AGSPR value for
the double GPT mutant, CbpA-NR12-Y205G/Y358G, is -9.8 kcal mol l1. These results show that
one R domain, either R1 or R2, is sufficient for CbpA to bind sIgA (and SC) with high affinity.
Affinity is diminished by about 1 kcal mol'l if one residue in the YPT motif in either R1 or R2 in
CbpA-NR12 is mutated and by about 3.5 kcal mol' if one residue in each YPT motif in CbpA-
NR12 is mutated (Fig. 6A). CbpA-N failed to bind immobilized sIgA or SC-D15 in SPR
experiments at concentrations up to 1.5 [tM (data not shown), showing that the R domains within
CbpA-NR12 are the principal determinants of interactions with sIgA (and SC). Further, the
similarity of binding data for CbpA-R1 and -R2, and the two single GPT mutants of CbpA-
NR12, indicates that the R1 and R2 domains interact similarly with the two R domain binding
sites within sIgA and SC. It has been shown recently that CbpA binds to Ig-like domains 3 and 4
of secretory component (Elm et al., 2004a; Lu et al., 2003). It is possible that the two binding
sites we have identified are found within these two domains.
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Role of CbpA "R" domains in adhesion to nasopharyngeal epithelia
To understand whether there were parallels between our in vitro findings on the effects of
mutations within the YPT motifs on CbpA binding to pIgR and bacterial adhesion to cellular
receptors, we performed adhesion assays with pneumococci and human NE cells (Detroit cells).
We expressed wild-type and mutant CbpA proteins in a CbpA null pneumococcal strain (ACbpA-
) and measured adhesion of these bacteria to Detroit cells (Fig. 6C). While the reproducibility of
results from this biological assay is inferior to that associated with our SPR results, the adhesion
results clearly show the same trends as do results from SPR. For example, mutation of the Tyr
residue in one of the two YPT motifs does not have a statistically significant effect on the
number of pneumococci that adhere to epithelial cells. However, mutation of Tyr within both
YPT motifs reduces adhesion to the level associated with pneumococci that lack CbpA. These
results show that, while CbpA is not the sole determinant of adhesion to human target cells,
incorporation of mutations in two out of 693 amino acids in the CbpA sequence that significantly
decrease affinity for sIgA and SC in vitro (Fig. 6A) have similar effects on adhesion to human
cells.
Discussion
Novel structural features of CbpA domains
The mode of attachment of pneumococci to the surface of human epithelial cells is uniquely
characterized by the absence of pili or fibrillar bacterial protrusions. Rather, the pneumococcus
utilizes a novel mechanism to adhere to and invade human cells; this mechanism is mediated in
part by CbpA which is secreted and recaptured onto the bacterial surface. Amongst pathogenic
bacteria, the use of choline moieties on the bacterial surface as binding sites for functional
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proteins is uniquely essential to pneumococci (Rosenow et al., 1997; Tomasz, 1967). We show
here that domains R1 and R2 of CbpA adopt a strikingly simple structure comprised of three a-
helices that bundle together through anti-parallel interactions into a flat, raft-like structure. While
we have not experimentally determined the structure of CbpA-R1, the similarity of its primary
sequence, CD spectra and thermodynamic and kinetic properties to those of the R2 domain
strongly suggest that our homology model is accurate. The R domains are unusual in their helical
topology and in the highly polar and charged nature of their molecular surfaces. A prominent
feature with mixed polar and hydrophobic character-the tyrosine fork-near the loop between
Helices 1 and 2 contains several conserved residues that are likely to play a key role in binding to
Ig-like domains of pIgR. Most other conserved residues (Figs. 1C and 4D) are hydrophobic and
are involved in a-helix/a-helix interactions. These may be conserved to preserve the helical
topology of the R domains. Other conserved residues are charged and/or polar and are generally
surface exposed; these residues may also play roles in interactions with pIgR.
The arrangement of the three a-helices of CbpA-R2 is different from that of other LZ
proteins in that the anti-parallel a-helices are nearly co-axial, with crossing angles near -180° (-
178 ° for Helices 1 and 2, -176 ° for Helices 2 and 3). We identified four proteins with one pair of
anti-parallel a-helices comprised of LZ sequences that exhibit structural similarity to CbpA-R2
(Pdb file ROP, Dali Z-score, 5.4; 1GRJ, 4.9; 1CXZ, 4.8; and 1AQT, 4.2) (Holm and Sander,
1993; Oakley and Hollenbeck, 2001). The a-helix crossing angles in these proteins are -161°, -
153°, -160°, and -159°, respectively. These crossing angles arise due to the bulky nature of the
hydrophobic side chains of Ile, Leu and Val at positions a and d in the heptad repeats, which
forces the helices to twist in order to pack "knobs-into-holes" (Crick, 1953). The LZ motifs in
CbpA-R1 and -R2 differ from the classical motif in that alanine is often found at position d (Fig.
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1C). The presence of a limited number of small alanine side chains at the a-helix/a-helix
interface may allow nearly perfect anti-parallel packing of a-helices into the flat, raft-like
structure of CbpA-R2.
Phylogenetic analysis reveals conserved structural features of CbpA
Our CbpA mutagenesis results showed that preservation of the Tyr and Pro residues within at
least one YPT motif is essential for high-affinity binding to sIgA. Our results are consistent with
the findings of others. In particular, Elm et al. (Elm et al., 2004b) showed that a fragment of
SpsA (residues 37-283) with a single R2-like domain (SpsA is also termed PspC 2.1, which
constitutes Group 4 in Fig. 2) was a competitive inhibitor of pneumococcal adherence to human
cells that express pIgR. Importantly, this group also showed that a related CbpA fragment in
which Tyr 201 (within the YPT motif) was mutated to Asp was not an inhibitor of adherence.
We also observed that the isolated domains, CbpA-R1 and -R2, bind sIgA and SC with similar
kinetic and thermodynamic constants. This suggests that the conserved features of the R domains
are associated with receptor binding. Further, we reasoned that the residues in these domains that
are most highly conserved amongst different CbpA sequences are involved in receptor binding.
Our phylogenetic analysis showed that 22 residues that are conserved in all sequences (Figs. 1C
and 4D) are found in the C-terminal portion of Helix 1, in the loop connecting Helices 1 and 2,
and in the N-terminal portion of Helix 2. These residues, many of which are hydrophobic, are
evenly distributed on the two faces and within the two a-helix/a-helix interfaces of the CbpA-R2
structure. The majority are found in Helix 2. For the R2 domain of the TIGR4 strain, an
abundance of acidic residues in the midst of the conserved residues gives rise to a strong,
negative electrostatic potential on one face of CbpA. However, the electronegative character near
the loop containing the YPT motif is neutralized, in part due to the influence of two conserved
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basic residues, Arg 356 and Lys 364 (Fig. 4E). This causes the side chains of the two Tyr
residues (Tyr 358 and 363) of the tyrosine fork to protrude from one face of the raft-like
structure into a region of low electrostatic potential (< lkt). In addition, several other conserved
residues (Pro 359, Thr 360, and Thr 362) protrude prominently from the loop on the opposite
face of the raft-like structure. Together, our results from mutagenesis and binding experiments
and this structure-based analysis, strongly suggest that these conserved residues play important
roles in binding to SC. While these residues sit in a node in the electrostatic potential map, it is
possible that the SC surface has electropositive character that serves, in the initial stages of
binding, to attract the electronegative surface of CbpA-R2 and possibly other CbpA R domains.
Materials and Methods
Construction of CbpA expression plasmids and Expression and purification of CbpA proteins.
Expression plasmids for CbpA proteins were prepared using standard methods, as discussed in
detail under Suppl. Materials. CbpA proteins for structural and biophysical studies were
expressed in E. coli and purified using standard procedures, as given under Suppl. Materials.
Expression of SC-D15 in Sf9 cells andpurification. A gene encoding pIgR D1-D5 (residues 1-
589 of the mature protein with a C-terminal 6x His-tag) was subcloned into the baculovirus
transfer vector pAcGP67b (Pharmingen) in frame with the gp67 hydrophobic secretion signal.
Recombinant virus was generated by cotransfection of the transfer vector with linearized viral
DNA (Baculogold; Pharmingen). SC-D 15 was harvested from the supernatants of baculovirus-
infected High 5 Cells (Invitrogen), which were concentrated and buffer exchanged into 20 mM
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Tris pH 8.0, 150 mM NaCI. SC-D15 was purified on Ni-NTA resin (Qiagen) followed by gel
filtration chromatography (Superdex 200, Amersham-Pharmacia).
Adhesion experiments. Pneumococci were grown in C+Y media (Lacks and Hotchkiss, 1960) to
early stationary phase. All strains were grown in the presence of chloramphenicol (5 g ml-'), the
ACbpA- mutant strain with erythromycin (1 !xg ml-'), and those transformed with the
pNE1/CbpA vectors, with spectinomycin (500 [tg ml-'). Cells were pelleted and resuspended in
fluorescein isothiocyanate (FITC; 1 mg/ml; Sigma) (Rosenow et al., 1997; Gosink et al., 2000).
After incubation at 25 °C for 30 minutes, the bacteria were washed with PBS containing Ca2+
and Mg2+ (Mediatech), and diluted to 1 x 107 cfu/ml. Confluent monolayers of Detroit 562
epithelial cells (ATCC) were established in 96 well Terasaki trays and activated prior to infection
with human TNFa (10 ng/well) for 2 hours. The cells were infected with 105 cfu of labeled
bacteria for 30 minutes at 37 °C. The cells were washed four times with PBS containing Ca2+ and
Mg2+ and fixed with 2.5% (vol/vol) glutaraldehyde. The number of adherent bacteria was
determined by counting using fluorescence microscopy. We used the following procedure to
determine that pneumococci transformed with pNE1/CbpA vectors expressed equal amounts of
wild-type and mutant CbpA on the bacterial surface. The total bacterial CbpA and surface-bound
CbpA (extracted from the bacterial surface with 10% choline) were quantified by Western
analysis using a polyclonal anti-CbpA antibody generated against the CbpA N-terminus
(residues 39-443) in rabbits. The antibody was purified using affinity chromatography before
use.
NMR spectroscopy. Isotope labeled samples for NMR studies were prepared by culturing
BL21(DE3) cells in isotope-labeled MOPS-based minimal media (Neidhardt et al., 1974). For
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15N-labeling, 15 N-ammonium chloride was used; for 13C/15N-labeling, 13C-glucose was also used;
and for 2H/1 3C/SN-labeling, 2H20 was also used. 1 mM NMR samples were prepared in 10 mM
potassium phosphate, 50 mM NaCl, pH 6.5, 5 % (v/v) 2H20 and 0.02 % (w/v) sodium azide.
Gradient-, sensitivity-enhanced 2D 1H-'5N TROSY spectra (Rance et al., 1999; Weigelt, 1998;
Zhu et al., 1999) for CbpA-R2 and -NR12 were recorded using identical acquisition parameters:
1H: spectral width, 14,368 Hz; data size, lk complex points; 5N: spectral width, 2,433 Hz; data
size, 128 complex points. A Cosine window function and zero-filling were applied prior to
Fourier transformation in each dimension. Backbone resonance assignments for 2H/ 3C/15N-
labeled CbpA-R2 were determined through the analysis of multiple 3D and 4D spectra, including
3D constant time- (CT-) HNCA, CT-HN(CO)CA (Yamazaki et al., 1994b), CT-HN(CA)CB, and
CT-HN(COCA)CB (Yamazaki et al., 1994a), and 4D HNCOCA and HNCACO (Mulder et al.,
2000). In addition, a 4D 'H- 5N HSQC-NOESY-1 H-'5N HSQC spectrum was analyzed to
confirm backbone assignments and to obtain local backbone helical distance restraints. Side-
chain assignments were made through the analysis of 3D C(CO)NH-TOCSY, H(CCO)NH-
TOCSY, HBHA(CBCACO)NH, HCCH-COSY and HCCH-TOSCY spectra. Additional 3D and
4D NOESY spectra, including 3D NOESY-H-S5N HSQC, 3D NOESY-H- 3C HSQC, 4D 'H-
15N HSQC-NOESY-'H-'3 C HSQC and 4D 'H-'3C HSQC-NOESY-1H-'3 C HSQC, were used to
obtain distance restraints for structure calculations. Spectra were recorded at 25 °C using several
spectrometers: a Varian Inova 600, a Varian INOVA 900, and a Bruker AVANCE 800. Spectra
were processed using NMRPipe software (Delaglio et al., 1995) and analyzed using Felix
software (Accelerys, Inc.). The 1H dimensions of spectra were referenced to external TSP and
the '3C and '5N dimensions were referenced indirectly using the appropriate ratios of
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gyromagnetic ratios (Cavanagh et al., 1996). Secondary 13Ca chemical shift values (A813C,) were
calculated as described (Schwarzinger et al., 2001).
Structure Calculation, Refinement and Analysis. CbpA-R2 structures were calculated using
interproton distance restraints estimated from 3D and 4D NOESY cross peak volumes. Restraint
lower bounds were set to 1.8 A and upper bounds to 2.5, 3.5, and 6.0 A for large, medium, and
small volumes, respectively. The program TALOS (Comilescu et al., 1999) was used to estimate
backbone dihedral angles psi () and phi () based on Ha, 15N, 13Ca, 13Co, and 13C' chemical
shift values within the a-helical segments of CbpA-R2. In addition, hydrogen-bond (H-bond)
restraints were used within a-helices. Amide protons involved in H-bonds were identified on the
basis of slow exchange with 2H20. Restraints are summarized in Table 2. Structures were
calculated using torsion angle dynamics (TAD) (Stein et al., 1997) within CNS (Brunger et al.,
1998). The TAD protocol was performed in stages: (1) 75 ps high-temperature TAD (50,000 K)
followed by (2) cooling to 1,000 K over the course of 75 ps and ramping of the van der Waals
scaling term from 0.1 to 1.0. (3) The molecules were further cooled to 300 K over the course of
20 ps using conventional Cartesian dynamics followed finally by (4) 10,000 steps of conjugate
gradient energy minimization. The NOE (dihedral) restraint energy term was 150 kcal mol-1 (100
kcal mol 1) for stages 1-3 and 100 kcal mol-1 (300 kcal mol') for the last. Two hundred structures
were calculated, and the 40 lowest-energy structures were further refined by using the SANDER
module of AMBER 8.0 (Case et al., 2004). Solvent was represented by the Generalized-Born
(GB) model (Xia et al., 2002). Structures were first energy minimized for 1 ps without restraints
followed by 40 ps of simulated annealing from 400 K to 0 K with all restraints. The distance and
angle restraint force constants were 20 kcal mol'1 A-2 and 2 kcal mol-1 A-2, respectively. Statistics
for the 20 lowest-energy structures are given in Table 2. The program Define_S was used to
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determine the a-helix crossing angles for CbpA-R2 and other LZ-containing proteins (Richards
and Kundrot, 1988). Further, we compared the structure of CbpA-R2 with those of other proteins
using the Dali server (http://www.ebi.ac.uk/dali/Interactive.html).
Homology modeling of CbpA-RI. We used the program MOE (Chemical_Computing_Group) to
calculate a homology model of CbpA-R1 using the experimental structure of CbpA-R2 as the
template. Briefly, MOE first aligned the sequence of the target (R1) with that of the template
(R2). Next, the side chains of non-identical residues were built and side chain conformations
were adjusted by reference to a rotomer library followed by energy minimization using the
AMBER '94 forcefield.
SPR measurements. SPR experiments were performed at 25 C using a BIACORE 3000
instrument (Biacore, Inc.). sIgA and SC-D15 were covalently attached to different
carboxymethyl-dextran coated gold surfaces (CM-5 Chip, Biacore) using the manufacturer's
procedures. Binding was measured by flowing CbpA proteins in 10 mM HEPES, 150 mM NaCI,
3 mM EDTA, 0.005% Surfactant P20, pH 7.4 (HBS-EP buffer, Biacore) at a flow rate of 20
I[L/min through the reference and sIgA-containing flow cells in sequence. A blank was also run
consisting of only buffer. Following the injection, dissociation of CbpA proteins was measured
by flowing only buffer through the cells. The chip surfaces were regenerated by injecting 20 [tL
of 0.1% SDS through the cells. Data reported is the difference in SPR signal between the flow
cell containing sIgA and the reference cell. Contributions to the signal from buffer were removed
by subtraction of the blank (buffer only) injection from the reference-subtracted signal (Morton
and Myszka, 1998). Triplicate injections were made and the average taken. Data were analyzed
by simultaneously fitting association and dissociation phases at all concentrations using the
BiaEvaluation software (Biacore, Inc.). The model used for fitting was the simplest that was able
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to account for the observed binding. The concentrations of CbpA constructs used in these
experiments are given in the legend to Suppl. Fig. 3.
ITC experiments. ITC experiments were performed at 25 C using a VP-ITC (Microcal)
calorimeter. A preliminary 2 FtL injection of either CbpA-R1, CbpA-R2, CbpA-R12, or CbpA-
NR12 (all at 40 M) was followed by multiple injections of 5 [tL at 300 sec intervals into a
solution of 4 FM SC-D 15. All proteins were dissolved in 20 mM sodium phosphate, pH 6.5, 100
mM NaCl. Thermodynamic parameters were obtained using Origin software (OriginLab) using a
single binding site model after correcting heat values for the effect of dilution. The results of
titrations with the CbpA constructs and SC-D 15 indicated that the effective concentration of SC-
D15 was 1.42 [tM, indicating that only 36% of SC molecules were competent for binding CbpA.
This conclusion was confirmed using gel filtration chromatography, as follows. In the absence of
CbpA, SC-D15 migrated as a single species. Addition of an excess of CbpA-R1 caused only
-40% of the parent SC peak intensity to shift to a more rapidly migrating species (corresponding
to the CbpA-Rl:SC-D15 complex). Formation of this complex was complete upon addition of
approximately 0.8 molar equivalents of CbpA-R1. We used this effective concentration of SC-
D15 (1.42 jtM) when analyzing raw heat data to obtain CbpA:SC-D15 mole ratios (Table 1).
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Table 1. Thermodynamic parameters obtained from analysis of ITC data for CbpA fragments
binding to SC-D15 in solution.
Construct AG (kcal mol1 ) AH (kcal mol") -TAS (kcal mol") N.noaa.,d* (moles
CbpAlmoles SC)
CbpA-R1 -9.82 ± 0.01 -26.60 ± 0.05 +16.78 ± 0.10 1.86 ± 0.01
CbpA-R2 -10.23 ± 0.02 -21.19 ± 0.07 +10.96 ± 0.10 2.19 ± 0.01
CbpA-R12 -10.39 ± 0.02 -46.30 ± 0.14 +35.91 ± 0.10 0.87 ± 0.01
CbpA-NR12 -10.40 ± 0.01 -38.88 ± 0.07 +28.48 ± 0.10 1.07 ± 0.01
* Nnormed values were determined using 1.42 [tM as the effective SC-D1 5 protein concentration
(see Experimental Procedures for details). AG, AH and -TAS values are in units of kcal per mole
of CbpA construct.
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Table 2. Statistics of 20 lowest-energy structures of CbpA-R2 based on solution NMR data.
Total number of NOEs 2,292
Intra-residue 922
Inter-residue 1,370
Sequential 622
Medium-range (i, i up to ± 4) 599
Long-range (i, i 5 or larger) 149
Total number of dihedral restraints 166
VC 83
q~¢~~~~~ ~83
RMSD from mean structure (A)
All residues within structural region
Backbone heavy atoms (328-425) 1.1 ± 0.2
All heavy atoms 1.8 ± 0.4
Helixes 1-3 (residues 330-357, 365-390, 395-425)
Backbone heavy atoms 0.6 ± 0.1
All heavy atoms 1.5 ± 0.3
Distance restraint violations (average number per structure)
Restraints violated by >0.50 A 1.5
Maximum distance restraint violation (A) 1.7
Torsion angle restraint violations (average number per structure)
V restraints violated by >50 0
q restraints violated by >5° 0
Ramachandran , 0 statistics
Angles in most favored region 86.7%
Angles in allowed region 10.2%
Angles in generously allowed region 2.4%
Angles in disallowed region 0.7%
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Figure 1. Domain structure of CbpA (from the TIGR4 strain of Streptococcus pneumoniae). (A)
Domains labeled A, B, R1, R2 and C exhibit multiple repeats of the LZ motif, and the domain
labeled CBD (choline binding domain) contains eight repeats of the choline binding motif. (B)
Leucine zipper probability for CbpA determined using COILS (Lupas et al., 1991). (C)
Sequences of domains R1 and R2. The letters a-g and horizontal lines indicate the locations of
the 12 LZ heptad motifs. Within the LZ motifs, hydrophobic residues are colored brown (L, V, I,
and A); acidic residues, red (D and E); and basic residues, blue (K and R). Sites in the R1 and R2
sequences where an acidic residue is swapped for a basic residue, or vice versa, are indicated by
red and blue shading, respectively. Residues of the conserved RNYPT motif are colored green
and the three a-helices of CbpA-R2 are indicated by black rectangles. Residues that are
conserved in 87 R domain sequences from 47 pneumococcal strains are also given.
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Figure 1. Domain structure of CbpA (from the TIGR4 strain of Streptococcus pneumoniae).
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Figure 2. R domain structure is conserved in CbpA sequences from most pneumococcal strains.
(A) Phylogenetic tree showing the relationships between 47 CbpA sequences, which cluster into
six groups. The TIGR4 sequence is also termed PspC 3.4 (marked by arrow). (B) The histogram
illustrates the percentage of amino acid identity (relative to TIGR4 CbpA) for the R1 and/or R2
domains (R1, blue bars; R2, red bars). Details of this analysis are found in Supplementary data.
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Figure 3. Secondary structure of CbpA domains. (A) CbpA constructs used in this study. (B) CD
spectra for CbpA-N (violet trace), -R1 (blue trace), -R2 (red trace), and -NR12 (green trace). (C)
Thermal denaturation traces obtained by measuring CD ellipticity at 222 nm at different
temperatures. The coloring scheme is as in (B).
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Figure 4. Solution structure of CbpA R domains. (A) Secondary 13Ca chemical shift values for
CbpA-R2 showing the three a-helices. Resonances for residues marked by red asterisks are
unassigned. (B) Superposed ensemble of 20 lowest-energy structures of CbpA-R2 obtained from
solution NMR data; the backbone and select hydrophobic residues (in brown color) at the two a-
helix/a-helix interfaces are illustrated. Helix 1 is colored red; Helix 2 blue; and Helix 3 green.
The location of the YPT motif is noted. (C) End-on view of the three a-helices of domain R2,
colored as in (B). (D) Contour maps of electrostatic potentials (± lkt; red, negative potential;
blue, positive potential) for CbpA-R2 (left) and homology model of CbpA-R1 (right) generated
using GRASP (Nicholls et al., 1991). The ca-helices are colored as in (B). Tyr 358 & 363
(magenta; labeled "tyrosine fork"), Pro 359 (yellow), and Thr 360 & 362 (orange) are also
illustrated. The Ca atoms of other conserved residues are illustrated as colored spheres (Lys 346,
Arg 356 and Lys 364 (blue); Glu 352, Asp 354 and Glu 372 (red); Gln 350 & Thr 365 (gray);
Ala 347, Ile 368, Ile 370, Ala 371, Val 375, Val 377, Ala 80 and Leu 382 (yellow)). (E) Close-up
view of conserved residues in loop between Helix 1 and Helix 2 of CbpA-R2 that protrude into a
region of neutral electrostatic potential. Key residues are illustrated as in (D).
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Figure 6. Insights into the molecular mechanism of CbpA/pIgR interactions. (A) Histogram
illustrating the association (ka) and dissociation (kd) rate constants derived from SPR data for
different CbpA constructs interacting with immobilized sIgA. The rate constants were obtained
by fitting equations for a 1:1 binding model to raw data like those illustrated in Supplementary
Figure 2B. (B) Raw ITC data (top) and binding curves (bottom) for CbpA-R1 (blue), -R2 (red), -
R12 (black) and -NR12 (green) binding to SC-D15. In the bottom panels, the colored circles
show raw data points and the black lines show the fit of equations for a single binding site model
to the raw data. Only every second data point is illustrated although all points were included in
the analysis. The CbpA fragment:SC-D15 mole ratios at the reaction endpoints are noted in each
bottom panel. (C) Adhesion of pneumococci to NE (Detroit) cells. ACbpA- pneumococci were
transformed with pNE1 plasmids that encoded full-length CbpA or CbpA with one or two
mutations within the YPT motif. ACbpA- (control) corresponds to results for untransformed
ACbpA- bacteria.
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Supplementary Material
Materials and Methods
Construction of CbpA expression plasmid. The following segments of CbpA genomic DNA from
the TIGR4 strain of Streptococcus pneumoniae (accession number: nucleotide, AAK76241;
protein, AAK76241) were sub-cloned into plasmids for protein expression in E. coli: residues
39-174 (CbpA-N), 175-289 (CbpA-R1), 329-443 (CbpA-R2), 175-443 (CbpA-R12), 39-321
(CbpA-NR1) and 39-442 (CbpA-NR12). CbpA-N, CbpA-R1, CbpA-R2, and CbpA-R12 were
subcloned into the bacterial expression vector pET28a (Novagen). CbpA-NR1 and CbpA-NR12
were subcloned into pQE-30 (Qiagen). Site-directed mutagenesis was used to introduce
mutations into the expression plasmid for CbpA-NR12 (pQE-CbpA-NR12), as follows. In each
construct, the following residues were mutated to Gly, Tyr 205 (pQE-CbpA-NR12-Y205G), Tyr
358 (pQE-CbpA-NR12-Y358G), Tyr 205 and Tyr 358 (pQE-CbpA-NR12-Y205G/Y358G), Pro
206 (pQE-CbpA-NR12-P206G), Pro 359 (pQE-CbpA-NR12-P359G), and Pro 206 and Pro 359
(pQE-CbpA-NR12-P206G/P359G). Further, full-length genomic DNA for CbpA was subcloned
into pNE1 (Bartilson et al., 2001) (pNE1-CbpA) to express CbpA in ACbpA- pneumococci. Site-
directed mutagenesis was used to prepare pNE1 plasmids for expression of full-length CbpA
with the same mutations as described above; these plasmids were pNE1-CbpA-Y205G; pNE1-
CbpA-Y358G; pNE1-CbpA-Y205G/Y358G; pNEl-CbpA-P206G; pNEl-CbpA-P359G; and
pNE 1-CbpA-P206G/P359G.
Expression and purification of CbpA proteins. The pET and pQE CbpA plasmids were used to
express CbpA fragments as His-tagged polypeptides in E. coli BL21(DE3) (Studier et al., 1990)
using standard procedures. Proteins were purified using Ni2+-affinity chromatography
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(Amersham-Pharmacia resins), followed in some cases (CbpA-Rl, -R2, and -R12) by thrombin
(Calbiochem) cleavage to remove the His-tag. CbpA-N, -NR1 and -NR12 exhibited secondary
site cleavage by thrombin within the CbpA sequence and, therefore, were prepared with intact
His tags. Proteins were further purified by gel filtration chromatography (Superdex 200,
Amersham Biosciences) in 20 mM sodium phosphate, pH 6.5, 20 mM NaCl, and 0.02% (w/v)
sodium azide. CbpA proteins contained exogenous N-terminal residues, as follows: CbpA-N,
MGSSHHHHHHSSGLVPRGSHM; CbpA-NRl and -NR12, MRGSHHHHHHGSM; and CbpA-
R1, -R2 and -R12, GSHM. Protein concentrations were determined using absorbance at 280 nm
(Gill and von Hippel, 1989) and extinction coefficients determined using the ProteinParameters
tool at the ExPASy web site (http://us.expasy.org/tools/protparam.html).
CD experiments. Circular dichroism (CD) spectra (Fig. 3B and C) were recorded at 25 °C using
an AVIV 62A DS spectropolarimeter in 1.0 cm path length quartz cells. CbpA samples were
prepared by dialysis against 1 mM sodium phosphate, pH 6.5, 50 mM NaCl. In thermal
denaturation experiments, the ellipticity at 222 nm was recorded after 1 min. equilibration at
temperatures from 5 °C to 95 C in 2 °C steps.
CbpA-sIgA binding experiments using ELISA. To analyze CbpA-sIgA binding, each well of a 96
well plate was coated with 0.5 mg purified recombinant CbpA protein. Wells were blocked for 1
hour with rabbit serum (diluted 1:50 with 10 mM sodium phosphate, pH 7.2, 150 mM NaCl
(PBS)), and 0.5 mg sIgA protein (ICN) was applied for 1 hour. After washing with PBS, an
antibody to secretory component (Sigma) was applied after a 1:2000 dilution in PBS for 1 hour.
Biotinylated anti-mouse IgG (Vector Labs) and ABC detection reagent were then applied
119
according to the manufacturer's protocol. Turbo TMB (Pierce) was used as a chromogenic
substrate. Reactions were stopped with 1 M sulfuric acid, and the absorbance at 450 nm of each
well was determined with a plate reader. All reactions were performed in triplicate at room
temperature.
AUC experiments. Sedimentation equilibrium experiments were performed with CbpA-N,
CbpA-R1, CbpA-R2 and CbpA-A at 20 C in a Beckman XL-A analytical ultracentrifuge, at
operational speeds in the range 27,000 - 40,000 rpm. The polypeptide concentrations for CbpA-
N, CbpA-R 1, and CbpA-R2 ranged from 0.01 mM to 4 mM. Polypeptides were dissolved in 20
mM sodium phosphate buffer, pH 6.5, in the presence of 0 mM, 50 mM or 200 mM NaCl.
Depending on the protein concentration either 12 mm or 3 mm optical path length cells were
used. Data were manipulated using the Beckman XL-A software.
The software INVEQ (Rowe, in preparation) was employed to analyze sedimentation
equilibrium data. INVEQ fits the data set to the following equation:
r = {(ln(crc) + 0.5*(ow/(1+2BMcr))*ri2) / (0.5*(ow/(1+2BMcr)))}0.5 (Equation 1)
where r is any radial position at which the solute concentration c has the value cr, and ri and c; are
the values of these parameters at a defined reference position. The latter radial position is
usually taken as being the data point closest to the meniscus. The parameter a is the reduced
molecular weight of the solute, defined as
o = M(1 - vp)co2/2RT (Equation 2)
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where M is the molecular weight of the solute, v (ml/g) its partial specific volume, p is the
density of the solvent, w (radians/sec) the angular velocity of the rotor, R is the gas constant and
T the temperature (K).
For any monomer-dimer equilibrium system it is simple from a knowledge of the
equilibrium association constant (Ka) and the solute molar concentration to define the mole
fraction a of monomers which have dimerised, from which the weight averaged a value ((Cw, in
mass rather than molar units) can be derived. Representing the thermodynamic non-ideality by a
single second virial coefficient term BM (formally the B value is a B,1, term) assumed to be the
same for both monomer and dimer, the apparent a value (apparent ) to be used in the equilibrium
equation is given by
0
apparent = (w/(l+2BMcr)). (Equation 3)
It should be noted that equation 1 is simply a usual form of the equation for sedimentation
equilibrium inverted to give r = f(c) rather than the normal c = f(r) format. Although apparently
trivial, this is important for stability in curve fitting. The more usual (c = f(r)) format becomes
recursive when terms covering self-association and/or non-ideality are introduced. The INVEQ
format avoids this problem, and by providing a more rigorous way of fitting for Ka than is
employed in direct fitting methods (Rowe, in preparation) it becomes possible to float both Ka
and the non-ideality term (BM) in the fitting algorithm. Using this approach, it was possible to
estimate weak (Kd up to 100 mM) interaction coefficients despite the inevitable presence of a
non-ideality term of similar numerical magnitude.
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All data were analyzed using locally written programs in the software Pro FitTM
(Quantumsoft). In order to obtain a fit when lower solute concentrations were being studied we
either fixed BM = 5 ml/g, a typical value for this system, and/or we floated the baseline offset E.
The latter quantity can justifiably be set equal to zero for higher c values, where absorption
optics are in use, but small errors can cause problems with more dilute systems.
CbpA sequence analysis. Methods. The analysis of CbpA (Fig. 2) was performed using Vector
NTI 9.0.0 software (Informax). The accession numbers for CbpA sequences are as given in
Tables 1 and 2 of Iannelli, et al. (Iannelli et al., 2002). The sequences of the C-terminal choline
binding domains were deleted before analysis so that relationships within the N-terminal
segments could be more clearly observed. The phylogenetic tree illustrated in Fig. 2A was
generated using the Align feature in Vector NTI, which uses the Neighbor Joining (NJ)
algorithm of Saitou and Nei (Saitou and Nei, 1987). For Fig. 2B, all CbpA sequences were
individually aligned with the sequences of domains R1 and R2 from the TIGR4 strain. If
similarity to one or both domains was identified, the percentage identity was determined. Also,
whether the sequence RNYPT was identified within the R domains was noted. The sequences of
the R1 and/or R2 domains were aligned; the consensus sequence illustrated in Fig. 1C shows
residues that are identical in all 87 R domain sequences. The sequence of the R2 domain of
PspC 5.2 used in this analysis consisted of residues 308-371 which correspond to Helices 1 and 2
of the CbpA TIGR4 R2 domain.
Results. The N-terminal segments of the 47 CbpA sequences can be divided into six
phylogenetically related groups. The CbpA sequences in Groups 1, 2, 5 and 6, including the
TIGR4 sequence (also referred to as PspC 3.4) (Iannelli et al., 2002), are highly related and all
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but four (PspC 3.12, PspC 5.2, PspC 6.4, and PspC 6.14) exhibit two R domains that are very
similar to domains R1 and R2 of the TIGR4 sequence (Fig. 2B). The sequence of PspC 3.12
(Group 1) exhibits only one R domain, which is most similar to the TIGR4 R2 domain. PspC 5.2
(Group 5) exhibits a typical R1 domain but lacks a complete R2 domain. However, a segment of
this sequence is 85% identical to the Helix 1 and Helix 2 segment of domain R2 of CbpA-
TIGR4, including the conserved residues illustrated in Fig. 1C. PspC 6.14 (Group 6) exhibits a
single R2-like domain while PspC 6.4 (Group 6) exhibits a single Rl-like domain. A lone
sequence constitutes group 4, PspC 2.1, which contains a single R2-like domain. R domain
sequence similarity is illustrated in Fig. 2B. Group 3 is comprised of three CbpA and four
CbpA-like sequences that each exhibits a single R2-like domain, with identity to that of the
TIGR4 sequence ranging from 50% to 78%. All of the aforementioned sequences contain the
conserved consensus sequence (Fig. 1C), including the YPT motif and other conserved residues
(Fig. 1C and 4D).
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Supplementary Table 1. Values of the non-ideality term (2BM) and equilibrium dissociation
constant (KD) derived from analysis of sedimentation equilibrium centrifugation data for CbpA
domains.
Self-association parameters
Construct 2BM (ml g' ) KD (mM) Polypeptide
concentration
(mM)
CbpA-RI, 0 mM NaCI 4.2 22.2 4.5
CbpA-R1, 50 mM NaCI 15.0 2.4 1.9
CbpA-R1, 200 mM NaCI 8.0 4.0 3.4
CbpA-R2, 0 mM NaCI 13.4 75.8 2.4
CbpA-R2, 50 mM NaCI 9.5 106.0 2.7
CbpA-R2, 200 mM NaCI 15.0 67.3 1.9
CbpA-N, 0 mM NaCI 10.0* 10.0 0.4
CbpA-N, 50 mM NaCI 10.0* 10.0 0.4
CbpA-N, 200 mM NaCI 10.0* >100.0 0.4
* The non-ideality term (2BM) was set to these values to analyze AUC data under these
conditions.
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Supplementary Table 2. Association (k.) and dissociation (kd) rate constants obtained from
analysis of surface plasmon resonance data for CbpA fragments binding to immobilized sIgA or
SC-D15. Results from triplicate measurement are given.
Binding to sIgA Binding to SC
Construct k, (s" M') kd (s"') k, (s9 ' M') kd (s-')
CbpA-R1 1.93 ± 0.10 _10 2.71 ± 0.13 _10 2.11 ± 0.21 _ 10 5.65 ± 0.53 _ 10-
4
CbpA-R2 9.13 ± 0.59 _ 10- 3.71 ± 0.13 _ 104  4.38 ± 0.84 104 4.99 ± 0.14 _ 10'
4
CbpA-R12 138 ± 0.03 _ 10' 7.06 ± 0.47 _ 10 4.04 ± 0.34 _ 0s  2.50 ± 0.38 _ 10
4
CbpA-NRI2 2.55 ± 0.07 _ 10 5.57 ± 1.17 _ 10s  5.01 ± 0.20 _ 104 4.83 ± 0.30 _ 10
CbpA-NR12-Y205G 2.22 ± 0.63 _ 10s 2.41 ± 0.0.94 _ 104 9.69 ± 3.59 _ 104 8.49 ± 3.68 _ 10
CbpA-NR12-P206G 1.27 ± 0.01 10' 2.72 ± 0.12 _ 10 1.93 ± 0.71 _ Is 4.06 ± 0.57 _ 10
S
CbpA-NR12-Y358G 3.29 ± 0.02 _ 10 3.14 ± 0.26 _ 10 1.27 ± 0.03 _ 10s 2.51 ± 0.21 _ 10'
4
CbpA-NR12-P359G 6.64 ± 0.09 _ 10W 3.30 ± 0.13 _ 104 6.66 ± 3.62 _ 10 1.66 ± 0.62 _ 10'
4
CbpA-NR12-Y205G/Y358G 4.17 ± 1.26 -_ 1 2.90 ± 0.64 10.2 1.74 ± 0.86 _ 10s 1.83 ± 0.43 _ 10'
2
CbpA-NR12-P206G/P359G 1.03 ± 0.09 _ los 1.91 ± 0.27 - 10.2 ND* ND
SND, not determined.
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Supplementary Figure 1. Characterization of CbpA domains by NMR (A) and AUC (B-D).
(A) 900 MHz 2D 'H-'5N TROSY spectrum of 2H/'3C/'SN-labeled CbpA-R2. Resonances of
many residues overlap due to the repeating nature of the amino acid sequence (Fig. 1C). We
overcame resonance overlap by using TROSY (Pervushin et al., 1997) to narrow 'H and 15N
resonances and by using high magnetic field strengths. The crowded, central region is expanded
in the upper left panel. Representative sedimentation equilibrium data obtained for (B) CbpA-N
(0.4 mM), (C) CbpA-R1 (1.9 mM), and (D) CbpA-R2 (2.7 mM) dissolved in 20 mM sodium
phosphate, pH 6.5, 50 mM NaCl. Experimental data points are shown as colored circles and the
fit of Equation 1 to the raw data as a solid black line.
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Supplementary Figure 1. Characterization of CbpA domains by NMR (A) and AUC (B-D).
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Supplementary Figure 2. Molecular mechanism of CbpA/pIgR interactions. (A) Binding of
wild-type and mutant CbpA fragments to sIgA based on results from ELISA. Results for CbpA-
R1 (blue), CbpA-R2 (red) and CbpA-NR12 (green) are emphasized. NUS(-) corresponds to
background binding in the absence of a CbpA construct. (B) Raw SPR data for CbpA-R1 (blue),
CbpA-R2 (red) and CbpA-NR12 (green) binding to immobilized sIgA. The black lines show the
fit of equations for a 1:1 binding model to the experimental data (colored points). The
concentrations of CbpA constructs in the solutions that flowed over the sIgA or SC-D15 surfaces
were as follows (based on amino acid analysis): CbpA-R1, 1462, 731, 292, 146, 73.1, 29.2, 14.6
nM; CbpA-R2, 1450, 725, 290, 145, 72.5, 29, 14.5 nM; CbpA-N, 1584, 792, 396, 198, 99, 49.5,
24.8 nM; CbpA-R12, 4.0, 2.0, 1.0, 0.4, 0.2, 0.1, 0.04 nM; CbpA-NR1, 665, 333, 133, 66.5, 33.3,
13.3, 6.7 nM; and CbpA-NR12, 207, 82.9, 41.4, 20.7, 8.3, and 4.1 nM. The concentrations of
mutant CbpA-NR12 constructs used were as follows: 500, 250, 125, 62.5, 31.8, 12.5 and 6.3 nM.
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Supplementary Figure 2. Molecular mechanism of CbpA/pIgR interactions.
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CHAPTER 4
Expression and Crystallization Trials of pIgR, Fcca/tR, dFca and CbpA
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Introduction
As described in the previous chapters, pIgR plays a key role in mucosal immunity by
transporting pIgs to mucosal surfaces. Although the recent crystal structures of the pIg-binding
domain (D1) of pIgR (Hamburger et al., 2004) (Chapter 2) and the Fc fragment of IgA (Fca)
(Herr et al., 2003) have shed some light on IgA-based immunity, many questions remain to be
answered. For example, the extracellular region of pIgR contains five tandem Ig-like domains
(Mostov et al., 1984) and the detailed structural features of D2-5, and the overall arrangement of
the five domains, remain unknown. The high-resolution structure of dIgA also has not been
determined. Previous work has shown that dIgA is arranged in an end-to-end configuration with
one J chain molecule covalently bridging two IgA molecules (Garcia-Pardo et al., 1981) via a C-
terminal 18-residue extension in IgA, called the tailpiece (tp). The Fca structure revealed the
arrangement of the Ca2 and Ca3 domains (Herr et al., 2003), but did not contain tp. Further,
nothing is known about the high-resolution structure of J chain, or about the precise arrangement
of the two IgA (or Fca-tp) molecules with J chain in dIgA (or dFca). Ultimately, the cocrystal
structure of the pIgR-dFca complex will be necessary to fully understand the molecular details
of the mechanism by which pIgR binds dIgA.
Another point of interest is to determine the molecular basis for the specificity of pIgR
for pIgA and pIgM. FcaRI binds both monomeric and dimeric forms of IgA (Monteiro and Van
De Winkel, 2003), and Fca/!xR can bind to monomeric IgA in addition to pIgA and pIgM
(McDonald et al., 2002; Shibuya et al., 2000). Further structural studies of pIgR and Fca/tR are
needed to be able to compare the recognition properties of these receptors with those of FcaRI
(Ding et al., 2003; Herr et al., 2003). Although detailed structural information about the human
Fca/tR is currently unavailable, sequence analysis predicts an approximately 50 kDa
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extracellular region with an N-terminal Ig-like domain that shares 43% sequence identity with
the human pIgR D1 (Shibuya et al., 2000).
Although pIgR provides immunologic protection at mucosal surfaces, it is also used by
Streptococcus pneumoniae (pneumococcus) to invade human cells (Zhang et al., 2000). CbpA,
the major pneumococcus adhesin (Rosenow et al., 1997), contains two regions, R1 and R2,
which bind to D3-4 of human pIgR (Zhang et al., 2000)((Elm et al., 2004; Lu et al., 2003). The
recent solution structure of R2 revealed a unique three-a-helical structure, with the three helices
in an antiparallel orientation and a "tyrosine fork" involved in pIgR binding between the first two
helices (Luo et al., 2004) (Chapter 3). However, to determine the molecular details of the
interaction between pIgR and CbpA, the structures of full-length CbpA, D3-4 of pIgR, and the
complex between the two proteins need to be elucidated.
In order to address the topics mentioned above, I set out to obtain high-resolution crystal
structures of these proteins, alone and in complex with each other. To obtain diffraction quality
crystals of pIgR, dFca, Fca/[tR and CbpA, milligram quantities of these proteins are necessary.
With large and flexible proteins, such as these, a "divide and conquer" approach is sometimes
required either to get high expression levels, or to obtain diffracting crystals. Therefore, I made
a series of expression constructs (Table 1) based on secondary structure predictions, sequence
alignments with proteins of known structures, and available biochemical and mutagenesis data.
Another consideration for maximizing protein expression levels is what expression
system to use (Table 1). The extracellular region of pIgR contains seven N-linked glycosylation
sites (Hughes et al., 1999), which seem to be required for the efficient transport of pIgR during
transcytosis or for release from the apical surface (Matsumoto et al., 2003). However, these
carbohydrates are not necessary for specific binding to dIgA (Bakos et al., 1991). Therefore, I
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tried expressing pIgR fragments in both bacteria and baculovirus-infected insect cells. Since the
extracellular portion of Fca/[tR also has several N-linked oligosaccharide attachments sites
(Shibuya et al., 2000), baculovirus-infected insect cells were utilized for protein expression. An
E. coli expression system was used to express CbpA.
The most challenging of these proteins to express was dFca because of the complexity of
this protein. First, two molecules of Fca-tp form a homodimer and then two Fca-tp homodimers
and one molecule of J chain together from dFca. The human IgA tp contains a cysteine residue
and an N-linked glycosylation site that are required for efficient polymer assembly (Atkin et al.,
1996). Mature human J chain contains 137 amino acids including eight cysteine residues (Max
and Korsmeyer, 1985) of which six are involved in intramolecular disulfide bonds and two
intermolecular disulfide bonds to the tp penultimate cysteine in polymeric Igs (Bastian et al.,
1992; Bastian et al., 1995; Frutiger et al., 1992). J chain also has an N-linked oligosaccharide
attachment site, which appears to be important for the efficient assembly of dIgA (Krugmann et
al., 1997). J chain CyslS forms a disulfide bond with tailpiece Cys471 in the first Fcct
homodimer, and J chain Cys69 forms a second disulfide bond with Cys471 in the tailpiece from
the second Fca homodimer. The other two tailpieces, one from each homodimer, are linked
directly to each other by a disulfide bond (Bastian et al., 1995; Krugmann et al., 1997). Due to
the presence of essential N-linked oligosaccharide attachment sites and the extensive disulfide
bonding between J chain and Fca-tp, both baculovirus-infected insect cells and stably transfected
mammalian cells were used to coexpress the two proteins.
After optimizing the expression and purification conditions, I set up extensive
crystallization screens of the proteins alone and in complex with each other (Table 2). I have
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obtained small, disk-shaped crystals of the full-length pIgR ectodomain, although the current
crystals do not diffract. Additional crystallization and optimization trials are ongoing.
Materials and Methods
Expression and purification of pIgR
The cDNA encoding the full-length human pIgR was kindly provided by Roland K. Strong at the
Fred Hutchinson Cancer Research Center in Seattle, WA. Three constructs for bacterial
expression were generated: D1, MBP-D1 and D3-4 (Table 1). Expression, refolding and
purification of D3-4 (residues N214-V448) were performed as described for D1 (residues K1-
V109) (Hamburger et al., 2004) (Chapter 2). Briefly, the protein was expressed in E. coli
BL21(DE3) cells (Novagen) in inclusion bodies, which were solubilized in 8 M guanidine-HCl
and 10 mM DTT. The protein was refolded by rapid dilution in refolding buffer (100 mM Tris
pH 8.0, 400 mM L-arginine, 2 mM EDTA, 0.5 mM oxidized glutathione, and 5 mM reduced
glutathione) (Garboczi et al., 1992). The refolded protein was purified by gel filtration
chromatography. D1 was also subcloned into the pMAL-p2x expression vector (New England
Biolabs) for periplasmic expression as a fusion with the maltose binding protein (MBP). E. coli
BL21(DE3) cells (Novagen) were induced with 0.3 mM isopropyl-o-D-thiogalactoside (IPTG) at
an OD = 0.5 for 3-5 hours. The cells were lysed by osmotic shock and the protein was purified
on an amylose resin column. D1 was cleaved from MBP with Factor Xa protease (New England
Biolabs) according to the manufacturer's recommendations.
Seven additional pIgR constructs were generated by PCR for protein expression using
baculovirus-infected insect cells (Table 1). Six of the genes (D1, D1-3, D145, D1-5, SC577 and
SC607) were first subcloned into the pET20b vector in frame with the C-terminal 6xHis tag, and
then re-amplified by PCR to acquire the His tag, and subcloned into the pAcGP67A baculovirus
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expression vector (BD Biosciences) in frame with the gp67 hydrophobic secretion signal. D3-4
was amplified by PCR and subcloned directly into a modified version of pAcGP67A, containing
an N-terminal 6xHis tag and Factor Xa cleavage site. Expression and purification of the proteins
were carried out as previously described for SC607, which was referred to as SC-D15 (Luo et al.,
2004) (Chapter 3). Briefly, recombinant baculovirus was generated by cotransfection of a
transfer vector with linearized viral DNA. Recombinant proteins were isolated from the
supernatants of infected High five cells, which were concentrated and buffer exchanged into TBS
(20 mM Tris pH 8.0, 150 mM NaCl) and purified by NiNTA affinity and size exclusion
chromatography. Protein purity was analyzed by SDS-PAGE.
Expression and purification of Fca4pR
The cDNA encoding the full-length human Fca/[tR was kindly provided by Kenneth J.
McDonald at the Renal Unit, Western Infirmary in Glasgow, UK. Four Fca/tR constructs were
generated for protein expression using baculovirus infected insect cells (Table 1). The full-
length ectodomain (ecto; residues L1-R434) and the N-terminal Ig domain (residues L1-A165)
were subcloned into the pFastBacI vector (Life Technologies) with its native secretion signal
sequence and a C-terminal 6xHis tag and Factor Xa cleavage site. Ecto and the Ig domains were
also subcloned into the pAcGP67A expression vector in frame with the gp67 hydrophobic signal
sequence and an N-terminal 6xHis tag and Factor Xa cleavage site. Protein expression and
purification was carried out as described above.
Expression and purification of dFca (Fca-tp and J-chain) and dIgA
The cDNA encoding the human J chain was kindly provided by K. R. Chintalacharuvu at the
University of California, Los Angeles. For coexpression in baculovirus infected insect cells,
Fca-tp and J chain were subcloned into the pFastBacDual expression vector (Life Technologies)
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(Table 1). J chain, including its natural hydrophobic signal sequence (M1-D 159, the numbering
reflects inclusion of the secretion signal), was subcloned into the pFastBacDual multiple cloning
site (mcs) 1. Fca-tp (S240-Y473, encoding the IgAl Ca2 and Ca3 domains and the 18 residue
tailpiece) was first subcloned into a modified version of pAcGP67A (containing an N-terminal
6xHis tag and Factor Xa cleavage site) in frame with the gp67 hydrophobic secretion signal. The
gene was then re-amplified by PCR to acquire the signal sequence, 6xHis tag and protease
cleavage site and subcloned into pFastBacDual mcs2. To increase the amount of J chain
expressed, and therefore to increase the levels of secreted dimeric Fca, J chain (Q23-D159) was
also subcloned into the pAcGP67B expression vector in frame with the gp67 secretion signal for
co-infection with the pFastBacDual(Fca-tp/J chain) construct. Protein expression and
purification was performed as described above.
For expression in mammalian cells, Fca-tp (S240-Y473) containing an N-terminal 6x-
His tag and Factor Xa cleavage site was subcloned into the in pBJ5-GS-MCS3 expression vector
in frame with the rat IgG2a hydrophobic secretion signal (Martin and Bjorkman, 1999). J chain
(residues M1-D159) was subcloned into two mammalian expression vectors, pBJ5-GS-MCS and
pcDNA3.1(-) (Invitrogen). Chinese hamster ovary (CHO) cells were cotransfected with pBJ5-
GS-MCS3(Fca-tp) and pBJ5-GS-MCS(J chain) and stable colonies were selected and amplified
using methionine sulfoximine (MSX) as described previously (Martin and Bjorkman, 1999). To
increase the amount of secreted dFca, the stably transfected CHO cells were retransfected with J
chain in the pcDNA3.1(-) vector. Selection and amplification of stable cell lines using 100 tM
MSX and 750 [tg/mL Geneticin (Gibco) were carried out. A CHO cell line expressing Fca-tp
alone was also generated as described above, using 100 ptM MSX selection.
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Human dIgA was isolated from the sera of a patient with a pIgA-producing myeloma
(Vaerman et al., 1995) and purified as described previously (Hamburger et al., 2004) (Chapter
2).
Expression and purification of CbpA, R1 and R2
The S. pneumoniae TIGR4 strain CbpA gene was kindly provided by Elaine Tuomanen at St.
Jude Children's Research Hospital in Memphis, TN. CbpA (E39-A444), R1 (T174-A280) and
R2 (L327-A433) were amplified by PCR and subcloned into pET19b in frame with an N-
terminal 10xHis tag and Enterokinase cleavage site (Table 1). The proteins were expressed in E.
coli BL21(DE3) cells (Novagen) by induction with 0.4 mM IPTG at an OD = 0.5 for 5 hours at
37 C. The cells were lysed by sonication and the soluble proteins were purified by NiNTA
affinity followed by size exclusion chromatography on a Superdex 75 16/20 column (Amersham
Pharmacia).
Binding studies
Surface plasmon resonance (SPR) binding assays were performed using a BIAcore 2000
instrument (Pharmacia Biosensor, Uppsala, Sweden). Using this system, binding between a
molecule coupled to a biosensor chip and a second molecule injected over the chip results in
changes in the SPR signal that are monitored in real time as resonance units (RUs) (Malmqvist,
1993). To test whether the pIgR constructs were folded properly, dIgA was covalently coupled
at three different densities (412, 763, and 1426 RUs) to a reagent-grade CM5 sensor chip
(Biacore) using primary amine coupling, and the various pIgR proteins (the analytes) were each
injected over the chip. Similarly, to test whether CbpA, R1 and R2 were folded properly, each of
the three proteins was coupled to a CM5 sensor chip and pIgR SC607 was injected over the chip.
To test the activity of recombinantly-expressed dFca from CHO cells, pIgR SC607 was coupled
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to the biosensor chip at three different densities (2615, 5599, and 6567 RUs) and dFca was
injected over the chip. Fca-tp was also coupled to a chip and FcaRI was injected over the chip.
In each case one flow cell was mock coupled with buffer for background subtraction. To obtain
equilibrium dissociation constants (KDS) for D1 and D1-3, the sensorgrams were processed and
analyzed with the Scrubber software package (BioLogic Software, Australia). KDS were derived
by nonlinear regression analysis of plots of Req (the equilibrium binding response) versus the log
of the concentration of the injected analyte, and the binding data were fit to a single-site binding
model.
Protein crystallization
Purified proteins were concentrated to -5-110 mg/mL in an Amicon Ultra centrifugal filter
device with 10 kDa molecular weight cut-off for crystallization trials. Protein concentrations
were determined spectrophotometrically at 280 nm using extinction coefficients calculated from
the amino acid sequence of each protein using the ProtParam tool on the ExPAsy Proteomics
Server (Gill and von Hippel, 1989). Crystallization trials with grid screens and commercially
available sparse matrix screens were set up using both the hanging drop and sitting drop vapor
diffusion methods (Table 2).
Results and Discusssion
Expression, purification and characterization of pIgR
To produce sufficient amounts of pIgR for crystallization, three bacterial constructs (D1, MBP-
D1 and D3-4) were generated and tested for expression levels (Table 1). MBP-D1 was
expressed in the periplasm of E.coli, and purified on amylose resin. Cleavage of the fusion
protein with Factor Xa protease resulted in the release of insoluble D1 and not pursued further.
Expression, refolding, purification and characterization of D1 was described in Chapter 2
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(Hamburger et al., 2004), and the same methods were used to generate D3-4. Refolded D3-4
migrates in the position expected for the folded monomer on a gel filtration column (data not
shown).
Seven baculovirus expression constructs (D1, D1-3, D145, D3-4, D1-5, SC577, and
SC607) were also produced to test expression levels in baculovirus infected insect cells (Table
1). D1-5 expressed at less than 1 mg/L of insect cell supernatant and was not further pursued.
Slightly longer C-terminal truncations of the full-length extracellular region of pIgR, SC577 and
SC607, and the other constructs (D1, D1-3, D145 and D3-4) all expressed and were secreted
between 6 and 35 mg/L (Table 1). The recombinant proteins were harvested from baculovirus-
infected insect cell supernatants and purified by NiNTA and gel filtration chromatography to
over 95% purity (Figure 1). Each protein migrates in the position expected for the monomer on a
gel filtration column (data not shown).
To determine if the pIgR proteins were folded properly, a surface plasmon resonance
(SPR) binding assay using human dIgA was utilized. dIgA was isolated from the serum of a
patient with a pIgA-producing myeloma (Vaerman et al., 1995) and dIgA was purified as
described (Hamburger et al., 2004) (Chapter 2). dIgA was coupled to a biosensor chip and the
various pIgR proteins were injected. Both D1 proteins (refolded nonglycosylated, and insect
cell-expressed glycosylated) bind dIgA with an equilibrium dissocation constant (KD) of -300
nM (Hamburger et al., 2004) (Chapter 2). In the same binding assay, D1-3 bound dIgA with a
KD of -1 [M (data not shown). Since the N-terminal D1 domain of pIgR is necessary for
binding to dIgA (Frutiger et al., 1986), D3-4 was not expected to bind dIgA and therefore not
tested. However, in collaboration with Richard Kriwacki's laboratory at St. Jude Children's
Research Hospital, the ability of D3-4 to bind to CbpA was confirmed (data not shown). The
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other constructs (D145, SC577 and SC607) all contain Cys467 in D5, which forms a disulfide
bridge with Cys311 in Ca2 (Fallgreen-Gebauer et al., 1993). Due to the covalent nature of this
interaction we were unable to obtain off-rates or equilibrium dissociation constants for these
proteins. We were, however, able to show qualitatively that the binding interaction took place
and approximately 33% of the injected proteins remained covalently bound to the biosensor chip
(data not shown). The low pH and high salt conditions used to regenerate the chip after injection
of D1 and D1-3 did not result in obtaining the original baseline after injection of proteins
containing D5 because of the covalent interaction with dIgA.
Expression and purification of Fcal/tR
To try to obtain large amounts of Fca/pR sufficient for crystallization trials, baculovirus-infected
insect cells were used to express four different constructs (Table 1). Two of the constructs
contained the putative full-length ectodomain of the protein (residues L1-R434 of the mature
protein): one with the natural hydrophobic secretion signal and a C-terminal 6xHis tag, while the
other contained the baculovirus gp67 secretion signal and an N-terminal 6xHis tag. The other
two constructs contained the N-terminal region of the ectodomain, including the Ig-like domain
(residues L1-A165 of the mature protein). Similar to the full-length constructs, one of them
contained the natural secretion signal with a C-terminal 6xHis tag, while the other had the gp67
secretion signal and an N-terminal 6xHis tag. Analyses of the baculovirus infected insect cell
supernatants by SDS-PGE revealed that expression levels were very low (less than 1 mg/L),
regardless of the secretion signal used or the position of the affinity tag. Nonetheless, protein
was purified from the supernatants of baculovirus infected insect cells by NiNTA affinity and gel
filtration chromatography. The gel filtration profile indicated that the majority of the protein was
aggregated and eluted in the void volume. Therefore, due to the low expression levels and the
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apparent misfolding of the protein, further characterization and crystallization trials were not
attempted.
Expression, purification and characterization of Fca-tp and J-chain
In order to produce dFcca capable of binding to pIgR, expression levels in both baculovirus
infected insect cells and mammalian CHO cells were tested. For expression in insect cells, J
chain and Fca-tp (encoding IgA1 Ca2 and Ca3 domains and the 18 residue tailpiece) were
coexpressed using a dicistronic expression vector, pFastBacDual (Life Technologies). The
protein was purified by NiNTA and gel filtration chromatography, which revealed the presence
of both monomeric Fcca as well as polymeric Fcca (pFca) in the preparation (Figure 2A). Others
have observed that polymerization of another polymeric immunoglobulin, pIgM, depends on the
amount of J chain present, where an increase in J chain production results in an increase in J
chain-containing IgM secretion (Niles et al., 1995). Therefore, in order to try to increase the
ratio of secreted dFcct to monomeric Fca, the J chain gene was subcloned into another
expression vector, pAcGP67B, for coinfection with the dicistronic vector. However, coinfection
with the two recombinant baculoviruses resulted in the drastic decrease in expression levels of
both proteins (P.M. Snow and A.E.H., unpublished observations). Later protein preparations,
using a new viral stock of recombinant baculovirus containing the dicistronic vector showed an
increase in the amount of pFca and dFcct relative to the amount of monomeric Fca (Figure 2B).
For expression in mammalian cells, CHO cells were cotransfected with Fca-tp and J
chain in the expression vectors pBJ5-GS-MCS3 and pBJ5-GS-MCS, respectively, and a stable
cell line expressing both proteins was generated using MSX selection. As was the case for the
insect cells, both monomeric Fcca and pFca were purified from the supernatants of the CHO cells
(Figure 2C). The pFca peak was broad with two shoulders. The peak that eluted first was
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assumed to be higher ordered oligomers, and the peak that eluted second was assumed to be
dFcca. To increase the amount of secreted dFca, the stably-transfected CHO cells were
retransfected with the J chain gene in another vector, pcDNA3.1(-) (Invitrogen), which uses a
different selection marker, G418 or Geneticin. Selection and amplification of a stable cell line
was repeated using both MSX and Geneticin (Gibco). Although the amount of secreted pFca
increased proportionally over the amount of monomeric Fca in the new cell line, both complexes
were nonetheless present (Figure 2D). Biosensor analyses of the purified proteins revealed that
dFca bound to pIgR SC607 coupled to the chip, but no binding was observed when monomeric
Fca was injected (Figure 3).
Expression, purification and characterization of CbpA, R1 and R2
The pIgR-binding protein on the surface of Streptococcus pneumoniae, CbpA, and two smaller
pIgR-binding CbpA fragments, R1 and R2, were expressed in E. coli and purified by NiNTA and
gel filtration chromatography. An SPR binding assay with SC577 coupled to the biosensor chip
and the CbpA proteins injected confirmed that the recombinantly expressed CbpA, R1 and R2
were folded properly and retained their ability to bind to pIgR (data not shown).
Protein crystallization trials
Proteins estimated to be over 95% pure by SDS-PAGE were concentrated to 5-110 mg/mL.
Protein concentrations were determined spectrophotometrically at 280 nm using extinction
coefficients calculated from the amino acid sequence of each protein. Crystallization trials with
pIgR constructs (refolded D1 and D3-4 as well as insect cell-expressed D1, D1-3, D3-4, D145,
SC577 and SC607); dIgA fragments (CHO cell-expressed Fcct-tp, dFca and commercially
available IgA (Sigma)), and CbpA constructs (bacterially-expressed CbpA, R1 and R2) were set
up using both grid screens and commercially available sparse matrix screens (Table 2).
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Although an extensive number of conditions were tested, diffracting crystals have not yet been
obtained. SC577 has yielded small crystals but attempts to improve these disk-shaped crystals
(Figure 4A) have not been successful. SDS-PAGE analyses of the highly reproducible disks
suggest they are protein crystals (Figure 4B), however X-ray diffraction was not observed.
In addition to setting up crystallization trials with the individual proteins, we also tried to
cocrystallize several protein complexes (Table 2). Soluble pIgR and dIgA are thought to interact
with a 1:1 stoichiometry (Morrison et al., 1997; Rindisbacher et al., 1995). Therefore, D1 or
SC577 were each mixed with dFcct in a 1:1 molar ratio prior to crystallization. ITC results
presented in Chapter 3 show that the stoichiometry of the CbpA:pIgR interaction is 1:1, while the
R1 and/or R2:pIgR ratio is 2:1 (Luo et al., 2004). Consequently, D3-4 or SC607 were each
mixed with CbpA in a 1:1 molar ratio, and both refolded and insect cell-expressed D3-4 were
each mixed with R1 and R2 with a 1:1:1 molar ratio prior to cocrystallization.
Summary
In the absence of high-resolution structural information, previous electron microscopy studies,
mutagenesis results and binding data have been used to propose models for the relative
arrangements of pIgR and dIgA (including J chain) in SIgA (reviewed in (Norderhaug et al.,
1999b; Rojas and Apodaca, 2002)). Given the complexity of the interactions between, and the
flexibility within, the molecules in SIgA, many potential structural arrangements are possible.
By combining data from available literature and results from the studies presented in Chapters 2
and 4, two of the more simple but structurally accurate models are described below (Figure 5).
In monomeric IgA, tp appears to fold up against the Ca3 domain (Boehm et al., 1999),
however its position in dIgA is unknown. Since dIgA is arranged in an end-to-end orientation
with disulfide bonds between the tp penultimate cysteine residues either directly to each other or
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to J chain, it is possible that at least the tps that are covalently bound to each other extend away
from the Ca3 domains, toward the partner molecule (Figure 5). Alternatively, if the tps remain
folded against the C3 domains, the two IgA molecules would be overlapping, with J chain
between two of the Ca3 domains.
Inhibition studies with Fab fragments specific for IgA have shown that the Ca3, and
possibly Ca2, domains of dIgA are involved in noncovalent binding to pIgR (Geneste et al.,
1986). Peptide binding studies have further implicated two loops in the Ca3 domain in the
binding interaction (Hexham et al., 1999; White and Capra, 2002) (Chapter 1, Figure 5A).
Additionally, the fact that J chain is a required component in pIgs for binding to pIgR suggests
that J chain may also form part of the binding interface with D1. Therefore it is likely that D1 of
pIgR interacts through noncovalent interactions with one of the two dIgA Ca3 domains whose tp
is covalently bound to J chain (Figure 5).
The SPR based binding experiments described in Chapters 2 and 4 showed that D1 binds
to dIgA with an equilibrium dissociation constant of 300 nM (Hamburger et al., 2004) (Chapter
2), D1-3 binds with an equilibrium dissociation constant of 1 [iM, and D145 retains its ability to
bind to dIgA through both noncovalent and covalent interactions (Chapter 4). Together, these
results suggest that D2-3 do not contribute to the binding affinity of human pIgR for dIgA.
Similarly, D2-3 in rabbit (Deitcher and Mostov, 1986; Frutiger et al., 1986) and murine (Crottet
and Corthesy, 1999) pIgR are not necessary for high affinity noncovalent interaction with dIgA,
and chicken pIgR has no ortholog to the mammalian D2 (Wieland et al., 2004). Therefore, in
these species pIgR D2-3 are not expected to interact with dIgA (Figure 5A). However, contrary
to our results, others have observed that D2-3 are required for human pIgR expressed on the
surface of cultured cells to bind to and transcytose dIgA (Norderhaug et al., 1999a). It is difficult
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to reconcile the difference between the two findings. Although the surface expressed D145
retained the ability to bind to pIgM, it was not recognized by an antibody specific for D5
(Norderhaug et al., 1999a), indicating the protein might have been misfolded in a way that
artificially disrupted binding to dIgA, but not pIgM. However, bovine pIgR also utilizes D2-3,
although to a lesser extent than D1, for binding dIgA (Beale, 1988), suggesting that in certain
cases pIgR D2-3 might make additional contacts with dIgA, either through Fcca, J chain, or both
(Figure 5B).
In human SIgA, pIgR D5 is covalently linked to the Ca2 domain of the second IgA
molecule in dIgA (Fallgreen-Gebauer et al., 1993). Since the Ca2 and Ca3 domains are
arranged symmetrically in monomeric Fca (Herr et al., 2003) human pIgR D5 may bind to either
monomer in the second Fcct homodimer with similar preference (Figure 5A). However, because
of J chain, dIgA is asymmetric so in cases where D2-3 enhance binding between the two
molecules, those domains may interact with dIgA such that it would orient D5 to be sterically
closer to one of the two Fcca homodimers (Figure 5B).
The models presented here take into account currently available data and represent two
likely arrangements of dIgA and pIgR. However, to fully understand the detailed intermolecular
interactions in SIgA, a cocrystal structure of pIgR in complex with dFca (or dIgA) is necessary.
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Table 1. pIgR, Fca/[tR, dFca and CbpA protein expression constructs. The table shows the
name of the constructs; the system used for expression (bacteria, baculovirus infected insect cells
or mammalian CHO cells); the expression vectors used, the name of the signal sequence used to
direct the protein for secretion; the type and location (C- or N-terminal) of the affinity tag; the
protease cleave site present to remove the affinity tag; the residues in the mature proteins; the
approximate molecular weights of the proteins not taking into account potential glycosylation;
the number of N-linked carbohydrate sites (listed as zero for all constructs expressed in bacteria);
and the expression level of each protein in mg/L.
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Table 2. Crystallization trials for pIgR, dFca, CbpA and complexes. The table shows the
different crystallization condition tested for each protein and protein complex. The names of the
commercially available sparse matrix screens are listed, and the numbers in parentheses indicate
the number of conditions in that kit. Crystal Screen I, Crystal Screen II, Peg/Ion, Salt Rx and the
Index screens were purchased from Hampton Research; Cryo I, Cryo II, Wizard I, and Wizard II
were purchased from Emerald BioStructures; and the Cation, Anion, and the PHClear Suite
screens were purchased from Nextal.
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Figure 1. SDS-PAGE analysis of purified pIgR proteins. plgR Dl (lane 1), D1-3 (lane 2), D145
(lane 3), SC577 (lane 4), SC607 (lane 5), and D3-4 (lane 6) were purified from the supernatants
of baculovirus infected insect cells. Protein preparations were analyzed by SDS-PAGE prior to
crystallization trials. The purity of each protein was estimated to be over 95%. Dl (lane 1) runs
as a doublet due to partial glycosylation at the two N-linked carbohydrate sites.
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Figure 2. Size exclusion chromatography profiles of dFca protein preparations. (A) Small scale
coexpression of Fca-tp and J chain in baculovirus infected insect cells results in the secretion of
mainly monomeric Fca. (B) Large scale coexpression of Fca-tp and J chain using a different
viral stock results in mainly dFca and pFca. (C) pFca purified from the supernatants of CHO
cells cotransfected with Fca-tp and J chain, both under selection with MSX. (D) pFca purified
from the supernatants of CHO cells retransfected with J chain under Geneticin selection.
Positions of molecular weight standards are indicated with arrows.
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Figure 3. Biosensor analyses of monomeric and dimeric Fcc binding to pIgR. Sensorgrams
from binding experiments in which monomeric Fcct-tp (A) or dFca (B) were injected over plgR
SC607 immobilized on a biosensor chip at three different densities. The end of the injection is
indicated with an arrow.
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Figure 4. SDS-PAGE analysis of pIgR SC577 crystals. (A) Disk-shaped crystals (~120 [Lm in
diameter) of SC577 were grown by hanging drop vapor diffusion and photographed in the drop.
(B) Three to four crystals were removed from the drop, washed three times in the crystallization
solution and analyzed by SDS-PAGE: last wash (lane 1), SC577 crystals (lane 2), molecular
weight standards (lane 3) and SC577 protein used for the crystallization trials (lane 4).
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Figure 5. Putative models for the structure of SIgA. pIgR (red) Dl binds to the Ca3 domain,
and possibly Ca2 domain and J chain, in the first IgA molecule in dIgA. (A) If pIgR D2-3 do
not interact with, or contribute to, dIgA binding, D5 might interact with the Cat2 domain in the
second IgA molecule that is sterically more accessible. (B) If pIgR D2-3 interact with dIgA,
pIgR D5 might be oriented to interact with the Ca2 domain in the second IgA molecule that is
on the opposite side of dIgA.
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APPENDIX I
Expression and Characterization of a Native Retroviral Envelope Glycoprotein
Appendix I describes my efforts to try to express a soluble, trimeric form of the Moloney Murine
Leukemia Virus envelope glycoprotein for structural studies.
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Introduction
Enveloped viruses such as influenza and the human immunodeficiency virus (HIV) pose a great
risk to human health. Although some important differences exist in the way they invade target
cells, it is likely that different families of enveloped viruses use similar mechanisms. In each
case the entry process requires fusion of the viral and cellular membranes, a process that is
mediated by the interaction between a key viral surface glycoprotein, env, and a cellular
receptor.
Retroviral envelope glycoproteins are synthesized as fusion-incompetent single chain
precursors that are post-translationally cleaved by a cellular protease to yield the surface (SU)
and the transmembrane (TM) subunits. The SU subunit is responsible for receptor recognition
and binding. The ectodomain of TM contains a hydrophobic region, called the fusion peptide,
which inserts into the membrane of the target cell. This initiates fusion between the viral and
cellular membranes, allowing the virus to deposit its genetic information into the cytoplasm of
the target cell. TM also contains a transmembrane region that anchors env to the viral membrane
and a cytoplasmic region that can vary in size from just a few residues to well over a hundred.
Env is thought to exist as a trimer of the SU/TM heterodimer on the surface of virions [1-3].
To date, the best-characterized surface protein involved in viral membrane fusion is
hemagglutinin (HA) of the orthomyxovirus, influenza. Similar to retroviral env glycoproteins,
HA is synthesized as a precursor protein, HAO, which is subsequently proteolyzed into two
disulfide-bonded subunits, HA1 and HA2 [4, 5]. HA1 is responsible for binding to the cellular
receptor, sialic acid, and is functionally equivalent to the retroviral SU subunit. HA2 is
membrane bound and is responsible for mediating fusion, similar to the retroviral TM subunit.
On the surface of virus particles, HA is a trimer of HA1/HA2 heterodimers [6].
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The structure of the native HA revealed that HA2 forms a mostly a-helical stalk with the
HA1 trimer at the membrane distal end contributing to the stalk, but primarily forming three
globular domains that contain the receptor-binding domain. The length of the molecule is
approximately 135 A and the fusion peptide is buried in a pocket close to the base of HA [7].
These observations suggested that the protein must undergo major conformational changes for
the fusion peptide to reach the target membrane. During infection, HA1 binds sialic acid at the
plasma membrane, but unlike retroviruses, fusion does not occur at this point. Instead, the virus
particle is taken up into the target cell by endocytosis. As the pH drops within the endosome,
HA undergoes major, irreversible conformational changes, as revealed by the low-pH converted
form [8]. HAl is thought to dissociate from the complex, the amino-terminus of HA2 is
displaced 100 A and at least 36 residues are recruited to the viral membrane distal end of the
triple stranded coiled coil seen in the native structure. This liberates and propels the fusion
peptide into the host membrane by the "spring-loaded" mechanism [9], resulting in membrane
fusion and the release of the viral core into the cytoplasm.
Based on striking structural and functional similarities to influenza HA, a membrane
fusion model for HIV, and presumably other retroviruses, has been proposed [10]. The envelope
protein is initially in its native, or pre-fusogenic, state on the surface of virions. Once SU (gp120
in the case of HIV) binds the cellular receptor (CD4 and chemokine coreceptor) conformational
changes occur in SU that alter the SU/TM (gpl20/gp41) interactions. This leads to
conformational changes in the TM subunit resulting in the insertion of the fusion peptide into the
target cell membrane. The TM domain then resolves into a fusion-active trimer-of-hairpins
structure, in which the N-terminal region forms a trimeric coiled coil and the C-terminal region
packs into the grooves of the coiled coil in an anti-parallel orientation [11]. This structural
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rearrangement results in the apposition of the cellular and viral membranes and leads to
membrane fusion. The fusion process can be inhibited in a dominant negative fashion by the
addition of synthetic C and N peptides, corresponding to the C and N terminal regions of the
prehairpin (Figure 1).
There are many high resolution structures of the fusion-active state of the membrane
anchored ectodomain subunits, including the retroviral TMs: HIV-1 gp41, simian
immunodeficiency virus (SIV) gp41, Moloney Murine Leukemia Virus (Mo-MLV) Mo-55, and
human T cell leukemia virus (HTLV-1) gp21 [11-15]; the orthomyxovirus influenza HA [8, 16];
and the filovirus Ebola GP2 [17, 18]. Despite considerable sequence diversity among these
viruses, they all share a number of common features. They all contain an N-terminal
hydrophobic fusion peptide (not seen in the crystal structures), an adjacent coiled coil forming
region, a disulfide bonded loop, and a second heptad repeat containing region at the C-terminus.
In contrast to the many fusogenic TM structures, there is only a limited amount of
structural information about retroviral SU subunits. A monomeric HIV-1 gpl20 structure at 2.5
A resolution was solved, although the variable loops, V1, V2 and V3 were deleted and the
construct was truncated at both the N- and C-termini. The protein is in complex with a two
domain fragment of human CD4 and an Fab from a neutralizing antibody that blocks coreceptor
binding, thus it may represent a non-native conformation [19]. A model of trimeric gpl20 has
been proposed, although the structure has not yet been solved [20]. The monomeric receptor-
binding domain (RBD) of Friend MLV (Fr-MLV), which comprises approximately half of the
SU subunit, has also been solved to 2.0 A resolution [21]. A model for the trimeric packing of
the Fr-RBD was also proposed [22]. However, currently there are no structures of trimeric
retroviral SU/TM complexes. Therefore, the location of the fusion peptide, the contacts between
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the SU and TM subunits and the interactions between the three SU/TM complexes within the env
are unknown in the native state.
The availability of a high-resolution structure of a native envelope protein would provide
a better understanding of retroviral binding and entry. This information would help to validate
and complete the current model for viral membrane fusion. It may also have implications for
structure-based drug discovery, the development of gene therapy vectors with defined cellular
receptor specificity, and for the identification of new targets for viral entry inhibitors.
Ultimately we want to understand how human pathogenic retroviruses, such as HIV,
invade cells. However, we expect that all retroviruses utilize very similar, if not identical,
mechanisms to gain entry into target cells. Therefore, for technical reasons we chose to study
one of the simple retroviruses, Mo-MLV, as a model system. Mo-MLV is expected to be a better
candidate than HIV for structural studies for a number of reasons. For example, Mo-MLV is
smaller in size, less heavily glycosylated, and the SU/TM subunit association is more stable (due
to the disulfide bond) than in HIV.
In the case of Mo-MLV, the precursor gp85 is cleaved into the SU (gp70) and TM (p15E)
subunits that remain covalently associated via a labile disulfide bond [23]. During or shortly
after viral budding, pl5E is further processed by the viral protease (PR), which removes the C-
terminal 16 residues of the cytoplasmic tail, the R peptide [24, 25] (Figure 2). This cleavage is
responsible for increasing the fusogenic ability of env [26, 27].
Mo-MLV is the prototype of the mammalian C-type retrovirus group. The murine
viruses within this group are further classified according to their host range and superinfectivity
resistance, a phenomenon in which prior infection with a retrovirus blocks further infection of
the same cell by another retrovirus that uses the same receptor. Replication of Mo-MLV is
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restricted to cells of mouse or rat origin, so it is classified as an ecotropic virus. The cellular
receptor for ecotropic MLVs is the 14-pass transmembrane murine cationic amino acid
transporter, mCAT-1 [28-30]. As with most other retroviruses, receptor binding and membrane
fusion occur at the plasma membrane at neutral pH.
In order to better understand the mechanism that retroviruses utilize to invade target cells,
we used biophysical and biochemical methods to characterize the Mo-MLV envelope
glycoprotein in its native state. We used several different recombinant expression systems to try
to obtain milligram quantities of purified protein necessary for crystallization trials. We also
characterized the protein using analytical ultracentrifugation, circular dichroism and chemical
cross-linking.
Materials and Methods
Construction of Mo-Env expression vectors
pCL-Eco [31] was kindly provided by Harvey F. Lodish (Whitehead Institute for Biomedical
Research, MIT, Cambridge, MA). pCL-Eco, which contains the Mo-MLV env gene from strain
J02255 of the virus, was used as the PCR template to generate expression constructs. See Table
1 for construct details.
Expression and purification of Mo-Env in bacteria
Constructs designed for bacterial cell expression (Table 1) were transformed into E.coli
BL21(DE3)pLysS or AD494 cells (Novagen). Protein expression was induced with IPTG and
analyzed by SDS-PAGE. A1-233, the protein with the highest expression level, was refolded
from inclusion bodies and purified by Ni-NTA affinity followed by size exclusion
chromatography on a Superdex 200 26/60 gel filtration column (Amersham Biosciences).
Expression of Mo-Env in Drosophila cells
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Stable Drosophila cell lines expressing the Mo-MLV env were generated according to the
manufacturer's DES protocol (Invitrogen). Briefly, cells were cotransfected with one of the two
Mo-MLV env DNA constructs (Table 1) and the selection vector, pCoHYGO, using the calcium
phosphate transfection reagents included in the kit. Stable cells were selected with 300 [tg/mL
hygromycin-B. Supernatant was continuously harvested from cells transfected with the
pAc5.1/V5-HisA(env) construct, which utilizes the Ac5 promoter for constitutive expression of
the gene of interest. Recombinant protein expression from the cells transfected with the
pMT/BiP/V5-HisA(env) construct was induced with the addition of 500 jiM copper sulfate.
Supernatants were analyzed for protein expression by SDS-PAGE and western blotting.
Expression and purification of Mo-Env in baculovirus infected insect cells
Two different systems were used for protein expression in baculovirus infected insect cells. All
of the constructs in the pFastBacl vector (Table 1) were expressed in Sf9 cells using the Bac-to-
Bac Baculovirus Expression System according to the manufacturer's protocol (GibcoBRL, Life
Technologies). Briefly, recombinant bacmid DNA was isolated from DH1OBac cells
transformed with the recombinant pFastBacl vector, and used to transfect Sf9 cells.
Recombinant baculovirus was harvested from the supernatant several days after the transfection
and used to amplify the virus and to infect Sf9 cells for recombinant protein expression. The
four constructs in the pAcGP67B and pAcSecG2T transfer vectors were cotransfected with
linearized viral DNA (Baculogold, BD Biosciences) to generate recombinant baculovirus and the
proteins were expressed in High Five insect cells. Secreted env proteins were harvested from the
supernatants of infected cells, which were dialyzed against or buffer exchanged into Tris
buffered saline (TBS; 20 mM Tris pH 8.0, 150 mM NaCl) and purified by Ni-NTA affinity
(Qiagen) followed by size exclusion chromatography. Supernatants were also passed over an
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immunoaffinity column prepared by coupling a purified monoclonal a-SU antibody from the
supernatant of a rat hybridoma (83A25) [32] to cyanogen bromide activated sepharose 4B beads
(Pharmacia).
Expression of Mo-Env in yeast
To test yeast as an expression host, Mo-MLV env constructs were made for expression in Pichia
pastoris and Saccharomyces cerevisiae (Table 1). Pichia expression tests were performed
according to the manufacturer's instructions (EasySelect Pichia Expression Kit, Invitrogen).
Briefly, the Mo-MLV env genes were subcloned into the pPICZa expression vector in frame
with the a-factor hydrophobic secretion signal. Pichia pastoris strains X-33 and GS1 15(his4)
were transfected with the recombinant plasmid and protein expression was induced by the
addition of methanol. Protein secretion was monitored by incubation of the media with Ni-NTA
beads and analyzed by SDS-PAGE. The constructs for expression in S. cerevisiae (Table 1)
were subcloned into the p423Gall vector and cells were transformed with the plasmids but
expression was not tested.
Expression of Mo-Env proteins in mammalian cells
Stable mammalian cells were also generated to express the Mo-MLV env protein (Table 1).
293T cells were transiently transfected with full-length env constructs using the ProFection
mammalian transfection system according to the manufacturer's protocol (Promega). Protein
expression was analyzed 48 hours post-transfection by SDS-PAGE and western blotting. For the
expression of secreted proein, stable CHO-K1 and CHO lecR- 3.2.8.1 cells [33] were generated
as described [34]. Briefly, CHO cells were transfected with approximately 16 [tg of DNA and
stable colonies were selected with 100 p.M methionine sulphoximine (MSX). Supernatants
containing secreted protein were harvested and analyzed by SDS-PAGE and western blotting.
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Chemical cross-linking
Chemical cross-linking experiments were carried out using a modified version of a published
protocol [35]. Briefly, 6.7 fig of AC was incubated with 0.08, 0.8 or 4.0 mM concentrations of
ethylene glycolbis(succinimidylsuccinate) (EGS; Pierce) in 10 FtL reactions at room temperature
for 30 minutes. 0.6 [L of Tris-HC1 pH 7.4 was added to quench the reaction and incubated on
ice for an additional 20 minutes. The cross-linked products were analyzed by SDS-PAGE. The
same experiment was also performed with a constant concentration of 0.2 mM EGS and
increasing amounts of AC (3.3, 6.7 and 10 g). The cross-linked samples were analyzed by
SDS-PAGE and western blotting using a monoclonal a-PentaHis antibody (Qiagen).
Circular dichroism analyses and thermal denaturation
CD experiments were performed with an AVIV 62A DS spectrometer. Absorbance readings
from 190 to 250 nm were recorded on a 4.5 IM solution of AC in Hepes buffered saline (HBS;
20 mM Hepes pH 7.0, 150 mM NaCl) at 25 C. The thermal denaturation of AC (4.5 [LM in
HBS) was monitored at 220 nm from 1 to 99 °C in 2 °C increments.
Sedimentation velocity analytical ultracentrifugation
Sedimentation velocity analytical ultracentrifugation experiments were performed with a
Beckman Coulter Optima XL-1 analytical ultracentrifuge. Two solutions of ARBD (11.1 and
-31 M in TBS) were centrifuged at 36,000 rpm at 20 C, and two solutions of AC (2.3 FLM in
HBS and 2.9 FM in citrate buffered saline (CBS; 20 mM sodium citrate pH 5.6, 150 mM NaCl))
were centrifuged at 30,000 rpm at 20 C. Absorbance readings for ARBD and AC were
measured at 280 and 230 nm, respectively. The data were fit using the c(s) and c(M) analyses of
SEDFIT, which calculates the differential sedimentation coefficient distribution or molar mass
distribution, respectively, taking into account sample diffusion [36].
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Crystallization attempts
RBD, ARBD and AC were concentrated to approximately 28, 20 and 7 mg/mL, respectively, and
crystallization trials were set up using both the hanging drop and sitting drop vapor diffusion
methods. Commercially available sparse matrix crystallization solutions (Hampton and Emerald
BioStructures) as well as homemade grid screens were used.
Viral infectivity and inhibition assay
Mo-36 [37] (the Mo-MLV N peptide; D481-F515) and Mo-MLV C peptide (T536-E565)
were synthesized on a Perkin Elmer Model 431 peptide synthesizer. Both peptides had an
acetylated N terminus and C terminal amide. The peptides were purified by reverse-phase high-
performance liquid chromatography on a Vydac C18 column using a water-acetonitrile gradient
in the presence of 0.1% trifluoroacetic acid and lyophilized. a-Mo-92 [37] polyclonal antibodies
were purified from rabbit serum on a protein A column (Pierce).
293T cells were cotransfected with pCL-Eco [31] and pMX-IRES-GFP [38] to generate a
replication defective virus carrying the gene for GFP, Mo-GFP. 48 hours post-transfection, cell
supernatants containing Mo-GFP virions were harvested. To titer the virus, NIH/3T3 mouse
cells were then infected with increasing amounts of Mo-GFP in the presence of 4 [tg/mL
polybrene. Based in the viral titer, inhibition experiments were carried out with 4 ItL of Mo-
GFP in the presence of increasing concentrations of Mo-MLV C-peptide (0, 0.01, 0.1, 1, 10 and
50 ItM) or ac-Mo-92 antibodies (0, 1.6, 16, 32, 80 and 160 nM).
Results and Discussion
Structural studies of retroviral envelope proteins have been hindered in part because the
glycoprotein complexes are difficult to produce in high quantities, many are heavily glycosylated
and the instability of the SU/TM complexes often leads to dissociation of the two subunits. In
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order to obtain a soluble, trimeric form of the native Mo-MLV env, we made a series of
constructs for recombinant protein expression using a number of different expression systems
including bacteria, stably transfected Drosophila cells, baculovirus infected insect cells, yeast
and stable mammalian cells (Table 1).
Protein expression and purification in baculovirus infected insect cells
To allow for proper folding and processing to occur, baculovirus infected insect cells were used
to express the Mo-MLV env protein in its native state. The original construct contained the
native Mo-MLV hydrophobic signal sequence to direct the protein into the endoplasmic
reticulum, the complete gp70 (SU) subunit and the ectodomain of p15E (TM), terminating just
prior to the transmembrane anchoring domain resulting in secretion of the protein. Similar
constructs have been used to successfully express a stable, soluble, trimeric ectodomain of the
SIV gpl60 in insect cells using a baculovirus expression system [35], and HIV gp140 [39] in
mammalian cells.
Analyses of the supernatants of insect cells expressing the Mo-MLV env protein revealed
that cleavage between the SU/TM subunits was only approximately 50% efficient using the
baculovirus expression system (data not shown). Others have also noted that proteolytic
processing is sometimes inefficient in insect cells when the level of protein synthesis is high.
For example, HA cleavage is slow and inefficient when produced in insect cells using a
baculovirus expression system compared to when expressed in a vertebrate cell line. Similar
observations have been reported for other viral proteins such as the HIV-1 gpl60 ([40] and
references therein). The heterogeneity of the protein due to partial cleavage is expected to cause
difficulties with crystallization. In addition, after cleavage of the precursor, the Mo-MLV SU
and TM subunits remain linked through a labile disulfide bond. The majority of viral SU and
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TM proteins derived from mammalian cells migrate independently by SDS-PAGE even in the
absence of a reducing agent. If virions are pretreated with N-ethylmaleimide (NEM) they
migrate as a covalent complex [23]. It has been proposed that this phenomenon is caused by an
endogenous reducing agent in the Mo-MLV env, a free thiol from an unpaired cysteine, that can
cause disulfide rearrangement and lead to the loss of the SU/TM association. The NEM would
block the free thiol and prevent the disulfide rearrangement [22]. Regardless, in the absence of
NEM long-term storage conditions could lead to the loss of the covalent SU/TM association and
result in shedding, which would be disadvantageous in attempts to crystallize the protein.
Therefore, to stabilize the SU/TM complex and to avoid heterogeneity due to incomplete
cleavage or shedding, we eliminated the SU/TM cleavage site (Table 1). The cleavage
recognition site, RHKR, was mutated to RHAA using site directed mutagenesis. Expression of
these mutants (AC) resulted in no detectable cleavage between the two subunits (data not
shown). We expect this mutation to still represent the native state of the ectodomain for two
reasons. First, the 2.8 A resolution uncleaved influenza HAO structure as compared to the
cleaved HA structure showed mainly minor changes in the overall structure, and all of them were
centered around the cleavage site [41]. Second, uncleaved Mo-MLV env is still incorporated
into virions, although they are non-infectious [42].
To eliminate another source of potential heterogeneity among the secreted proteins, we
also made a number of mutants to minimize the number of the N-linked glycosylation sites. The
mature SU subunit of Mo-MLV contains seven N-linked oligosaccharides [43]. Mutagenesis
studies have revealed that when each glycosylation site is mutated individually, five of the seven
mutants produce viable and infectious virions. Mutations at positions 2 and 3 (A2 and A3,
respectively) result in a detectable phenotype. A2 is temperature sensitive while A3 is lethal to
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the virus. A triple mutant, A147, also results in viable virus [44]. Friend Murine Leukemia
Virus (Fr-MLV), a related ecotropic MLV, contains eight N-linked glycosylation sites. The Fr-
MLV A4 mutation is analogous to Mo-MLV A3, and is the only mutation to yield non-infectious
virions [45]. These studies indicate that the oligosaccharide at position 3 in Mo-MLV and the
corresponding one at position 4 in Fr-MLV may be sufficient for function.
To determine the minimum number of glycosylation sites required to retain full activity
of the Mo-MLV env, we constructed A14567, a mutant lacking all five glycosylation sites which
produced no phenotype when individually mutated [44]. The gene for this construct was made
by site-specific oligonucleotide-directed mutagenesis (Quickchange, Stratagene) in the
pcDNA1.1/Amp mammalian expression vector (Invitrogen). Wild type env and a A147 mutant
were also generated to use as controls (Table 1). To generate a high-titer, helper-free retrovirus
by transient transfection, the packaging cell line Anjou [46] was cotransfected with the
pcDNA1.1/Amp plasmid carrying the env gene and pMX-IRES-GFP, a vector that contains the
retroviral packaging signal and the gene for the green fluorescent protein (GFP) [38]. The
resulting replication deficient virus is capable of undergoing a single round of infection and
expresses GFP. NIH/3T3 mouse cells were infected and assayed for infection by fluorescence
activated cell sorting (FACS) by monitoring GFP expression. However, we were unable to
detect virions in the Anjou cell supernatants by western blotting and therefore could not test for
infectivity in NIH/3T3 cells. Moreover, the expression level of secreted A14567 was even lower
than for A147 in baculovirus infected insect cells, potentially indicating that the oligosaccharides
at positions 5 and 6 aid in protein folding and may be necessary. Therefore, overexpression of
A14567 was not pursued further.
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The amount of secreted protein in the supernatants of baculovirus infected insect cells
was very low with the original constructs (<0.5 mg/L), all of which contained the native Mo-
MLV env hydrophobic signal sequence. To increase expression and secretion levels, the Mo-
MLV secretion signal was replaced with the signal sequences of two secreted baculovirus
proteins, the ecdysteriod UDPglycosyltransferase (EGT) and the envelope glycoprotein gp67 for
baculovirus expression. This method increased expression of HIV-1 gpl20 6- to 20-fold over
using its native signal sequence [47]. To further optimize the chances of successfully
overexpressing the Mo-MLV env, we also made a number of constructs with different
combinations of truncation points, signal sequences, affinity tags, membrane anchors, intact
glycosylation sites and the presence or absence of the SU/TM cleavage site (Table 1). The four
best expressing proteins from baculovirus infected insect cells, RBD, ARBD, AC and A147C,
were overexpressed in large-scale infections. These 6xHis tagged proteins were purified by Ni-
NTA affinity and size exclusion chromatography to about 90% purity as determined by SDS-
PAGE analysis. Secreted insect ferritin, a minor contaminant, was consistently present in the
protein preparations of the lower expressing constructs ( 1 mg/L; ARBD and A147C) when
isolated from the supernatant of baculovirus infected insect cells. Attempts to further purify
these proteins with an immunoaffinity column prepared with a monoclonal a-SU antibody
isolated from the supernatant of a rat hybridoma (83A25) failed because the protein did not bind
to the column.
Protein expression in Drosophila S2 insect cells
The Mo-MLV ectodomain was also expressed in stably transfected cell lines derived from
Drosophila melanogaster, Schneider 2 (S2) cells (DES, Invitrogen). Two stable cell lines were
generated, each of them expressing the A147C glycosylation and cleavage mutant form of env
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with enhanced signal sequences (Table 1). One cell line was transfected with the pAc5.1/V5-
HisA(env) construct, which drives the constitutive expression of recombinant protein from the
Drosophila actin 5C (Ac5) promoter and the env protein contained the EGT signal sequence.
The second cell line was transfected with the pMT/BiP/V5-HisA(env) construct, which contains
the Drosophila BiP signal sequence and an inducible metallothionein (MT) promoter. Both
secreted proteins contained a C-terminal 6xHis tag, which was used for purification using Ni-
NTA resin (Qiagen) and detection by western blotting. Although both versions of the protein
were detected, the expression and secretion levels were very low (<0.5 mg/L), which was not
sufficient for purification of the quantity of protein necessary for biochemical characterization
and crystallization.
Protein expression and purification in bacterial cells
Mo-MLV env constructs (Table 1) were also expressed in E.coli BL21(DE3)pLysS and
AD494(DE3)pLysS cells (Novagen). AD494(DE3)pLysS is a thioredoxin thioreductase-
deficient strain with a mutation in the trxB gene, which allows disulfide bond formation and
proper folding for some proteins in the E.coli cytoplasm (Novagen). However, bacterial
expression of Mo-MLV env resulted in the production of insoluble protein localized to inclusion
bodies using both cell lines. The highest expressing construct, A1-233, was purified from
inclusion bodies and refolded. The refolded protein was completely aggregated and eluted from
a Superdex 200 26/60 gel filtration column in the void volume (data not shown).
Protein expression in yeast
Several Mo-MLV env constructs were also made to test expression in two yeast strains,
Pichia pastoris and Saccharomyces cerevisiae (Table 1). A147C and ARBD were transformed
into Pichia pastoris X-33 and GS115(his4) cells and protein expression was induced with the
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addition of methanol. Protein expression was not observed during analyses of the media by Ni-
NTA affinity and SDS-PAGE. After failure to detect protein expression with Pichia pastoris,
expression tests in S. cerevisiae were not pursued.
Protein expression in mammalian cells
Mammalian cells were also employed to overexpress the Mo-MLV env protein. Stably
transfected wild type chinese hamster ovary cells (CHO) K1 and CHO lecR- 3.2.8.1 cells [33], a
variant cell line which N-glycosylates with only simple oligosaccharides to decrease the
heterogeneity in glycosylation sometimes seen in wild type CHO cells, were generated (Table 1).
As with the other expression systems, very low expression levels were observed for all of the
constructs, regardless of the signal sequence used.
Biochemical and biophysical characterization
To determine if the Mo-MLV env ectodomain secreted by baculovirus infected insect
cells is a soluble, trimeric species we used gel filtration chromatography, chemical cross-linking
and sedimentation velocity experiments. ARBD, AC, and A147C, but not RBD, eluted from size
exclusion chromatography columns as multiple, overlapping peaks indicating the presence of
multiple species (Figure 3A). The peak fractions in the region expected to contain the trimeric
form of the env protein were pooled and used for further characterization. The oligomeric state
of the Mo-MLV env was investigated by chemical cross-linking (Figure 3B). Various
concentrations of AC were mixed with increasing concentrations of the cross-linking reagent,
EGS, and analyzed by SDS-PAGE. This method was used to show that the SIV gpl60 protein is
trimeric [35]. The results with AC, however, suggested there was a mixture of different
oligomeric states and aggregated protein present as a smear of high molecular weight bands were
observed rather than distinct bands corresponding to ordered oligomers.
176
Sedimentation velocity analytical ultracentrifugation experiments were also performed to
investigate the oligomeric state of the Mo-MLV env protein. Two solutions of ARBD were
centrifuged at 36,000 rpm while sedimentation was monitored at 280 nm, whereas two solutions
of AC were centrifuged at 30,000 rpm and absorbance was measured at 230 nm. The data for
both experiments were fit using SEDFIT [36] to calculate the sedimentation coefficient, c(s), and
molar mass, c(M), distributions of each sample. Analyses of the sedimentation coefficient
distributions revealed the presence of a mixture of many different oligomeric species, primarily
aggregates for both ARBD and AC (Figures 4A-B), suggesting that the proteins are misfolded
and/or nonspecifically aggregated.
The stability of the protein was examined by thermal denaturation, monitoring circular
dichroism (CD). CD analyses were preformed on a 4.5 M solution of AC in HBS to detect
secondary structural elements. The absorbance scan from 190 to 250 nm showed the presence
of a mixture of secondary structural elements or possibly random coil (Figure 5A). A thermal
denaturation experiment failed to detect a melting transition between 1 and 99 °C (Figure 5B).
This further supports the hypothesis that the protein is in a partially folded or aggregated state
rather than in a stably folded, trimeric conformation.
Initial crystallization attempts of ARBD resulted in the crystallization of a minor (10%)
contaminant, secreted insect ferritin. Further crystallization trials with AC yielded microcrystals
that were too small to characterize. Optimization of the crystallization solutions and seeding
attempts did not improve the crystals. RBD did not yield any crystals.
Viral infectivity and inhibition assay
To determine if the mechanism used by Mo-MLV to invade target cells is similar to other
retroviruses, we established a viral infectivity and inhibition assay (Figure 6A). The HIV TM
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(gp41) contains two regions, the N and C peptides, which are transiently exposed after SU
(gp120) interacts with the cellular receptor and coreceptor. The N peptides form a trimeric
coiled coil and the C peptides pack into the hydrophobic grooves on the N core in an antiparallel
orientation to resolve into the fusion-active trimer of hairpin structure [11]. The gp41 transient
intermediate has been identified as an attractive target for inhibition [48]. The fusion process can
be inhibited in a dominant negative fashion by the addition of synthetic C or N peptides
(reviewed in [49]). To inhibit the infection of mouse NIH/3T3 cells by Mo-GFP, Mo-36 [37],
the functional equivalent of the N peptide and Mo-MLV C peptide were synthesized and purified
by reverse-phase HPLC. Antibodies raised against the Mo-MLV N/C core, Mo-92 [37], were
also purified to test these antibodies' ability to inhibit viral infection (Figure 6B). When Mo-
MLV C peptide (up to 50 tM concentration) or ct-Mo-92 antibodies (up to 160 nM
concentration) were added to NIH/3T3 cells in the presence of 4 [LL Mo-GFP, no inhibition of
infection was observed (Figure 6C-D).
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Table 1. Mo-MLV envelope expression constructs
Expression of the Mo-MLV env was tested in five different expression systems: bacteria, stably
transfected Drosophila cells, baculovirus infected insect cells, yeast and stably transfected
mammalian cells. The table shows the expression host, expression vector, presence or absence on
the SU/TM cleavage site recognition sequence, origin of the hydrophobic secretion signal,
presence of an affinity tag, presence of a cleavage site for the removal of the affinity tag or
another modification, the residues in the mature protein, the approximate molecular weight of the
mature protein not taking into account the potential glycosylation, the number of potential N-
linked glycosylation sites and the expression level in mg/L.
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Figure 1. Model for retroviral membrane fusion and its inhibition
Prior to exposure to the cellular receptor, the viral envelope protein is in its native state. Binding
of the viral SU subunit to the host receptor triggers major conformational changes in the TM
subunit causing the N-terminal fusion peptide to be exposed and inserted into the target
membrane, forming a transient prehairpin intermediate. The TM subunit N peptides, which form
a trimeric coiled coil, also get exposed and the C peptides pack into the hydrophobic grooves on
the N core in an antiparallel orientation. The prehairpin N and C peptide regions are vulnerable
to inhibition by the addition of exogenous N and C peptides in a dominant negative manner. In
the absence of inhibitors, the intermediate resolves into the fusion-active trimer of hairpins
structure, brining the two membranes together and allowing fusion to occur. Figure adapted
from [10].
185
Y Y Y Y Y YYSSI ft•RBD(9.) FP: Mo-55 :TM
SU (gp70) TM (pl5E)
Figure 2. Schematic representation of the Mo-MLV full-length envelope protein
Mo-MLV is synthesized as a precursor protein, which undergoes post-translational modifications
and processing: The signal sequence (SS) is cleaved off after insertion into the endoplasmic
reticulum; seven N-linked oligosaccharides are added to the SU subunit (indicated by Y); a
cleavage between the SU and TM subunits exposes the fusion peptide (FP); the transmembrane
region (TM) anchors the protein to the lipid bilayer; and the R-peptide is removed during or
shortly after budding. Disulfide bonds are shown with yellow lines, hydrophobic regions are
shown with diagonal lines, and the shaded areas indicate regions of the MLVs for which X-ray
crystal structures are available.
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Figure 3. Gel-filtration and chemical cross-linking of Mo-MLV AC
(A) Gel filtration profile of AC (blue line) on a Superdex 200 16/60 column. Fractions that were
pooled and used for characterization are marked with a black line. Molecular weight standards
are shown in red.
(B) Chemical cross-linking of AC with various amounts of EGS as indicated by numbers above
the lanes. Western blot probed with PentaHis antibody (Qiagen) is shown on the left and
coomassie stained gel is shown on the right.
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Figure 4. Sedimentation velocity analytical ultracentrifugation of Mo-MLV ARBD and AC
(A) Sedimentation velocity analytical ultracentrifugation of ARBD was performed. Data were
collected at 20 0 C at 36,000 rpm and fit with SEDFIT [36].
(B) Sedimentation velocity analytical ultracentrifugation of AC at pH 5.6 and pH 7.0 are shown.
Data were collected at 20 TC at 30,000 rpm and fit with SEDFIT [36].
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Figure 5. Circular dichroism analyses and thermal denaturation of Mo-MLV AC
(A) CD spectrum of a 4.5 RM solution of AC in HBS was collected at 25 *C. A baseline
spectrum recorded from buffer alone was subtracted from the signal.
(B) Thermal melt of AC (4.5 tiM in HBS) is shown. CD signal was measured at 220 nm in 2 TC
increments from 1 C to 99 *C.
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Figure 6. Viral infectivity and inhibition
(A) Schematic representation of infectivity and inhibition assays. Human 293T cells were
cotransfected with pCL-Eco and pMX-IRES-GFP to generate replication deficient virions, Mo-
GFP. NIH/3T3 mouse cells were infected with Mo-GFP in the absence or presence of inhibitor.
Infected cells express GFP and can be analyzed by FACS.
(B) Schematic representation of the Mo-MLV TM subunit. Mo-36 (equivalent of the N peptide)
and the Mo-MLV C peptide are shown with the sequences specified.
(C) Infection of mouse NIH/3T3 cells with Mo-GFP. Percentage of infected cells is plotted
against the volume of virus added. Blue box indicates the amount of virus added to the viral
infection inhibition experiments in part (D), based on the viral titer.
(D) Results from individual viral infection inhibition experiments. Increasing concentrations of
Mo-MLV C peptide (blue) or an a-Mo-92 antibody (red) were added to NIH/3T3 cells at the
time of infection with 4 FL Mo-GFP based on the titer of the virus in part (C). Infection was
detected by FACS, monitoring for GFP expression. The percentage of infected cells is plotted
against the concentration of inhibitor added.
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APPENDIX II
Crystal Structure of a Secreted Insect Ferritin Reveals a Symmetrical Arrangement
of Heavy and Light Chains
Appendix II has been submitted for publication. This project started when yellow-tinted ferritin
crystals grew during crystallization trials of the Moloney Murine Leukemia virus envelope
glycoprotein (Appendix I). My contributions to this work include "purification" and
crystallization of ferritin, identification of the two subunits, isolation of the heavy and light chain
genes, collecting the first data set and writing part of the manuscript. Anthony West Jr. helped
me find the molecular replacement solution, did the structure refinement, collected the high-
resolution data set and wrote the manuscript. Zsuzsa Hamburger taught me how to handle and
freeze the crystals and we collected the initial data set together. Peter Hamburger contributed to
the mathematical discussion.
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Summary
Ferritins are iron storage proteins made of 24 subunits forming a hollow spherical shell.
Vertebrate ferritins contain varying ratios of H and L chains, however, known ferritin structures
include only one type of chain and have octahedral symmetry. Here we report the 1.9 A structure
of a secreted insect ferritin from Trichoplusia ni, which reveals equal numbers of H and L chains
arranged with tetrahedral symmetry. The H/L-chain interface includes complementary features
responsible for ordered assembly of the subunits. The H chain contains a ferroxidase active site
resembling that of vertebrate H chains with an endogenous, bound iron atom. The L chain lacks
the residues that form a putative iron core nucleation site in vertebrate L chains. Instead, a
possible nucleation site is observed at the L chain 3-fold pore. The structure also reveals inter-
and intra-subunit disulfide bonds, mostly in the extended N-terminal regions unique to insect
ferritins. The symmetrical arrangement of H and L chains and the disulfide crosslinks reflect
adaptations of insect ferritin to its role as a secreted protein.
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Introduction
Iron is an essential element in biological systems whose levels are strongly regulated to
ensure availability but prevent toxicity (Arosio and Levi, 2002). Key to this regulation are the
two stable oxidation states of iron. In the ferrous (Fe2+) state, iron is soluble and readily used, but
it is quickly oxidized under aerobic conditions, potentially producing harmful reactive species.
The ferric (Fe3+) ion resulting from oxidation has extremely low solubility under physiological
conditions, rendering it inaccessible for incorporation into metalloproteins. Ferritin, which
functions as a ferroxidase to control the transition between hydrated Fe2+ and insoluble Fe3+ and
provides a site for storage of Fe3+, represents a solution to this chemical dilemma that is utilized
by bacteria, fungi, plants, insects, and vertebrates (Harrison and Arosio, 1996).
Ferritin functions as a spherical assembly of one or more types of individual subunits. In
most cases, 24 subunits come together to form a hollow sphere with octahedral (O or 432)
symmetry (Arosio and Levi, 2002). Up to 4500 Fe3+ atoms can be stored in a mineralized form
inside the protein shell. Mammalian ferritins contain a variable mixture of two types of subunits:
heavy (H) and light (L) chains. The H subunit contains a ferroxidase center and the L chain
contains a site for nucleation of the mineral core. Ferritins isolated from different tissues contain
varying and characteristic ratios of H and L chains, thought to reflect tuning of ferritin function
for specific organs (Arosio and Levi, 2002).
An unusual property of ferritin is the existence of functional forms in both cytoplasmic
and vacuolar/extracellular environments. In bacteria and vertebrates, ferritin is predominantly a
cytoplasmic protein. However, a secreted form of ferritin is found in mammals, and serum
ferritin is a clinically important measure of iron stores (Harrison and Arosio, 1996). The
mechanism by which mammalian ferritin is secreted is unclear, since no conventional
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hydrophobic leader peptide sequence is present. A recent study provides evidence that cytosolic
ferritin can be directed to the secretory pathway through a regulated process (Ghosh et al., 2004).
Insect ferritins are primarily extracellular or vacuolar, and their sequences include recognizable
hydrophobic leader peptides (Nichol et al., 2002). An interesting contrast in iron regulation
between mammals and insects is provided by the roles of ferritin and transferrin. In mammals,
transferrin is the primary iron transport protein, and serum ferritin is an acute phase protein
whose concentrations increase dramatically during infection. In insects, secreted ferritin is a
major iron storage/transport molecule, while transferrin is strongly upregulated by infection
(Nichol et al., 2002).
Here we report the structure of a secreted ferritin from the cabbage looper/tiger moth
Trichoplusia ni (T. ni), which is the first structure of a secreted ferritin, and the first structure in
which two different subunit types are resolved. T. ni ferritin contains an equal number of H and
L chains arranged with tetrahedral (T or 32) symmetry, as compared with previous bacterial and
vertebrate ferritin structures, which have octahedral (O or 432) symmetry and only a single type
of resolved subunit. The tetrahedral symmetry arrangement of T. ni ferritin creates two distinct
types of 3-fold axis pores. The 3-fold pore made by the L chain subunits contains several
coordinated ions. The innermost of these, modeled as Fe3+, is a potential site for nucleation of the
iron core. The pore created by three H chain subunits is relatively open, providing for passage of
ions in and out of the ferritin cavity. The H chain ferroxidase sites of T. ni ferritin each contain a
single Fe3+ ion. The structure also reveals both intra- and inter-subunit disulfide bonds, consistent
with insect ferritin being a secreted protein.
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Results and Discussion
Isolation of Insect Ferritin Protein and Genes
Secreted ferritin was isolated from the supernatants of baculovirus-infected T. ni cells as a
contaminant during purification of an unrelated recombinant 6xHis-tagged protein on a Ni-
agarose column. The affinity of ferritin for the Ni-agarose may reflect binding of the Ni-NTA to
an iron-binding site. Crystallization trials of the recombinant protein yielded yellow-tinted
crystals in several different conditions, both with and without added divalent ions. The largest
crystals, which grew in 20% Jeffamine, 0.1 M Hepes (pH 7.5), were in space group C2 (a =
203.8 A, b = 146.6 A, c = 206.9 A, 3= 92.7°) with one complete ferritin shell per asymmetric
unit. Analysis of the crystals by SDS-PAGE under reducing conditions revealed the presence of
two bands of equal intensity migrating at 22 and 27 kDa rather than the 45 kDa expected for the
recombinant protein. N-terminal sequencing of the two bands and a BLAST search revealed
sequence similarity to insect ferritin H and L chains, but the sequence of the T. ni ferritin L chain
had not been previously determined and only a partial EST was available for the H chain. Using
the N-terminal protein sequence information, degenerate oligonucleotides were designed, and the
genes for the two subunits were isolated to obtain the sequence of the entire protein for use in the
crystallographic structure determination.
The derived amino acid sequences for the two T. ni ferritin chains are shown in
Supplementary Figures lA-lB. The smaller of the two chains (191 residues not including the
hydrophobic leader peptide) includes seven conserved residues that define the ferroxidase center
(Lawson et al., 1989) that are not present in the other chain (212 residues not including the
hydrophobic leader peptide). By analogy with vertebrate ferritin subunits, we refer to the insect
subunit containing the ferroxidase site as the H chain, although it is the smaller of the two T. ni
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subunits, and the subunit lacking the ferroxidase site as the L chain. Several other nomenclatures
have been used to designate insect ferritin subunits. The subunit containing the ferroxidase site
has been called the heavy chain homolog (HCH), the S (small) subunit, FER1, or Fersubl
(Nichol et al., 2002). The other subunit is known as the light chain homolog (LCH), the G
(glycosylated) subunit, Fer2LCH, or Fersub2. LCH is a misleading name for the non-ferroxidase
subunit because it is not more similar to vertebrate L than to vertebrate H chains (Nichol et al.,
2002).
The T. ni H chain shares a high level of sequence identity with previously reported
Lepidoptera sequences: Manduca sexta (84%), Galleria mellonella (83%), and Calpodes ethlius
(77%). The mature L chain sequence includes a potential N-linked glycosylation site (Asnll 15)
observed in other Lepidoptera L chains. The L chain sequence identity with other butterfly and
moth L chain sequences is also high: Manduca sexta (80%), Galleria mellonella (78%) and
Calpodes ethlius (70%). The T. ni H and L chains are related by only 22% sequence identity.
While the T. ni H chain has 30% sequence identity with the human H chain, the T. ni L chain has
low identity with both vertebrate H and L chains (20% with the human H and 17% with the horse
L chain).
Structure Determination
The structure of T. ni ferritin was solved at 3.1 A by molecular replacement using the bullfrog M
ferritin structure (PDB code 1MFR) (Ha et al., 1999) as a search model. Since the search model
contained 24 copies of one chain type, it was initially unclear whether the H and L chains in the
T. ni structure were randomly distributed or symmetrically arranged. Therefore, we repeated the
molecular replacement using a search model with tetrahedral symmetry (constructed from
1MFR) containing conserved H chain residues, which yielded a structure with 12 copies of two
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apparently distinct chains (Figures 1A-IB). Confirmation of this symmetric arrangement was
provided by an anomalous difference Fourier map (Figure 1C), which revealed 12 strong peaks
in the H chain ferroxidase sites but no significant peaks in the corresponding regions of the L
chains. A 1.9 A native data set was later collected from crystals grown in 20 mM Tris (pH 8.0),
150 mM NaCl at 40C (Table 1) and used for subsequent refinement.
H and L Chains are Packed in a Symmetrical Arrangement
Although vertebrate ferritins are composed of a mixture of H and L subunits, structures have
been determined only for recombinant ferritins made of a single chain type (amphibian H and L,
human H, horse L, and mouse L) (Granier et al., 2001; Ha et al., 1999; Hempstead et al., 1997;
Trikha et al., 1994), and for native ferritins modeled with a single chain type representing the
predominant chain (horse spleen ferritin (Granier, 1997)). Ferritins containing a single type of
subunit have octahedral (432) symmetry. When 24-mer shells are assembled from two different
chain types, the highest possible symmetry is tetrahedral, as seen in the T. ni ferritin crystal
structure. Another ferritin structure with tetrahedral symmetry was found for a dodecameric
ferritin from Listeria innocua (Ilari et al., 2000), although this ferritin includes 12 copies of a
single subunit (rather than 12 copies of a heterodimer), which form a spherical molecule with an
inner cavity capable of storing only 500 iron atoms (Bozzi et al., 1997) as compared with 4500
for conventional ferritins.
Octahedral symmetry ferritin shells contain three 4-fold symmetry axes, eight 3-fold
axes, and six 2-fold axes (not counting 2-fold axes along the 4-fold axes). A consequence of the
tetrahedral symmetry of the T. ni structure is that the 2-fold axes, about which homodimers of
ferritin subunits are arranged in an octahedral structure, are lost because the 2-fold symmetric
homodimers are replaced by heterodimers of H and L chains. Likewise, the exact 4-fold axes in
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octahedrally-symmetric ferritins become pseudo 4-folds or true 2-fold axes in tetrahedrally-
symmetric ferritin. The 3-fold axes remain, although there are two distinct local 3-folds: one
made of three H chains and one made of three L chains.
Folding Topology of Insect Ferritin H and L Chains
The overall structures of insect ferritin H and L subunits closely resemble the structures of
mammalian ferritin subunits - each contains a core of four helices (A, B, C, and D) and a fifth
helix (E) that is involved in intersubunit interactions near the pseudo 4-fold axis (Figure 2A). A
notable difference from mammalian ferritins is an approximate 10 or 20 residue N-terminal
extension in the T. ni H and L subunits, respectively. These extensions, which are unique to
secreted insect ferritins (Nichol et al., 2002), form extended loops that bridge adjacent subunits
on the outside of the ferritin shell (Figure 2A). Excluding the N-terminal extensions, the T. ni
ferritin H and L chains are structurally very similar to mammalian ferritins: the root mean square
(rms) deviation of the H chain Ca positions from those of the human H chain (PDB code 2FHA)
is 1.08 A (calculated for 160 residues) (Figure 2B). Other comparisons reveal comparable
degrees of similarity: rms deviations for the following pairs are all close to 1 A: insect L chain
versus human H chain (1.11 A for 159 Ca positions), insect H chain versus insect L chain (1.27
A for 156 Ca positions) (Figure 2C), insect L chain versus horse L chain (PDB code 1AEW)
(1.08 A for 159 Ca positions). The largest difference between the T. ni ferritin chains and
previously reported ferritin structures is in the L chain loop connecting helix B to helix C
(residues 99 to 121). In mammalian ferritin structures, short segments of the BC loops from
adjacent subunits form antiparallel, hydrogen bonded P-strands. In T. ni ferritin, the L chain BC
loop, which is longer than its mammalian counterpart, extends away from the subunit-subunit
interface, with the side chain of Tyrl 16 inserted into a hydrophobic region between helices A
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and C. This loop is relatively disordered, perhaps due to the N-linked glycosylation site at
Asnl 15 (although no ordered carbohydrate is observed in the crystal structure).
The H Chain Ferroxidase Site Contains a Bound Iron Atom
The initial difference Fourier and anomalous difference Fourier maps revealed that a dense ion
was bound at the H chain ferroxidase site in the T. ni ferritin (Figure 3). The ferroxidase center is
located within the hydrophilic core of the four-helix bundle of the H subunit and resembles those
of vertebrate ferritins. Divalent ions (mainly Cd+2 or Mg+2), which compete for the iron-binding
site, have been critical in the crystallization solutions for vertebrate ferritins. Hence, the only
ferritin structures containing native Fe3+ are of bacterial origin: the bacterioferritin from
Desulfovibrio desulfuricans (Coelho et al., 2001; Macedo et al., 2003) and the unusual
dodecomeric ferritin from Listeria innocua (Ilari et al., 2000). Because T. ni ferritin crystallized
in the absence of added divalent ions and showed a very strong anomalous signal (over 35 in
the 12-fold NCS-averaged map) at this site, we have modeled the ion as Fe3+. The ion-ligand
distances (Figure 3) are similar to those seen in other ferritin ferroxidase sites (Macedo et al.,
2003; Stillman et al., 2001). The low B value of the ion (19 A2 compared with 14-22 A2 for 29
Ca atoms within approximately 10 A of the ion) supports the Fe3+ assignment. The Fe3+ ion is
coordinated in an approximately octahedral geometry by Glu32, Glu67, His70 and two water
molecules with one coordination site unoccupied (Figure 3). In the ferroxidase centers of
previous ferritin structures, two metal ion-binding sites (called A and B) were observed
(Langlois d'Estaintot et al., 2004). The conserved residues that normally coordinate the two
metals in mammalian ferritins (Hempstead et al., 1997) are also conserved in insects
(Supplementary Figure 1A). The T. ni ferritin contains one metal ion at site A as observed in
previous ferritin structures that contain a single bound ion (Langlois d'Estaintot et al., 2004).
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Potential coordinating residues at the B site include Glu67 (shared with site A), Gln153, and
Glul 16. Although site B is unoccupied in the 1.9 A structure, a weak anomalous signal was seen
at this site in the 3.1 A resolution structure and in data sets from crystals that were soaked in
ferrous ammonium sulfate prior to cryopreservation (data not shown).
Inter- and Intra-Subunit Disulfide Bonds
In common with other secreted proteins but in contrast to cytoplasmic ferritins, the T. ni H and L
chains both contain intrasubunit disulfide bonds. In the H chain, a disulfide bond between
residues 21 and 130 connects the N-terminal region of helix A to the C-terminus of helix C. In
the L chain, a disulfide bond between residues 4 and 24 contributes to forming the relatively
compact N-terminal region of this subunit (Figure 2A). This domain is on the outside of the
ferritin shell, and it makes contact with an L chain related by a 3-fold. Specifically, the helical
portion on this domain contacts the N-terminal region of the adjacent subunit's C helix.
The T. ni ferritin also includes intersubunit disulfide bonds (Figure 2A) connecting H
chain residue 3 to residue 12 of a non-adjacent L chain (for example, subunits I and VIII of
Figure 1B). Although intersubunit disulfide bonds have not been observed in previous ferritin
structures, such crosslinking has been suggested to occur in artemin, a ferritin homolog in brine
shrimp (Chen et al., 2003). Confirmation of the crystallographically-observed interchain
disulfide bond is provided by SDS-PAGE analysis of T. ni ferritin: a single band of apparent
molecular weight -50 kDa is observed under non-reducing conditions as compared with two
bands of molecular weights of 22 kDa and 27 kDa under reducing conditions (data not shown).
With the exception of the ferritin sequences of Anopheles gambiae and Aedes aegypti, which
have divergent N termini, the three cysteines in the N-terminal region of the L chain and the
cysteines at positions 3, 21, and 130 in the H chain are conserved among insect ferritins (Nichol
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et al., 2002) (Supplementary Figures A-iB), suggesting that the pattern of disulfide bonds
observed in the T. ni ferritin structure is common to secreted insect ferritins. Others have
speculated that fatty acylation of the conserved cysteines in the N termini allows ferritin to be
retained in the endoplasmic reticulum (ER) and in vacuolar compartments (Nichol and Locke,
1999), which are major sites of localization of insect ferritin (Locke, 2003)). Although the T. ni
structure does not show evidence of fatty acylation, an alternative hypothesis is that the "knobs"
formed by the N-terminal extensions on the surface of insect ferritin bind an ER-resident
receptor.
The Major H and L Chain Interface and Subunit Assembly
Assembly of ferritin shells with octahedral symmetry is thought to begin with the formation of
homodimers of ferritin subunits (Ford et al., 1984; Hempstead et al., 1997). The corresponding
dimer for insect ferritin is the H/L heterodimer (molecules I and II from Figure B). If subunits
first associate at the I-II interface to exclusively form H/L heterodimers, and 12 dimers assemble,
the ferritin shell will contain a 1:1 ratio of H:L subunits. The T. ni ferritin structure suggests a
molecular basis for the specificity of heterodimer versus homodimer assembly. Examination of
the I/II interface suggests that two tryptophan residues contribute to the specificity of
heterodimer assembly (Figure 4). L chain Trp84 is located near the pseudo-2-fold axis relating
the H and L chains at the "heterogen" binding site (where bacterioferritins (Coelho et al., 2001)
and horse spleen ferritin (Michaux et al., 1996) bind hemes). The L chain Trp84 position is
usually an arginine in mammalian ferritins and a methionine in bacterioferritin, and both of these
residues play a role in heme binding (Frolow et al., 1994; Precigoux, 1994). The corresponding
residue on the T. ni H chain is Arg68, which makes cation-pi interactions (Gallivan and
Dougherty, 1999) with L chain residues Trp84 and Tyr53 and forms a salt bridge with L chain
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Asp81. The arginine at this position in mammalian ferritin usually forms an intra-helix salt
bridge with a glutamate at position i+4, but the L chain i+4 residue is an isoleucine in T. ni and
most other insects (Supplementary Figure B). Hence, the L chain intrasubunit salt bridge in
mammalian ferritins is replaced by an intersubunit salt bridge in insect ferritins. The second
tryptophan at the I/II interface of T. ni ferritin is H chain residue Trpl4. Together with H chain
IlelO and Ile15, this tryptophan forms a hydrophobic binding pocket for L chain Tyr65.
Computer models of insect H/H and L/L homodimers reveal that the described interactions
around both tryptophans are possible only in the heterodimeric H/L structure (data not shown),
contributing to the preferential formation of heterodimers from a mixture of H and L chains. The
conservation of these key residues (Supplementary Figures 1A-iB), in addition to the cysteines
involved in intersubunit disulfide bonds, suggests that T symmetry ferritin is common in the
lepidopteran, coleopteran, hemipteran, and, to a lesser extent, dipteran orders.
Although stepwise assembly beginning with H/L heterodimers assures a 12:12 mixture of
H and L chains, this is not enough to ensure tetrahedral symmetry because there are 186 distinct
shells that can be formed from 12 heterodimers (Appendix). To obtain a tetrahedral symmetry
shell, additional specificity must occur at either the 3-fold subunit-subunit interfaces (to create
two distinct 3-folds), at the pseudo 4-fold subunit-subunit interfaces, or at both. The significant
differences between the H and L chain 3-fold pores (see below) suggest that assembly may be
more favorable with three identical chains. Also, around the pseudo 4-fold axis a salt bridge
between adjacent H and L chains involving His174 (H) and Asp196 (L) may contribute to a
preference for alternating H and L subunits rather than forming a 4-fold with identical subunits.
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The 3-fold and Pseudo 4-fold Symmetry Axes
The hydrophilic channels located along the 3-fold axes of ferritins are believed to be the major
site of iron entrance into the central cavity (Arosio and Levi, 2002). The T. ni ferritin structure
contains two significantly different types of 3-fold pores. The pores formed from H chains are
relatively open and contain a number of ordered water molecules, while the pores formed by
adjacent L chains contain several coordinated ions. Three peaks in the electron density map are
observed along the L chain 3-fold pore (Figure 5A). The middle peak is the strongest, and the
corresponding ion is fully coordinated by the side chains of Glnl61 and Glu164 from the three
adjacent L chains. Previous ferritin structures have also contained ions along the 3-fold pores,
although these ions were partially or fully hydrated (Granier et al., 2003; Langlois d'Estaintot et
al., 2004). The outermost peak is a hydrated ion coordinated by Glu164 and potentially His144.
The innermost peak is a partially hydrated ion and is coordinated by the side chains of the three
symmetry-related Glu165 residues in the 3-fold pore.
Along the pseudo 4-fold axis, the E helices of two H and two L chains form a
hydrophobic interface without any large cavities or bound ions. Beneath the polar surface
residues (H chain His174 and L chain Asp196) at the pseudo 4-fold, two hydrophobic layers
consisting of L chain Leul99 and H chain Leul77 and, more inward, L chain Val203 and H
chain Ile 181, make it unlikely for ions to permeate along this axis.
Possible L Chain Ferrihydrite Nucleation Site at the 3-fold Pore
L chain is thought to assist formation of the iron core by providing a nucleation site on the inside
of the ferritin shell. For mammalian L chains this nucleation site has been proposed to consist of
a cluster of four glutamates directed into the cavity (Chasteen and Harrison, 1999). A high-
resolution structure of mouse L chain ferritin has revealed details of this site: four cadmium ions
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are coordinated by Glu57, Glu60, Glu61 and Glu64 (Granier et al., 2003). These glutamates are
not conserved in bacterial or insect ferritins, and the corresponding residues in the T. ni L chain
are Lys78, Asp81, Glu82, and Ser85. The side chain of Asp81 points away from the other three
residues and is involved in a salt bridge to H chain residue Arg68. We observed no non-protein
electron density in this region, further suggesting that these residues are unlikely to provide a
ferrihydrite nucleation site.
There is a possible ferrihydrite nucleation site on the inside of the ferritin shell at the L
chain 3-fold pore, where we observed an ion coordinated by Glu165 (Figures 5A-5B). We
modeled this peak as an Fe3+ ion because it showed a strong anomalous peak in the original 3.1 A
resolution data set, while we assigned the two outer peaks as Ca2+ ions due to their weak
anomalous signals. Additional density in Fo-Fc and anomalous difference Fourier maps around
the Fe3+ ion suggest the presence of other metal ions and/or water molecules (data not shown),
however the density is not sufficiently strong to model more ions. Ordered water molecules and a
small cluster of metal ions were also observed at the analogous site in the horse L chain
structure, although in this case the ions were thought to derive from the crystallization solution
(Hempstead et al., 1997). In addition to the presence of metal ions near the T. ni L chain 3-fold
pore, the region surrounding the pore seems particularly suited for serving as the ferrihydrite
nucleation site. The surface around the pore is highly charged: the inner surface within 12 A of
the 3-fold axis is covered by 12 negatively-charged residues (Glu165, Glu166, Glu169 and
Asp 170 from each of the three L chains) (Figure 5B).
Mathematical Basis of Tetrahedral Symmetry
An equal number of H and L chains can be assembled into ferritin shells in 113,048 distinct
configurations (Appendix). We consider two questions: what is unique about the T symmetry
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arrangement found in T. ni ferritin, and is this the only conceivable symmetrical arrangement?
Two types of subunits could potentially be assembled into ferritin shells with point groups T, D4
(requiring a 16:8 subunit ratio), D 3, D2, C4, C3, C2 or C,. Besides T being the largest proper
subgroup of O, T symmetry has another unique property: only with the tetrahedral arrangement
will each of the 12 subunits (of both types) always be in the same environment. A closely related
property is that the T configuration is the only perfect 2-coloring of a polyhedron representing
ferritin (see Appendix). A coloring of a polyhedron is 'perfect' if each symmetry operation of the
underlying polyhedron causes a permutation of the colors. The molecular consequence is that
this is the only arrangement in which each interface surface of each subunit will always contact
one type of subunit (e.g., the I-II interface is always heteromeric and the I-III interface is always
homomeric). For all other arrangements, there will be at least one class of interface (e.g., the I-II
interface of H chains) that joins subunits of the same type at one position of the ferritin shell
while joining different types elsewhere.
Conclusions
The structure of the T. ni secreted ferritin reveals, for the first time in a ferritin structure, the
molecular basis by which two different subunits are assembled into a ferritin shell. The T. ni
structure contains 12 H and 12 L chains arranged with tetrahedral symmetry. An advantage of
ferritin with two subunits arranged with tetrahedral symmetry, versus two subunits arranged
randomly, could be a greater tendency to crystallize. For example, we observed that T. ni ferritin
formed crystals readily - during storage in a saline buffer and as a minor contaminant during
crystallization trials of an unrelated protein. The tendency of native T. ni ferritin to crystallize
may reflect a general property of secreted insect ferritin. Crystals of insect ferritin have been
observed in vivo (Locke and Leung, 1984), and crystallization appears to assist in the formation
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of protein storage granules in fat bodies of insects (Locke, 2003). For example, crystals of
secreted ferritin are found in the storage granules of the premetamorphic fat body of Calpodes
ethlius (Larsen, 1976).
The existence of homopolymeric ferritins in bacteria and the structural similarity of H
and L chains in eukaryotes strongly suggest that the earliest ferritins were homomeric. The
presence of heteromeric ferritins in animals suggests that there is an adaptive value in altering
ferritin function by mixing two types of subunits. The random mixture of H and L subunits in
vertebrate ferritin compared to the symmetrical arrangement in insect ferritin may be a reflection
of the localization of these proteins. Vertebrate ferritin is principally cytoplasmic, and the ability
to vary the ferritin H/L ratio in different cell types permits ferritin function to be tuned to
different tissues (Arosio and Levi, 2002). For secreted insect ferritins that enter a common
extracellular space, this regulatory mechanism would not be applicable. What might be the
adaptive value of a non-random arrangement of subunits? If a particular subunit arrangement
creates a favorable feature (e.g., a specialized pore), then a symmetric configuration would
ensure that all assembled shells contained the maximum number of these features. As an
example of an activity that depends on the specific arrangement of subunits, one study showed
that the redox activity of recombinant human ferritin heteropolymers reached a maximum in
molecules that contained a 1:1 ratio of H:L chains, which was suggested to be a result of specific
interactions at the H/L interfaces (Johnson et al., 1999). In addition to the distinct H and L 3-fold
pores, the tetrahedral arrangement in T. ni ferritin also permits all of the subunits to be involved
in intersubunit disulfide bonds increasing the stability of the ferritin shell. Further studies will be
required to fully understand how the structural features of insect ferritin relate to its function as a
secreted protein.
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Experimental Procedures
Purification and Identification of T. ni Ferritin
Secreted ferritin was harvested from supernatants of baculovirus-infected T. ni (Tn5-B 1-4, High
Five) cells, exchanged into 20 mM Tris (pH 8.0), 0.3 M NaCI and subjected to Ni-NTA
chromatography (Ni-NTA Superflow, Qiagen). Protein from a 250 mM imidazole elution was
further purified by gel filtration chromatography on a Superdex 200 column (Amersham
Biosciences). The H and L chains were resolved by SDS-PAGE and transferred to PVDF
membrane. The bands were excised and sequenced by automated Edman degradation, yielding
the sequences ADTCYNDVALDC (L chain) and TQCNVNPVQIP (H chain).
Isolation of Ferritin H and L Chain cDNAs
mRNA was prepared from baculovirus-infected T. ni cells using the QuickPrepTM mRNA
Purification Kit (Amersham Biosciences). cDNA was generated from the mRNA with murine
reverse transcriptase and random hexadeoxyribonucleotides (Amersham Biosciences).
Degenerate 5' primers were designed based on the N-terminal protein sequences and a 3' primer
was designed based on a partial EST sequence of the T. ni H chain (accession code CF258131).
A 3' poly dT oligonucleotide was used for the L chain. DNA fragments were amplified by PCR
with Taq DNA polymerase (Boehringer Mannheim) and cloned into pCR®2.1- TOPO
(Invitrogen) and sequenced with M13 forward and reverse primers.
Crystallization, Data Collection, and Processing
Initial crystals (space group C2; one 24-mer per asymmetric unit) of "as isolated" T. ni ferritin
were grown at 18 C in hanging drops containing 20% v/v Jeffamine M-600, 0.1 M Hepes (pH
7.5), and flash frozen in 30% v/v Jeffamine M-600, 0.1 M Hepes (pH 7.5). Data were collected
at -150°C to 3.1 A resolution at the Stanford Synchrotron Radiation Laboratory beamline 9.1
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with X=0.95369 A. Large crystals of T. ni ferritin also appeared after several months at 4 °C in
the gel filtration column elution buffer (20 mM Tris [pH 8.0], 150 mM NaCl, 0.05% sodium
azide). These crystals were transferred stepwise into 2.6 M sodium malonate (pH 7.0), prior to
flash cooling and data were collected at -150°C to 1.9 A resolution at the Advanced Light Source
beamline 8.2.2 with X=1.1 A. Data were processed and scaled with DENZO and SCALEPACK
(Otwinowski and Minor, 1997).
Structure Solution and Refinement
The structure was determined by molecular replacement using AMoRE (Navaza, 1994) and a
polyglycine version of the 2.8 A structure of bullfrog M(H) ferritin (PDB code 1MFR (Ha et al.,
1999)) as a search model. The R value of the initial molecular replacement model was 49.3%.
The assignment of H and L chains was determined by repeating the molecular replacement with
a tetrahedral symmetry model of 1MFR (polyglycine model except the conserved H chain
ferroxidase residues were retained). Rebuilding was performed using the program O (Jones et al.,
1991) with maps calculated by solvent flattening, histogram matching, and 12-fold non-
crystallographic symmetry (NCS) averaging using the program DM in the CCP4 suite
(Collaborative Computational Project, 1994). Anisotropy and bulk solvent corrections were
applied, and the model was refined with 12-fold NCS constraints and individual temperature (B)
factors using the program CNS (Briinger et al., 1998). The NCS constraints were retained since
nearly all subunit-subunit contacts should obey the NCS (except those at crystal contacts). The
final model (1/12 of the asymmetric unit) contains residues 1 to 212 of the L chain and 1 to 191
of the H chain, 375 water molecules, 2 Fe3+ ions, and 2 Ca2+ ions. The average B factors for the
H chain, L chain, and water molecules are 25.9, 29.8, and 39.1 A2, respectively. The ferroxidase
site Fe3+ has a B factor of 18.9 A2. The L chain pore ions were modeled as two Ca2+ ions (with B
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factors of 18.5 and 63.9 A 2) and an Fe3+ ion (with a B factor of 34.0 A2 and occupancy of 0.78).
Buried surface areas were calculated using a 1.4 A probe using CNS. Figures were generated
with MOLSCRIPT (Kraulis, 1991), BOBSCRIPT (Esnouf, 1999), and Raster3D (Merritt and
Bacon, 1997).
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Appendix
Calculation of the number of distinct arrangements of 12 H and 12 L subunits
This calculation is equivalent to finding the number of ways of 2-coloring a polyhedron with 24
faces and octahedral symmetry. We have modeled ferritin as a pentagonal icositetrahedron
(Figure 1B); it has previously been modeled as a "split" rhombic dodecahedron (Hempstead et
al., 1997), where each face is bisected by a line parallel to one pair of its edges, in such a way
that each edge meets a single bisector. These two models have identical symmetries, and are
therefore interchangeable for our purposes. Two colorings are considered the same if one can be
obtained from the other via some rotation of the polyhedron. This calculation can be performed
using the P61lya-Burnside method of enumeration (based on an extension of the Cauchy-
Frobenius lemma). The lemma, as applied in our case, states that the average number of fixed
elements (colorings left unchanged by a rotation) of a group (O) acting on a set (of all possible
colorings) is equal to the number of orbits (distinct colorings taking rotations into account). This
results in the following expression (see Table 2) for the number of distinct arrangements (Gilbert
and Nicholson, 2004)
)24 + 9( +6+ 8(4+ 6(3)] =113,048
The calculation can be understood as follows: if we do not allow the polyhedron to rotate,
then we have 12 = 1212 = 2,704,156 different colorings. Many of these are only rotations of
each other; in fact, if one considers a coloring with no symmetry at all (one which looks different
after any non-identity rotation), then it will be counted 24 different times. Colorings with
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symmetry, however, are going to be counted fewer times. Hence, 1/24th of (12 is almost
correct, but we need to add back terms for symmetrical colorings.
To account for the symmetrical colorings, for each rotation we will count the number of
colorings that are fixed by that rotation (i.e., that look the same after rotation). For a rotation
about a particular 3-fold, the 24 faces divide into 8 groups of 3 faces related by the rotation. In
this case, symmetrical colorings are those in which each group of 3 faces has a single color.
Since there are an equal number of faces of both colors, there are (4) different symmetrical
arrangements for this rotation. There are 8 distinct 3-fold rotations, so we need to add this term 8
times. Similar terms need to be added for rotations about 2-fold and 4-fold axes. By the end, we
have counted every coloring 24 different times, so we need to divide by that number to get our
final answer.
Formally, the Burnside-Cauchy-Frobenius lemma can be stated as follows (Gilbert and
Nicholson, 2004). Let G be a group that acts on the elements of a set X. For each g E G, let Fix g
= {x E X I g(x) = x}, the set of elements of X left fixed by g. If N is the number of orbits of X
under a group G, then
S gGFix gl
(where IGI = number of elements of G). When applied to our case (Table 2) we have
Z 2,713,152N = 113,048
101 24
Table 2. Colorings of a pentagonal icositetrahedron with octahedral symmetry
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The number of distinct ways of assembling 12 heterodimers is calculated in a similar
manner. Without considering rotations, there are 212 distinct colorings, with asymmetric
colorings counted 24 different times. For symmetric colorings we find that 24 colorings are fixed
by a given rotation around a degree 3 axis, 23 colorings are fixed by a 90° rotation around a
degree 4 axis, 26 colorings are fixed by 180° rotation around a degree 4 axis, and that no
colorings are fixed by rotations about the 2-fold axes. Thus the number of distinct arrangements
of heterodimers is
24(212 +8 24 +6.23 + 326)=186
24
Perfect Coloring
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Type of element, gi, Number of
of the octahedral Number, s, of colorings left fixed
group Order of gi such elements by gi, IFix giI s IFix gil
Identity 1 1 (24 24
90 ° rotation 4 9 12 12
120° rotation 3 8 ( 8(4)
180° rotation 2 6 (3) 6
101 = 24 = 2,713,152
When considering the different ways that a polyhedron could be colored, perfect coloring is
defined as when each symmetry operation causes a permutation of the colors. In other words,
perfect coloring means when each symmetry operator of the underlying polyhedron is applied,
all faces of a particular color are rotated onto a single color, which could be the same or different
(Cromwell, 1997). Consider the 113,048 different ways that a 24 sided polyhedron representing
ferritin (e.g., the O symmetry pentagonal icositetrahedron shown in Figure B) could be colored
with 12 green and 12 blue faces. Of these possibilities, the only one with perfect coloring is the
one with T symmetry.
Sketch of proof that there is only one perfect 2-coloring of the O symmetry pentagonal
tetraicosahedron
Consider three adjacent faces related by a 3-fold axis: if two faces are colored blue, and the third
face is green, then a rotation about this axis will take one blue face to blue and the other blue
face to green. Hence, perfect coloring requires the three adjacent faces to have the same color.
This is true of all eight "trimers". Now consider a 90° rotation about a 4-fold axis. Two adjacent
trimers related by this rotation have either the same or different colors. If they have the same
color, perfect coloring requires a set of four trimers related by rotations about this 4-fold to have
the same color. Consider a perpendicular 4-fold: two adjacent trimers related by this 4-fold have
already been assigned the same color, hence the other two trimers related by this 4-fold also must
have this color. Continuing in this manner, we see that all eight trimers would be required to
have the same color - this is not a 2-coloring. Therefore, two adjacent trimers related by a 90°
rotation about a 4-fold axis must have different colors. Considering the three 4-fold axes, this
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alternating coloring completely determines the coloring: it is the T symmetry coloring depicted
in Figure 1B.
Proposition: For a 2-colored polyhedron with identical faces, consider the edges of the polygon
that makes up each face. A 2-coloring is perfect if and only if each type of edge always joins
faces of the same color or always joins faces with opposite colors.
Sketch of Proof
Consider a perfect 2-coloring. Taking any two adjacent faces, the edge between these faces either
joins the same color or different colors. A symmetry operation will either leave the colors of
these faces unchanged or reverse them. In either case the edge will still join faces of the same
color or different colors. This proves the "if" part of the proposition. Consider a non-perfect 2-
coloring. There is a symmetry operation that leaves some faces the same color, while reversing
the colors of other faces. For this symmetry operation, we have two sets of faces: "reversing"
faces and "non-reversing" faces. Choose an edge joining a reversing face to a non-reversing face.
Before the symmetry operation, this edge joins faces of either the same color or different colors;
after the operation the edge joins faces in the other manner.
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Atomic coordinates and structure factors will be deposited in the Protein Data Bank. The
sequences of the T. ni H and L chain cDNAs will be deposited in GenBank.
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Table 1. Data Collection and Refinement Statistics
Space group
Unit cell (A)
Data collection
Resolution (A)
Number of observations
Unique reflections
% Complete*
I/oI
Rmerge(%)t
Refinement
Resolution (A)
Reflections in working set IFI>O
Reflections in test set IFI>O
Rcryst (%)
Rfree (%)
Number of non-hydrogen atoms
Protein (403 residues) §
Water
Other (2 Fe+ 3, 2 Ca+ 2)
Model geometry
Rmsd bond length (A)
Rmsd angles (deg)
Ramachandran plot
Most favored region (%)
Additional allowed region (%)
Generously allowed region (%)
Disallowed region (%)
C2
203.8, 146.6, 206.9; P = 92.7 
30.0-1.90 (1.97-1.90)
875,805
463,465
97.0 (98.7)
11.7 (2.2)
6.5 (34.4)
20.0-1.90
440,103
23,175
18.9
19.4
3,225
375
4
0.009
1.26
91.7
8.3
0.0
0.0
Values in parentheses indicate the high-resolution shells. *Complete is the number of
independent reflections/total theoretical number. tRmerge ()= (Il(i) - <I(h)>llE(i)), where l(i) is
the ith observation of the intensity of the hkl reflection and <I> is the mean intensity from
multiple measurements of the h,k,l reflection. RC,,st (F) = ~hIFob(h)l - IFcaic(h)II ]hlFo b(h)l,
where IFotb(h)l and IFa,,,,(h)l are the observed and calculated structure factor amplitudes for the
h,k,l reflection. Rfee is calculated over reflections in a test set not included in atomic refinement.
§Number of atoms in strict NCS refinement.
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Figure Legends
Figure 1. Structure of Secreted T. ni Ferritin Reveals Symmetric Arrangement of H and L
chains.
(A) Ribbon diagram showing the H (green) and L (blue) chains. Native Fe3+ ions at the
ferroxidase sites are shown as red spheres.
(B) Schematic diagram illustrating the tetrahedral symmetry of insect ferritin. Each face of this
pentagonal icositetrahedron represents a subunit. The total buried surface areas at the subunit-
subunit interfaces are: I/II (heterodimer) 3250 A2, I/III (H chain trimer) 1690 A2, I/VI (pseudo 4-
fold) 1250 A2, I/VII (pseudo 4-fold) 1525 A2, II/VII (L chain trimer) 2560 A2.
(C) Stereoview of a 4 A anomalous difference Fourier map (not NCS averaged; contoured at 3
a). Each of the 12 peaks results from an iron atom bound at the ferroxidase site in a ferritin H
subunit. When this map is contoured at a lower level additional peaks appear along the L chain
3-fold pores, but not in the L chain four helix bundle. The superimposed chiral, non-regular
icosahedron whose 12 vertices correspond to the peaks in the anomalous difference Fourier map
is the simplest polyhedron with exact T symmetry.
Figure 2. Structures of T. ni Ferritin H and L Chains.
(A) Ribbon diagrams of the H (green) and L (blue and light blue) subunits. The Fe3 + ion at the
ferroxidase site is shown in red. Also shown are the approximate locations of the 3-fold axes
(blue and green triangles) and the pseudo 4-fold axes (black ovals). Disulfide-bonded cysteines
are shown in yellow in ball-and-stick representation. The N-terminal region of each subunit
extends on the outside of the ferritin shell and forms a disulfide bond with a non-adjacent subunit
of the opposite type. Helices A-E are labeled in green for the H chain and in blue for the L chain.
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(B) Stereoview of a superposition of the T. ni ferritin H chain (green) with the human ferritin H
chain (magenta, PDB accession code 2FHA). Rms deviation for the superposition is 1.08 A
calculated for 160 Ca atoms.
(C) Stereoview of a superposition of the T. ni ferritin H (green) and L (blue) chains. The rms
deviation value for the superposition is 1.27 A calculated for 156 Ca atoms.
Figure 3. Stereoview of a Close Up of the H Chain Ferroxidase Site.
Residues at or near the Fe3" binding site are shown in ball-and-stick representation. The Fe3" ion
is shown as a dark red sphere and the two water molecules are shown as small red spheres.
Coordinating side chains and their distances (A) are shown.
Figure 4. Packing of the Major H/L Interface.
Residues involved in key intersubunit interactions are shown in ball-and-stick representation.
The H and L chains are colored green and blue, respectively. Hydrogen bonds and salt bridges
are shown as dashed lines. The location of the pseudo 2-fold is shown as an open oval.
Figure 5. Close Up of the L Chain 3-fold Pore.
(A) A side view of the L chain 3-fold pore shown with the inside of the shell at the bottom. A 12-
fold NCS-averaged annealed omit Fo-Fc electron density map (cyan mesh) is contoured at 8o.
The NCS-averaged anomalous Fourier map (red mesh) is contoured at 13o. The Fo-Fc electron
density was calculated excluding the coordinates of the ions coordinates. The top two ions (cyan)
were modeled as Ca2*, while the lower ion (red) was assigned as Fe3", based in part on the
stronger anomalous signal at the Fe3+ location.
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(B) The L chain 3-fold pore viewed from the inside of the shell. A large cluster of negatively
charged residues line the inner surface near the 3-fold axis.
Supplementary Figure 1. Sequence Alignment of Insect H and L Chains.
(A) Sequence alignment of insect ferritin H chains. Residues at the ferroxidase center are
highlighted in yellow. Cysteines involved in disulfide bonds are shown in red.
(B) Sequence alignment of insect ferritin L chains. Cysteine residues involved in disulfide bonds
are shown in red and asparagines with potential N-linked oligosaccharides are shown in blue.
Pairs of cysteines in disulfide bonds are marked with symbols (* for L chain 4 and L chain 24, #
for L chain 12 and H chain 3, and @ for H chain 21 and H chain 130).
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Figure 4. Packing of the Major H/L Interface.
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Figure 5. Close Up of the L Chain 3-fold Pore.
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Trichoplusia ni H chain
Manduca sexta
Galleria mellonella
Calpodes ethlius
Apriona germari
Leptinotarsa decemlineata
Drosophila melanogaster
Nilaparvata lugens
Anopheles gambiae
Aedes aegypti
Trichoplusia ni
Manduca sexta
Galleria mellonella
Calpodes ethlius
Apriona germari
Leptinotarsa decemlineata
Drosophila melanogaster
Nilaparvata lugens
Anopheles gambiae
Aedes aegypti
Trichoplusia ni
Manduca sexta
Galleria mellonella
Calpodes ethlius
Apriona germari
Leptinotarsa decemlineata
Drosophila melanogaster
Nilaparvata lugens
Anopheles gambiae
Aedes aegypti
Trichoplusia ni
Manduca sexta
Galleria mellonella
Calpodes ethlius
Apriona germari
Leptinotarsa decemlineai
Drosophila melanogaster
Nilaparvata lugens
Anopheles gambiae
Aedes aegypti
Trichoplusia ni
Manduca sexta
Galleria mellonella
Calpodes ethlius
Apriona germari
Leptinotarsa decemlineata:
Drosophila melanogaster
Nilaparvata lugens
Anopheles gambiae
Aedes aegypti
: TQCNVN PVQIPK DWITMHRSCRNSMRQQIQMEVGASLQYLAM
: TQCHVN PVNIQR EWITMHRSCRDSMRRQIQMEVGASLQYLAM
: TQCTVN PVNIPK EWITMQRPCRDSMRRQIQMEVAASLQYLAM
: TQCNVN PVTIPT DWITMTSGCRTSVRHQIQMEVAASLQYLAM
: E IECRGE NVNVPT DWLDMQQFCVSSVRNQIEEELKAAMQYMAM
: A LECSYK ELDIPK DWIDMEKACVKKMRAQVEDELKAAMQYMAM
: DFKCSLA VPEITK WVDMKDACIKGMRNQIQEEINASYQYLAM
: QNANDRCSIDMDDTLEKVEWKTMHSNCTLEVKDQIKMEYNAAMIYLSL
: QVT DTDAPSSTDEWNYMNRSCSAKLQDQINKEFDAAIFYMQY
: QEQTVGATDNYQWDSVDDQCLAALHRQINKEFDASIIYLKY
: GAHFSKDVVNRPGFAQLFFDAASEEREHAMKLIEYLLMRGELTNDVSS
: GAHFSKDKINRPGFAKLFFDAAGEEREHAMKLIEYLLMRGELTNDVTS
: GAHFSKDTINRPGFAKLFFDAGSEERGHAMKLIEYLLMRGELTSDVTS
: GAHFSRDGINRPGFAKLFFDASSEERGHALKLIEYLLMRGELTSNISS
: GAHFSKDIVNRPGFAKMFFEAASEERQHAIKLISYLLMRGELTSKVSE
: GAHFSKDTVNRPGFAEIFFKSASEERERAIKLISYLLMRGELTSKVSS
: GAYFSRDTVNRPGFAEHFFKAAKEEREHGSKLVEYLSMRGQLTEGVSD
: GVHFSRDFVNRPGFAKFFFESASEERQRAIKLIEYLSMRGESVTDIAK
: GAYFAQYQVNLPGFEKFFFNAASEEREHGMKLIEYALMRGQKPIDRNT
: AAYFAQEKINLPGFEKFFFHAAABEREHGIKLIEYALMRGKAPAD KH
: L LQVRP PTRSSWK GGVEALEHALSMESDVTKSIRNVIKACEDD
: L IQVRA PQRNKWE GGVDALEHALKMESDVTKSIRTVIKACEDD
: L IQIRP PERKSWS SGVEALEHAVKMESDVTKSIRTVISDCESD
: L ITIRP PERKSWE SGQEALEHALRMETAVTKSIKNVIVNCEHD
: L IRSRK LVPQKTYWD SGVEALKDALNLEASVTKKIRKVIKNCEED
: L IK RN LMPSQTTWT NGVSALKDALKLEASVTRKIRDVIKVCEEA
: L INVPT V AKQEWT DGAAALSDALDLEIKVTKSIRKLIQTCENK
: L VKLDPETMPGMASVSLNGKEALEKALQQEVLVTNNILKVMKACENE
: FSLNFANPAARVDAEQGSVALTALKAALAKEQEVTKSIRELIKICEED
: FKLNYDHEV PTVTT GESALETALQKEVEVTKSIRGVIKACEDG
: SEFN DYHLVDYLTGDFLEEQYKGQRDLAGKASTLKKLMDRH
: PEFN DYHLVDYLTGEFLEEQYKGQRDLAGKASTLKKMLDRN
: PNFN DYHLVDYLTGEFLEEQYKGQRDLAGKASTLKKMMDRH
: REANGRDDNDYHLVDYLTGEFLDEQYKGQRDLAGKAATLKKMMDRH
: S FN DYHIVDYLTGDFLTEQYQGQRDIAGKVSTLEKLKVKH
: KSFN DYHLVDYLSGDFLGEQYQGQRDIAGKISTLEKMTEKH
: P YN HYHLVDYLTGVYLEEQLHGQRELAGKLTTLKKMMDTN
: EVKDAAWTLPNDYHLVDWLTAEFLDEQYKGQRDIAGKLSTLLKMGSSN
: HN DYHLVDYLTGEFLEEQHQGQRDLAGKITMLSKLLRTN
: SN DFHLADYLTGEYLDEQHKGQRELAEKIATLKKMKKSA
EALGEFIFDKKLLGIDV
SALGEFIFDKKLMGMDI
ASLGEFIFDKKLLGIDV
SALGEFIFDKRLLGMDI
GALGEFLFDKKLLNGEL
GALGEWLFDKKLLKGEL
GELGEFLFDKTL
YHLGEFLFDKKLLSNEA
PKLGEFMFDKQNM
PKLGEFLFDKNHM
42
90
133
174
191
Supplemental Figure 1A. Sequence alignment of insect H chains
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ta
Trichoplusia ni L chain
Manduca sexta
Galleria mellonella
Calpodes ethlius
Apriona germari
Drosophila melanogaster
Nilaparvata lugens
Anopheles gambiae
Aedes aegypti
Trichoplusia ni
Manduca sexta
Galleria mellonella
Calpodes ethlius
Apriona germari
Drosophila melanogaster
Nilaparvata lugens
Anopheles gambiae
Aedes aegypti
Trichoplusia ni
Manduca sexta
Galleria mellonella
Calpodes ethlius
Apriona germari
Drosophila melanogaster
Nilaparvata lugens
Anopheles gambiae
Aedes aegypti
Trichoplusia ni
Manduca sexta
Galleria mellonella
Calpodes ethlius
Apriona germari
Drosophila melanogaster
Nilaparvata lugens
Anopheles gambiae
Aedes aegypti
Trichoplusia ni
Manduca sexta
Galleria mellonella
Calpodes ethlius
Apriona germari
Drosophila melanogaster
Nilaparvata lugens
Anopheles gambiae
Aedes aegypti
: ADTCYNDVALDCGITSNSLALPRCNAVYGEYGSHGNVATELQA
: ADTCYQDVSLDCSQVSNSLTLPNCNAVYAEYGHHGNVAKEMQA
: EDACYNDVSLQCAQASNNLGLAHCNSIYGEYGRHGNVATEMQA
: DVCYQDASMECGLASNSLELSNCNAVYGNYGRHGNVASEMQA
: QVEDHLSKSCYNDIDTICKHSKLSPKDSYCSAKYGGIN KVQEGLQK
: KD DEYCQNTVITACSTSAFS GNSICNARFAGIDH IEPEIQS
: IKPDAEKGACVKSVANFCHATEQ KISDCNAQYSGF HH VHSDLQQ
: TDLSANDCEINVE ECSPTYSSF LSRSGKT VENDLKQ
: DNNNSTVSFT AQFSSIAH IGNDLQT
: YAKLHLERSYDYLLSAAYFNNYQTNRAGFSKLFKKLSDEAWSKTIDIIK
: YAALHLERSYEYLLSSSYFNNYQTNRAGFSKLFRKLSDDAWEKTIDLIK
: YANLHLERSYEYLLSAAYFNNYQTNRDGFSKLFKKLSDQAWEKTIELIK
: YANLHIERSYQYLLSPAFFDNYNTNRKGFSALFKKLSDHAWSKSIELIQ
: FVNDHFTLSFHYLLMATHFDNYNKNRPGFEKLFRGLSDDTWEDGIELIK
: YINANLAKSYDYLLLATHFNSYQKNRPGFQKLYQGLSDRSFEDSIALIK
: FVVTQIEQSFQFLTMATKFGNYKSNRPGFEKLYRGLADKSWEESIELMK
: YTSQLVDKSFHFLMMSSAFNKHSLDRPGFEKLYRKISDKAWADAIELIK
: FTSQQLEKSFDFLLLAFNFDQYMIDRPGFEKLYRKISDKAWEDTEKLIK
: HVTKRGDKMNFD QHSTMK TERKNYTA ENHELEALAKALDTQ
: HITMRGDEMNFA QRSTQKSVDRKNYTV ELHELESLAKALDTQ
: HITKRGGEMNFA QRSTQQPAERKNYTV ELHELESLAKALDTQ
: HITKRGDVMDFS RRSTLASTA KNVTL ELPELESLAHALDTQ
: YITKRGGEMNFN LQ SYFNETKP DA ELYEYYAVGKALDNH
: QVTRRGGIVDFN TRHESSGSVSTKRVTL EVDELHSLALALDTE
: YITSRGYDVNLK IT PYQYSNNTKSLTEISTYPEISELKSLSMALEMN
: YQSRRGSFGHL VQPS KGENYGKVL DVQELSSLQFALDYE
: YQSKRGLTVELKDLKGGVIGQLNDGKVGGSISLLDSDEISSLKVALGYE
: KELAERAFYIHREATR NSQ H LH DPEIAQYLEEEFIEDHA
: KELAERAFFIHREATR NSQ H LH DPEVAQYLEEEFIEDHA
: KEIAERAFYIHREATR NSQ H LH DPEVAQYLEEEFIEDHS
: KEMAERAFYIHREATR NSQ K TH DPEIAQYLEEEFVEYQA
: KKLALEAFEVQKEAAN KAK D YH DPEITSYLEHEFMHKHR
: KQLATGATHVHSRATH ATD A ER DPELAHYFEENFLGKQA
: KFLAEKAHDIHHNAAS HSKDK PH DAEVMSFLENTYVHKHA
: KQMAKEAHAIHRKISHAHSKAGSNGSDDVYHYDPDAAHYLDENIIEYQS
: KILAEESHHIHKKISHAHDNKA TY DPDVAHFLDEEIIEYQS
: EKIRTLAGHTSDLKKFITANNGHDLSLALYVFDEYLQKTV
: KTIRNLAGHTTDLKRFVSGDNGQDLSLALYVFDEYLQKTV
: KTIRELAGHTTDLKSFITVNNGQDKSLAFYLFDEYLQKTV
: KVIRDLAGHTTDLKKFVVSNKGQDLSLALYLFDEYLQKSV
: DIVK LAGYTSDLNKIL DGPDSSLSLYLFDEYLQKQ
: ESVRKLSGYANDLAKLM KVPDPSLSVYLFDEYLQKQ
: DTIRTLTGHVNDLHK ITQTRGVDANLATFMFDEFLLKA
: GVVRDLAGYVHNLKHFTSAKHAAN DLGNHVFDEFLAKVE
: GTIRKLTGYIYNLDSIIKEDKTKD LGIHMFDEYLDKVE
43
92
133
172
212
Supplemental Figure 18B. Sequence alignment of insect L chains
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APPENDIX III
Steric Accessibility of the HIV- 1 gp41 N-Trimer Region
Appendix III has been accepted for publication in the Journal of Biological Chemistry. I started
this project in Peter Kim's lab at MIT. My contribution to this work includes coming up with the
initial ideas for the study, cloning and expressing most of the proteins, performing the initial
syncytia assays and assisting in the editing of the manuscript. The initial viral infectivity assays
were done by Heng Chhay in the Kim lab. After the Kim lab closed, a former postdoc from the
Kim lab, Michael Kay, finished the project in his lab at the University of Utah in Salt Lake City.
Michael Kay's contribution includes supervising the research done in his lab, data analysis and
writing the manuscript. The viral assays, binding studies, Ub data collection, and the proteolysis
and precipitation studies were carried out by Brett Welch. Sunghwan Kim did the syncytia
assays, expression of IQN36, refolding and characterization of BPTI, and performing the
extended linker studies.
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STERIC ACCESSIBILITY OF THE HIV-1 gp4l N-TRIMER REGION
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During HIV entry, gp41 undergoes a series of conformational changes that induce
membrane fusion. Immediately prior to fusion, gp41 exists in a pre-hairpin intermediate, in
which the N-peptide and C-peptide regions of gp41 are exposed. Rearrangement of this
intermediate into a six-helix bundle composed of a trimeric coiled coil from the N-peptide
region (N-trimer) surrounded by three peptides from the C-peptide region provides the
driving force for membrane fusion, while prevention of six-helix bundle formation inhibits
viral entry. Because of its central role in mediating viral entry, the N-trimer region of gp4l
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is a key vaccine target. Extensive efforts to discover potent and broadly neutralizing Abs
against the N-trimer region have, thus far, been unsuccessful.
In this study, we attach a potent C-peptide inhibitor that binds to the N-trimer region
to cargo proteins of various sizes to examine the steric accessibility of the N-trimer during
fusion. These inhibitors show a progressive loss of potency with increasing cargo size.
Extension of the cargo/C-peptide linker partially restores inhibitory potency. These results
demonstrate that HIV defends its critical hairpin-forming machinery by steric exclusion of
large proteins and may explain the current dearth of neutralizing Abs against the N-trimer.
In contrast, previous results suggest the C-peptide region is freely accessible during fusion,
demonstrating that the N- and C- peptide regions are in structurally distinct environments.
Based on these results, we also propose new strategies for the generation of neutralizing
Abs that overcome this steric block.
HIV entry is mediated by the viral envelope (Env) glycoprotein. Env is initially produced as
gpl60, which is proteolytically cleaved into non-covalently associated transmembrane (gp41)
and surface (gpl20) subunits. gpl20 is primarily involved in recognition of cellular receptors,
while gp41 is anchored in the viral membrane and mediates membrane fusion. The gp41
ectodomain contains two helical heptad repeat sequences (N- and C-peptide regions) (1,2).
Peptides corresponding to these helical regions (N- and C-peptides) are dominant-negative
inhibitors of HIV membrane fusion (2,3). Isolated N- and C-peptides form a six-helix bundle
(trimer-of-hairpins) when mixed in solution (4-6). In this structure, three N-peptides form a
central parallel trimeric coiled coil (N-trimer) surrounded by three anti-parallel C-peptides that
nestle between neighboring N-peptides.
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Based largely on these inhibitory and structural data, a working model of HIV-1 membrane
fusion has been proposed (Fig. 1) (3,5). Initial interaction of Env with its target cell occurs via
gpl20 binding to CD4 and a coreceptor (typically CCR5 or CXCR4). This binding induces a
series of large conformational changes in gpl20, which are propagated to gp41 via the gp41-
gp120 interface. At this stage, gp41 transiently adopts an extended "prehairpin intermediate"
conformation that bridges both the viral and cellular membranes. This state is believed to persist
for at least 15 min (3,7,8), but eventually collapses into a trimer-of-hairpins structure, which
pulls both membranes into tight apposition and induces membrane fusion (Fig. 1).
In this model, the prehairpin intermediate exposes the isolated N-trimer, while the C-peptide
region exists in an unknown and possibly unstructured conformation remote from the N-trimer
(3). At this stage, the prehairpin intermediate is vulnerable to binding of exogenous N- and C-
peptides. Binding of these peptide inhibitors denies access of the endogenous N- or C-peptide
regions to their appropriate intramolecular partner, thwarting hairpin formation and membrane
fusion. This model predicts that any molecule that binds to the prehairpin intermediate and
disrupts association of the N- and C-peptides will inhibit membrane fusion and has been
successfully applied to the development of several potent entry inhibitors (9-11).
Additionally, the gp41 prehairpin intermediate has several promising features as an
inhibitory target (12). Peptide mimics of the N-trimer region have been structurally characterized
at high resolution (4-6). The interface between the N- and C-peptides is highly conserved among
diverse HIV strains of both lab-adapted and clinical isolates (9). The N-trimer also presents a
long (>100 A), deep groove with an extensive binding surface (4-6). These special properties
have led many groups to search for Abs that can disrupt this interface (reviewed in (13)).
C-peptide Inhibitors
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Several peptide fusion inhibitors derived from the N- and C-peptide regions of gp41 have
been described (2,3,12,14-16). The most potent are peptides derived from the C-peptide region
(e.g., C34, DP178/T20, T1249), which have low nM IC50's against viral entry in cell-cell fusion
(syncytia formation) and viral infectivity assays (reviewed in (17)). Several mutations leading to
T-20 resistance have been mapped to the N-peptide region of gp41 (18), providing strong
support that the N-trimer is the primary target of C-peptide inhibitors.
gp41 N-trimer as a vaccine target
As demonstrated by the efficacy of C-peptide inhibitors, the N-trimer region of gp41 is a
very attractive candidate for vaccine efforts. Many such efforts have been undertaken using
various peptide mimics of the N-trimer region (e.g., N-peptide, 5-helix, IZN36, and N35cCG-N13
(17,19-21)). These efforts have produced a large number of Abs with specific and high affinity
binding to their targets, but weak and/or narrow neutralizing activity in standard viral entry and
spread assays. Interestingly, some of these anti-N-trimer Abs can inhibit fusion if bound to a
temperature-arrested intermediate fusion state (19) or in the presence of soluble CD4 (sCD4)
(21). Currently, there are only two reported anti-gp41 Abs that exhibit potent and broadly
neutralizing activity, 2F5 and 4E10, which bind just outside the C-terminal border of the C-
peptide region, an area with uncertain structure (reviewed in (22)).
In this study, we test the hypothesis that the N-trimer of gp41 is sterically restricted in the
prehairpin intermediate, which may explain the current dearth of broadly neutralizing Abs
against this target (Fig. 1). All of the known fusion inhibitors that target this structure (e.g., C34,
T-20, T-1249, D-peptides) are small (<40 residue) peptides and could circumvent such a steric
block. We have constructed fusions of a well characterized C-peptide inhibitor (C34) to a series
of protein cargoes of varying sizes to determine if such a steric block exists and, if so, to define
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its size cutoff. Our results demonstrate that C-peptide fusion proteins lose inhibitory potency
with increasing size and that the N-trimer region of gp41 is likely to be poorly accessible to
proteins as large as Abs. These results have important implications for gp41 vaccine design as
well as for the production of second-generation C-peptide entry inhibitors. This steric restriction
also helps to better define the conformation of the pre-hairpin intermediate.
Materials and Methods
Reagents
Plasmids were obtained from the following sources: pET vectors (Novagen), pMAL-c2G
(NEB), pEBB-HXB2 and pEBB-JRFL (gifts from B. Chen) (23). Reverse phase HPLC (RP-
HPLC) was performed using a C18 column (Vydac). All Ni affinity purifications used His-Select
HC Nickel Affinity Gel (Sigma) or His-Select HC Nickel Magnetic Resin (Sigma). The NIH
AIDS Research and Reference Reagent Program provided the following reagents: pNL4-
3.Luc.R-E- (N. Landau), HeLa-CD4-LTR-B3-gal cells (M. Emerman), HOS-CD4-fusin cells (N.
Landau).
Protein Expression Purification, and Characterization
C37-H6 (C37), derived from the HXB2 Env sequence, was expressed and purified as
previously described (9). Proteins used in this study were Bovine Pancreatic Trypsin Inhibitor
(BPTI), Human Ubiquitin (Ub), Sperm Whale Myoglobin (Mb), enhanced Green Fluorescent
Protein (GFP, from Clontech), and E. coli Maltose Binding Protein (MBP, from NEB). Linker
sequences were Ser4Gly2 for BPTI-C37, Ub-C37, and GFP-C37 and Ser5Gly2 for Mb-C37 and
MBP-C37 (linker sequences are slightly different for cloning reasons). The extended linker
constructs had the following linker sequences: SSS(GGGS)3SSSGG (MBP1-C37) and
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SSS(GGGS)3S(GGGS)3SSSGG (MBP2-C37). The DNA encoding each protein was cloned into
the following plamsids: pET9a (for BPTI-C37, Ub-C37, Mb-C37, and GFP-C37), pET20b (for
BPTI-H6, Ub-H6, Mb-H6, and GFP-H6); pMAL-c2G (for MBP-H6, MBP-C37, MBP1-C37, and
MBP2-C37). Proteins were expressed in BL21(DE3)pLysS (Novagen) for pET9a and pET20b
vectors and XL1-Blue (Stratagene) for pMal-c2G vectors. All proteins have C-terminal His-tags
(His6) and were purified using Ni affinity chromatography.
BPTI required refolding after expression for correct formation of disulfide bonds. Briefly,
after Ni affinity purification, BPTI-C37-H6 and BPTI-H6 were reduced with 100 mM 13-
mercaptoethanol at pH 8 and dialysed into 5% acetic acid. The proteins were air oxidized in the
presence of a 1:10 ratio of oxidized:reduced glutathione at pH 8, 4C for 24 h. The correctly
folded proteins were isolated using RP-HPLC and were confirmed by near-UV circular
dichroism (Aviv 62DS) and measurement of trypsin inhibiting activity as previously described
(24).
Cys-Gly-Gly-Asp-IZN36 (10) was cloned into pET14b and expressed in BL21(DE3)pLysS.
IZN36 was purified from inclusion bodies (solubilized in 6 M GuHCl) using Ni affinity
chromatography. The protein was then dialyzed into 5% acetic acid and purified by RP-HPLC.
This material was reduced with TCEP (Pierce) and biotinylated at its unique Cys residue using
Biotin-HPDP (Pierce). After biotinylation, the His-tag was removed by thrombin cleavage
(Novagen) and the cleaved product was purified by RP-HPLC. The sequence of the final product
is:
GSHMCGGDIKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWG
IKQLQARIL.
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All protein masses were confirmed by MALDI or electrospray MS (U. of Utah Core Facility).
All proteins were judged >98% pure by SDS-PAGE. Protein concentrations were measured by
UV absorbance at 280 nm (25).
Surface Plasmon Resonance (SPR) Analysis
Binding experiments were performed using a Biacore 2000 optical biosensor (U. of Utah
Protein Interaction Core Facility) equipped with research-grade CM5 sensor chips (Biacore). A
standard coupling protocol was employed to immobilize streptavidin (SA, Pierce) (26).
Biotinylated IZN36 was captured on a SA surface, and free SA surfaces served as references.
Binding analysis of C37 and C37-fusion proteins was performed at 250C with a data
collection rate of 2.5 Hz. The binding buffer (PBS (Gibco) + 0.005% P20 detergent (Biacore) + 1
mg/mL BSA (fraction V, Fisher)) was prepared, vacuum filtered, and degassed immediately
prior to use. Stock solutions of C37, C37-fusion proteins, and corresponding control proteins
(without C37) were prepared in binding buffer at 100 nM. Protein binding was analyzed by
injecting samples for 1 min over the IZN36 and reference surfaces using KINJECT at a flow rate
of 50-100 yL/min. The dissociations were monitored for 3 min. The IZN36 surfaces were
completely regenerated using one 3 s pulse of 6 M guanidine-HCl or three 6 s pulses of 0.1%
SDS.
Data from the reference flow cells were subtracted to remove systematic artifacts that
occurred in all flow cells (27). The data were normalized to the highest point in the response
curve to facilitate comparison. Binding at one concentration was analyzed using a 1:1 binding
model in CLAMP (28) assuming enough information from the curvature of the responses to
determine the approximate kinetic parameters for the reactions (29).
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Cell-Cell Fusion and Viral Infectivity Assay
Cell-cell fusion was monitored as previously described (30). Briefly, HXB2 Env expressing
CHO cells (gift from M. Krieger (31)) were mixed with HeLa-CD4-LTR-Beta-gal cells in the
presence of inhibitors for 20 h at 37C. Syncytia were stained with X-gal (Invitrogen) and
counted.
Viral infectivity was measured as previously described (9). Briefly, pseudotyped viruses
were produced by co-transfecting 293T cells using Fugene (Roche) with pNL4-3.Luc.R-E- and
either pEBB-HXB2 or pEBB-JRFL. After 36-48 h, viral supernatants were collected and sterile
filtered. HXB2 or JRFL pseudotyped virus was added to HOS-CD4-fusin or HOS-CD4-CCR5
cells, respectively, in the presence of inhibitors. HXB2 assays included 20 g/mL DEAE-dextran
(23). After 12 h, virus and inhibitor were removed and replaced with fresh media. Cells were
lysed 40-44 h after infection using Glo Lysis buffer (Promega), and luciferase activity was
measured using Bright-Glo (Promega). IC50 values for both assays were calculated by fitting data
to the equation, y = k/(l+ [inhibitor]/IC,,), where y = normalized number of syncytia or
luciferase activity and k = scaling constant (k = 1 for syncytia assay and is floated for viral
infectivity assay, see Fig. 2B legend).
Assays for Inhibitor Proteolysis and Precipitation
C37 fusion inhibitors were incubated in tissue culture media (DMEM + 10% fetal bovine
serum, Invitrogen) at 37C for 20 h. Proteins were purified from the media by 1 h incubation at
RT with magnetic Ni affinity beads. The resin was washed 3x with PBS and proteins were eluted
by boiling in LDS sample buffer (Invitrogen). Eluted samples were separated by SDS-PAGE and
visualized with SimplyBlue stain (Invitrogen). Unpurified media samples were analysed before
and after centrifugation (10 min. at 18,000x g) by Western blot using polyclonal rabbit anti-His-
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tag Ab (Abcam) and SuperSignal West Pico substrate (Pierce), as well as visually analysed for
precipitate.
RESULTS
Production of Fusion Proteins
To test for steric constraints in accessing the gp41 N-trimer region, we have constructed a
series of inhibitors containing a C-peptide attached to cargo proteins of various sizes (Fig. 1).
The cargo partners used in this study were selected for the following properties: monomeric,
soluble, globular, stable, tolerant to C-terminal additions, and free of non-specific peptide
binding. Cargo proteins meeting these inclusion criteria and used in this study range from 6 to 41
kDa (Table 1). For these studies, C37 (9), the recombinant His-tagged version of the previously
characterized synthetic peptide C34 (30,32), was used as the reference inhibitor. In each fusion
protein, C37 is connected at its N-terminus to the cargo's C-terminus by a flexible six or seven
residue Ser/Gly linker. This linker was designed to be long enough to allow the proper
orientation of C37 as it binds to the N-trimer, but short enough for the attached cargo to prevent
access to an occluded binding site. The N-terminus of C37 was chosen for attachment of cargo
because this attachment site points away from the membrane (whereas, the C-terminus of C37 is
expected to be near the viral membrane, and, therefore, less accessible - see Fig. 1). For each
fusion protein, a matching control protein lacking C37 was also produced.
Size and inhibitory potency are inversely correlated
The inhibitory potency of each inhibitor was tested using a cell-cell fusion (syncytia) assay
utilizing HXB2 env and two viral infectivity assays utilizing either HXB2 (X4) or JRFL (R5)
envs (Table 1, Fig. 2). C37 shows high potency inhibition in all assays (IC50 = 0.85 to 8.2 nM).
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Inhibition is slightly weaker than seen with C34 (30), as expected from the loss of helix-
stabilizing synthetic blocking groups found in C34. For reference, the anti-gp41 Abs 2F5 and
4E10 have reported IC50 values of -0.2 to 7 nM against HXB2/IIIB lab strains in cell-cell and
viral infectivity assays similar to those used in this study (33,34).
The smallest fusion protein, BPTI-C37, also displays high potency in both assays, very
similar to C37, demonstrating that our C37-cargo linker does not interfere with inhibitory
activity. Ub-C37 is a slightly weaker (2.5 to 5.5-fold) inhibitor than C37, while Mb-C37 and
GFP-C37 both show more substantial (21 to 65-fold) reductions in potency in both assays. MBP-
C37 shows the most dramatic change with a 75 to 228-fold drop in potency. None of the control
proteins (cargo without C37 peptide) inhibit at up to 1 M (10 PM for MBP with JRFL env) in
either assay (data not shown).
In general, the cell-cell fusion and viral infectivity assays show similar losses of activity
with increasing size of the inhibitors with a slightly more pronounced effect on cell-cell fusion
and JRFL-mediated viral entry. For HXB2 env we observe up to a 4-fold greater potency in cell-
cell fusion vs. viral infectivity, as seen in studies of other fusion inhibitors (2,11,30,35). As
expected, inhibitors were less potent against the primary isolate JRFL in the viral infectivity
assay. For most of the inhibitors, the viral infectivity data shows a reproducible increase in
infectivity (above the uninhibited values) at low inhibitor concentrations (see legend Fig. 2B).
This "overshoot" has also occasionally been seen in other studies of fusion inhibitors (36-38), but
has not been explained.
The C-peptide remains accessible when linked to fusion partners
To ensure that linkage of C37-H6 to each of the partner proteins did not affect the
accessibility of C37 for binding to a sterically open target, the fusion proteins and C37 were
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assayed for binding to IZN36, a soluble mimic of the N-trimer (10), using SPR. Each fusion
protein was flowed over the control and IZN36 surfaces. C37 reversibly bound to IZN36 with a
low nM KD (Fig. 3). The calculated KD's for the fusion proteins are clustered in a narrow range
around the C37 value (2-fold lower to 2-fold higher). The estimated kinetic parameters are
similarly clustered, ranging from 3.2-fold slower to 1.4-fold faster (association rate) and up to
3.2-fold slower (dissociation rate). These rates are only approximate due to small systematic
deviations from the fitting model, but as expected there is a slight trend towards slower
association and dissociation rates with increasing molecular weight. These small differences in
binding kinetics are likely responsible for some of the variation in potency observed here but rule
out distinct binding kinetics as the major contributor to the substantial differences in potency
among these inhibitors. These results also show that the accessibility and affinity of C37 are not
significantly altered in the context of the fusion proteins. None of the cargo proteins alone
showed measurable association with IZN36 at 100 nM (inset, Fig. 3).
Partial restoration of inhibitory potency with extended Gly/Ser linkers
To test if a longer linker could overcome the steric block and restore inhibitory potency of
our weakest inhibitor, we extended the flexible linker in MBP-C37 from its original length of 7
amino acids to 20 (MBP1-C37) or 33 (MBP2-C37) using Gly/Ser residues (Table 1). Both
extended linker inhibitors exhibit partial recovery of inhibitory potency. Compared to MBP-C37,
MBP1-C37 and MBP2-C37 are 2.3 to 2.9-fold and 2.6 to 6.1-fold more potent, respectively
(Table 1). Compared to MBP-C37, MBP1- and MBP2-C37 interact similarly with IZN36 as
measured by SPR (Kds vary by <20%, ka and kd are <2-fold higher). In contrast to the other
cargo-C37 fusions, a significant portion of the increased potency in MBP1- and MBP2-C37 may
be attributable to an increased association rate.
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Stability of fusion proteins during fusion assays
Inhibitors were analyzed for precipitation or extensive proteolysis to demonstrate that these
processes did not cause the observed decrease in potency of the fusion proteins. C37 and the
C37-fusions were incubated in tissue culture media at 370C for 20 h to simulate the harshest
conditions faced by the inhibitors during the cell-cell fusion and viral infectivity assays. We
observed only trace (<2%) degradation for all of the inhibitors (data not shown), allowing us to
conclude that proteolysis did not cause a significant decrease in the potency of our inhibitors. We
cannot, however, rule out the contribution of minor proteolytic breakdown products to increased
inhibitory potency, particularly for the least potent inhibitors (1% contamination with free C37
would result in an apparent cell-cell fusion IC50 value of -100 nM for a completely inactive
inhibitor). Therefore, the described potencies of the inhibitors presented in this study should be
considered an upper limit. An anti-His tag Western blot comparing samples before and after
high-speed centrifugation revealed no precipitation (data not shown).
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DISCUSSION
In principle, the gp41 N-trimer is an especially promising inhibition target, but despite the
generation of numerous Abs with tight and specific binding against various mimics of the N-
trimer, none of these Abs display broadly neutralizing activity, reviewed in (17). Our results
suggest that HIV may have developed a strong steric defense against immune attack for its
critical N-trimer region. In this study we show that the gp41 N-trimer region has poor
accessibility to large proteins. It is a logical extrapolation of the data presented here that a protein
as large as IgG (150 kDa), even though it forms a somewhat elongated shape, will suffer a steric
block at least as severe as we observe with our largest protein, MBP (41 kDa), which is smaller
than the individual (-50 kDa) domains of an IgG. This defense may be a major factor in
frustrating efforts to induce neutralizing Abs against the N-trimer region and may also explain
why such neutralizing Abs against the N-trimer have not yet been observed in infected patients.
The steric restriction of the N-trimer stands in stark contrast to apparent accessibility of the
extreme C-terminal region of the gp41 ectodomain (between the C-peptide region and the
transmembrane domain). The only known potent and broadly neutralizing Abs against gp41 (2F5
and 4E10) target this region (22). Recent studies have suggested that this region may adopt a
helical or beta-strand conformation or cycle between the two (33,39). For the most thoroughly
studied Ab against this region, 2F5, a full length IgG (150 kDa) is more potent than the Fab
(-50 kDa) (33), suggesting a freely accessible site.
There is also suggestive evidence that the C-peptide region may be more accessible than the
N-trimer. The designed proteins 5-helix (25 kDa) (9) and NCcG-gp4 l (35 kDa) (40) target the C-
peptide region and are potent entry inhibitors. Recently, a Pseudomonas Endotoxin (PE) fusion
with 5-helix (5-helix-PE, 65 kDa) was shown to inhibit viral entry with similar potency as 5-
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helix (41), although a toxic effect from PE may mask a loss of potency. While the C-peptide
region is likely accessible, it is difficult to target for vaccine studies, as it is unclear what
organized structure (if any) this region adopts during viral entry.
C37 inhibits viral fusion by binding along the full length of the surface groove of the N-
trimer, including the deep hydrophobic "pocket" region, previously shown to be an essential
player in viral fusion. Inhibitors that specifically target this pocket have been developed ((10),
B.D. Welch and M.S. Kay, unpublished results). In future studies, it will be important to test
such pocket specific inhibitors to see if they can circumvent the steric block observed here. It
will also be important to check if cargo fused to the C-terminus of C37 shows a similar pattern of
steric blockage.
The steric block we observe in the gp41 N-trimer is reminiscent of steric restrictions
observed in gpl20. These restrictions have been attributed to glycosylation ("glycan shield")
(42,43) and/or inaccessible antigens (38,44,45). Previous studies with several broadly
neutralizing gpl20 Abs have shown that smaller versions of these Abs (Fabs or scFvs) often
have significantly improved potency, despite a loss of avidity (38,46). The N-trimer steric block
observed here may be more strict than seen in gpl20. Proteins the size of Fabs (-50 kDa) and
scFvs (25 kDa) are already too large to fully access the gp41 N-trimer. Interestingly, the N-
trimer region does not contain any glycosylation sites, probably due to its ultimate complete
burial in the six-helix bundle structure. The N-trimer, however, may be affected by nearby
glycosylation sites in gpl20 or other regions of gp41 (the C-peptide region and N/C-peptide
connecting loop are extensively glycosylated). A glycosylation site near the gpl20 V3 loop has
been shown to affect accessibility of the 2F5 Ab to its gp41 epitope in resistant strains (43).
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Implications for C-peptide inhibitors
Our results suggest that attempts to improve the longevity of C-peptide inhibitors in the
bloodstream may also be frustrated by steric issues. For instance, T-20, a 36-residue peptide
recently approved by the FDA, is rapidly cleared from the bloodstream by kidney filtration,
dramatically increasing dosing requirements. A reasonable approach for prevention of this rapid
clearance is to crosslink C-peptide inhibitors to larger proteins (e.g., albumin) or high molecular
weight polyethylene glycol (PEG), which also can reduce peptide immunogenicity (47). Our
results suggest that these straightforward approaches will likely reduce the potency of modified
C-peptides, although use of smaller proteins or low molecular weight PEG may lessen this effect.
Our extended loop constructs suggest the possibility that longer linkers between these bulking
groups and the C-peptide inhibitor could improve accessibility to the N-trimer. Stiffer (e.g.,
helical) linkers may provide better separation from large fusion partners and restore inhibitory
potency better than the flexible Gly/Ser linkers employed here.
An important caveat to applying our results to T-20 is that, compared to C34, T-20 is
derived from a gp41 sequence shifted about ten amino acids towards the C-terminus and its
binding site extends beyond the N-trimer region. Although they are thought to have a similar
mechanism of action, T-20 and C34 (and the similar T-1249) vary in their potencies against
different HIV-1 strains and their sensitivities to resistance mutations (18,48,49).
Future directions - Overcoming the steric block
We hope that the observation of this steric block can be used to improve the chances of
discovering a broadly neutralizing Ab against this valuable HIV target, rather than discouraging
this effort. Specifically, we suggest that a designed, sterically restricted N-trimer antigen could
be used to generate, boost, or screen for potent neutralizing Abs able to overcome the steric
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block. Currently used mimics of the N-trimer region (e.g., 5-helix, IZN36, NccG-gp41) could be
modified by attachment to bulky proteins or large inert particles such that only Abs capable of
penetrating a sterically recessed target would be selected.
Neutralizing Abs against sterically blocked gpl20 targets often utilize unusually long CDR
H3 loops to access recessed antigens (33,46,50). The insertion of longer linkers connecting MBP
to C37 results in partial recovery of inhibitory activity, suggesting that extended CDR H3 loops
may help penetrate the steric block on the gp41 N-trimer. These Abs are difficult to generate in
small animals, as Abs in primates have longer CDR H3 loops on average than rodents (51).
Potent N-trimer Abs may be more easily found using strategies that enrich for this type of Ab
(e.g., engineered Ab libraries, Ab phage display, immunization of primates). Alternatively, very
high affinity (sub-nM) Abs against the N-trimer may still be sufficiently neutralizing despite a
substantial decrease in potency caused by the steric block. Recently, Merck has reported
preliminary results on an antibody that binds to the N-trimer region and possesses neutralizing
activity against some HIV strains (M. Miller and R. Geleziunas, Abst. 13th International HIV
Drug Resistance Workshop, abstract #9, 2004). No detailed information on this Ab has yet been
published, but it will be interesting to see if or how this Ab circumvents the steric block we
observe here (e.g., high affinity Ab that can tolerate several hundred-fold loss in activity,
extended variable loops, specific targeting of a subsite in the N-trimer).
Finally, our results suggest that the traditional depiction of the prehairpin intermediate as a
symmetric structure (e.g., Fig. 1) may be inaccurate. The steric block of the N-trimer and
apparent accessibility of the C-peptide region show that they reside in very different
environments. Possible sources of this asymmetry include interactions with gp120, other regions
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of gp41, or cell surface proteins, as well as glycosylation and differences between the curvature
of the viral and cellular membranes.
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Table 1: IC50 in (nM) of fusion proteins in cell-cell fusion and viral infectivity assays
Protein Fusion Cell-cell IC50 ratio Viral IC50 ratio Viral IC50 ratio
partner fusion (cell-cell infectivity HXB2 infectivity JRFL
MW fusion) HXB2 JRFL
C37 0 0.85 1.0 2.8 1.0 8.2 1.0
BPTI-C37 6.5 kDa 1.5 1.8 3.1 1.1 4.8 0.6
Ub-C37 8.6 kDa 4.7 5.5 6.8 2.5 37.7 4.6
Mb-C37 17 kDa 30.8 36.2 58.0 21.0 414 50.5
GFP-C37 27 kDa 28.9 34.0 118 42.8 533 65.0
MBP-C37 41 kDa 192 225 206 74.8 1874 228
MBP1-C37 41 kDa 75.1 88.4 88.9 32.2 640 78.0
MBP2-C37 41 kDa 31.2 36.7 79.2 28.7 516 62.9
IC50 standard errors are <25% for both assays. IC50 ratios are relative to C37.
251
Native
cell membrane
CD4
co-receptor
gp120 -
gp41 -
Prehairpin
Intermediate
slow rxn
poes
viral membrane
Fig. 1. Model of HIV-1 membrane fusion pathway (adapted from (9)). Formation of the trimer-
of-hairpins drives the viral and cellular membranes together, leading to fusion. The N-peptide
region (gray), C-peptide region (blue), gpl20 (green), gp41 (light blue), gp41 fusion peptide
(red), and transmembrane domain (purple) are shown. gpl20 is removed from the prehairpin
intermediate for clarity. Also shown are a series of C37 fusion proteins of different sizes and an
anti-N-trimer Ab attempting to access the N-trimer, but potentially blocked by a steric
restriction. Sizes of the Ab and fusion proteins are only approximately to scale.
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Fig. 2. Inhibitory activity of C37 and C37-fusion proteins. Data points are averages of at least
quadruplicate measurements. Data are normalized to uninhibited fusion activity. A. Cell-cell
fusion assay (HXB2 env). Standard errors of each point are <0.05. B. Viral infectivity assay
(HXB2 env). Standard errors of each point are <0.1. An "overshoot" is observed at low inhibitor
concentrations (data above 1.0). Fitting the viral infectivity data to a simple Langmuir equation
with a fixed zero inhibitor point produces noticeable deviation from the data near the zero point
because of this overshoot. Fitting the data without fixing the zero inhibitor point (as done in this
study) improves the quality of the fit, but does not significantly affect the relative IC5 values of
the inhibitors.
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Fig. 3. Binding of C37 and C37-fusion inhibitors to IZN36 measured by SPR. Responses for
representative inhibitors were normalized and overlaid to facilitate their comparison (thick
traces). Fits to the interaction model are included (thin traces). Inset: Interaction of control
proteins (no C37) with IZN36 surface.
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